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“…Quando o conhecimento oculto na alma se 
manifesta, ficamos surpresos conosco mesmos, e 
nossos pensamentos de inverno se transformam 
em flores, que cantam canções nunca antes 
sonhadas. A vida sempre nos dará mais do que 
achamos que merecemos.”
- Khalil Gibran

“Sonhe com aquilo que você quiser.
Vá para onde você queira ir.
Seja o que você quer ser, porque você possui apenas 
uma vida e nela só temos uma chance de fazer aquilo 
que queremos.
Tenha felicidade bastante para fazê-la doce.
Dificuldades para fazê-la forte.
Tristeza para fazê-la humana. E esperança suficiente 
para fazê-la feliz.
As pessoas mais felizes não têm as melhores coisas.  
Elas sabem fazer o melhor das oportunidades que 
aparecem em seus caminhos.
A felicidade aparece para aqueles que choram. Para 
aqueles que se machucam. Para aqueles que buscam  
e tentam sempre.
E para aqueles que reconhecem a importância das 
pessoas que passam por suas vidas.
O futuro mais brilhante é baseado num passado 
intensamente vivido.
Você só terá sucesso na vida quando perdoar os erros  
e as decepções do passado.
A vida é curta, mas as emoções que podemos deixar,  
duram uma eternidade.
A vida não é de se brincar porque em pleno dia 
se morre.”
- Clarice Lispector
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“It is good to love many things, for therein lies the 
true strength, and whosoever loves much performs 
much, and can accomplish much, and what is 
done in love is well done.”
- Vincent Van Gogh
15
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Chapter 1
General introduction and outline of the thesis
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Interleukin 32: General properties 
Interleukin 32 (IL-32) was first described as a protein that was highly expressed in 
activated T- and NK-cells. It was therfore named natural killer cell transcript 4 (NK4) 
being induced after activation of T lymphocytes with mitogens (e.g. concanavalin 
A (ConA)) or NK cells with IL-2 (1). After 13 years, Kim et al. (2) showed that the 
recombinant NK4 had a biological function, being able to induce proinflammatory 
cytokines as tumor necrosis factor (TNFα) and IL-8 in murine RAW 264.7 
macrophages. Due to the proinflammatory activity, NK4 was renamed into IL-32. 
The structure of IL-32 did not match with the sequence homology of any other well-
known cytokine; consequently, the structure of IL-32 is completely different from 
the other cytokine families (3). 
In humans, IL-32 is located on chromosome 16 p13.3 and is mainly expressed 
in immune system organs and cells such as the spleen, lymph nodes, NK cells, 
monocytes, macrophages or T lymphocytes; additionally, it is expressed in non-
immune cells including endothelial and epithelial cells. Besides humans, IL-32 
is expressed in other species like bovine and porcine, but not in rodents (2, 4). 
Although,  rodents do not present IL-32 gene they respond to human IL-32γ, (2, 
5) what allowed the generation of human IL-32γ transgenic (IL-32γTg) mice and 
the use of them to investigate the IL-32 roles in diseases (6-8). IL-32 protein is 
predominantly expressed intracellularly, although some studies have shown that 
depending on the cell type and stimulus, the IL-32γ isoform may be secreted after 
cell death or in vesicles such as exosomes (9-12).  
IL-32 mRNA can be spliced by alternative splicing, generating nine isoforms namely 
IL-32s, IL-32α, IL-32β, IL-32d, IL-32γ, IL-32q, IL-32e, IL-32z and IL-32h of which not all 
functions are well known yet (13). These different isoforms of IL-32 originate from 
the pre-mRNA of IL-32γ.  A schematic overview of how IL-32 isoforms are generated 
by alternative splicing is shown in Figure 1.The IL-32γ isoform is the most potent 
isoform with respect to inflammation and cell death when compared with IL-32β 
or IL-32α isoforms  (3, 12, 14).  Moreover, it has been shown that the IL-32 isoforms 
can interact with each other to control their biological activities (13). This adds 
complexity in biological properties of IL-32, which depending on the isoform, the 
cell or stimuli can present different effects. 
The intracellular expression of IL-32 can be induced in both immune tissues and 
cells after exposure to different stimuli. Proinflammatory cytokines such as IL-1β, IL-
18 and IFNγ can induce IL-32 in an epithelial cell line whereas IL-12 and IL-18 cause 
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induction of IL-32 in NK cells and T lymphocytes (2, 15). IL-32γ levels were found to 
be higher in synovial biopsies from rheumatoid arthritis (RA) patients compared to 
healthy individuals after stimulation with TNFα or IL-1β (5, 16). Subsequently, Moon 
et al. (17) reported the involvement of spleen tyrosine kinase (Syk)/protein kinase 
Cδ (PKCδ)/c-Jun N-terminal kinase (JNK) pathways in the regulation of TNFα-
dependent IL-32 expression in fibroblast-like synoviocytes. Moreover, TNFα and 
IFNα synergistically induce IL-32 by activation of NF-kB and Jak/STAT signalling 
pathways, respectively in human monocytes. 
Figure 1: Graphical description of alternative splicing of IL-32. IL-32γ mRNA can be spliced into IL-
32β and IL-32α. Squares indicate the exons of the IL-32 gene. During the alternative mRNA splicing, 
exons sequences of IL-32γ mRNA are removed, which generate the others spliced variants isoforms 
determined as IL-32α and IL-32β.
Besides proinflammatory cytokines, pathogen-related products including the 
TLR4 agonist lipopolysaccharide (LPS), the TLR2 agonists zymozan or triacylated 
lipopeptide (Pam3cys), the NOD2 agonist muramyl dipeptide (MDP) and the TLR3 
ligand double-stranded RNA (poly I:C) have been described to be strong inducers 
of IL-32 in human monocytes, macrophages and monocyte-derived dendritic cells 
(DCs) (18-20). The identification of a receptor for IL-32 might be useful to clarify its 
biological functions. Despite the receptor for IL-32 is still unknown, some studies have 
shown the binding of IL-32 to proteinase 3 (PR3) and to membrane proteins such as 
αVβ3 and αVβ6 integrins (3, 21). PR3 is a neutrophil granule serine protease, which 
exists in a soluble or membrane form. The afftinity of IL-32α to PR3 was determined 
by surface plasmon resonance. Additionally, after limited cleavage by PR3, IL-32α 
was more active than intact IL-32α in inducing macrophage inflammatory protein-2 
(MIP-2) in mouse macrophages and IL-8 in humans PBMCs. This observation suggests 
the enzymatic action of PR3 in enhancing the biological activity of IL-32 (3).  
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It was also demonstrated that IL-32 activity could be modulated by alpha-1 
antitrypsin (AAT), a potent inhibitor of PR3 (22, 23). Furthermore, by predicting the 
seconday and tertiary protein structure of IL-32 isoforms, Heinhuis et al. (3) have 
shown that IL-32 contains RGD motifs, which potentially bind to integrins. Besides 
IL-32/integrins interactions, the authors have demonstrated that IL-32 is able to 
interact with intracellular proteins that are involved in integrin and focal adhesion 
signaling, including focal adhesion kinase (FAK) and paxillin (3). 
Role of IL-32 in the pathogenesis of infectious 
diseases  
IL-32 has been described to be involved in the pathogenesis of various 
inflammatory diseases such as RA, chronic obstructive pulmonary disease (COPD) 
and inflammatory bowel disease (IBD) (5, 24). These diseases are driven by the 
presence of proinflammatory cytokines, chemokines and immune cells. Important 
proinflammatory cytokines like IL-6, TNFα and IL-1β are known for a long time to 
play a role in the immunopathogenesis of the afore mentioned diseases. In contrast, 
the role of IL-32 in infectious diseases is relatively new.  Besides the role of IL-32 in 
several inflammatory diseases, the function was also described in the pathogenesis 
of infectious diseases like tuberculosis (TB), human immunodeficiency virus (HIV)/
Acquired immunodeficiency syndrome (AIDS) and sepsis, a disease caused by gram-
negative bacteria. It was observed that LPS could induce IL-32 (19, 20). Dependent 
on which isoform, IL-32α, IL-32β or IL-32γ  present in IL-32Tg mice suffering from 
sepsis, the outcome of the disease is different.  When the mice were transgenic for 
IL-32α or IL-32β high levels of TNFα, IL-1β and influx of immune cells caused animal 
death. On the other hand, IL-32γTg mice were protected from septic shock. This 
outcome was due to a decrease in systemic inflammatory cytokines released after 
LPS administration, suggesting protection against septic shock (8, 25, 26). Thus, 
these results indicate that the IL-32 isoform is crucial to control the inflammatory 
process during bacterial infection. Next to these animal studies, IL-32 was found 
to be elevated in circulation of some, but not all, patients with sepsis compared 
to healthy individuals. This could be explained by the fact that many other 
proinflammatory cytokines are upregulated such as TNFα and IL-6 that are known 
to affect IL-32 expression (2).
Another gram-negative bacteria, Helicobactor pylori, was also found to induce 
IL-32 in human gastric epithelial cell lines (27). One of the virulence factors of H. 
pylori is the cag pathogenicity island (PAI), a cluster of 30 genes responsible for the 
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progression of gastric diseases such as gastritis and gastric cancer (28).  H. pylori 
cagPAI can activate NF-kB and MAPK signalling pathways in infected epithelial cells 
thereby inducing proinflammatory mediators as CXCL1, CXCL2, IL-8, IL-1β, TNFα 
and also IL-32 (mostly IL-32β and to a much lesser extent IL-32e). IL-32 by itself can 
thereafter amplify NF-kB activation and induce more proinflammatory cytokines, 
contributing to the accelerated inflammatory responses in gastric inflammation 
(27). Isoform IL-32β was the major isoform detected in gastritis tissue and is the 
most expressed isoform in epithelial cells where it serves a critical function in 
vascular inflammation and sepsis (29). Therefore, IL-32 is also seen as an interesting 
target in inducing gastritis caused by H. pylori.  
In contrast to H. pylori infection, IL-32 isoforms (IL-32α, IL-32β, IL-32e and 
IL-32γ) were downregulated upon incubation of gingival fibroblasts with 
Porphyromonas gingivalis. Even when gingival fibroblasts were treated with rhuIL-
32γ proinflammatory cytokines such as IL-8 were downregulated. Moreover, 
P. gingivalis infection can result in severe periodontitis by reducing IL-32 expression 
(30). The data suggest a protective role of IL-32 against inflammation in healthy 
gingival tissue.
IL-32 was discovered to play a role in viral infections including HIV and Hepatitis C 
virus (HCV) infections. Just like in a chronic inflammatory disease such as RA, serum 
IL-32 levels were increased in patients infected with HIV (31). IL-32 was shown to 
induce a Th1 response resulting in an induction of proinflammatory mediators. In 
line with this, it was observed that silencing of IL-32 shifted this Th1 proinflammatory 
response to a more Th2-like response. Which isoforms of IL-32 actually caused these 
effects were not completely clear. However, there is also evidence that IL-32 could 
favor HIV infection by reducing anti-viral immune responses. IL-32 was shown 
in vitro to be capable of inducing immunosuppressive molecules indoleamine 
2,3-dioxygenase (IDO) and Ig-like transcript 4 (ILT4) in PBMCs. In addition, in vivo 
IL-32 was correlated with both IDO and ILT4 and inversely correlated with cell 
proliferation and cytotoxic NK/T cell markers in HIV-1-infected patients (32). 
Therefore, it remains difficult to state what is the exact role of IL-32 in HIV infection. 
For now, it seems to act as a double-edged sword, with on the one hand inducing 
proinflammatory cytokines triggering anti-viral responses, but on the other hand 
controling the immunoregulatory axis to prevent extreme pathology. 
Additional to HIV infections, viral infections caused by HCV, HBV (Hepatitis B virus) 
or influenza A have also been linked to IL-32 expression. Patients suffering from 
chronic HCV showed increased mRNA concentrations of IL-32 and increased liver 
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inflammation and fibrosis. Moreover, when a Huh-7.5 hepatocytic cell line was 
infected with HCV, IL-32 concentrations increased. Interestingly, IL-32 seemed to be 
more associated with liver inflammation and fibrosis than with the control of the 
HCV infection since silencing of IL-32 did not affect HCV virus replication (33). It is 
known that TNFα and IL-1β can induce IL-32 what occurs in hepatoma cells resulting 
in an inflammatory state, which contributes to tissue damage. Furthermore, IL-32 
signals via NF-kB triggering additional proinflammatory mediators. Therefore, it is a 
logical consequence that high levels of IL-32 induced by HCV and also HBV lead to 
liver damage/fibrosis. In addition, IL-32γ and IL-32β can induce apoptosis adding to 
the liver damage after hepatitis B infection (34, 35). 
Influenza A virus is a very contagious virus and affects lung tissue. Li et al. (36) and 
later Bae et al. (37) showed that IL-32 levels were increased in serum of influenza A 
virus-infected individuals. Moreover, when A549 human lung epithelial cells were 
infected with influenza A virus, IL-32 expression was upregulated. In addition, these 
patients showed increased levels of COX2-induced PGE2. The use of COX2 inhibitors 
was able to block PGE2 levels, but also blocked virus-induced IL-32 showing a role for 
COX2 in the regulation of IL-32 expression. Furthermore, IL-32 was shown to exert a 
negative feedback control of COX2-associate PGE2 production (36). In this same cell 
line, influenza A virus induced iNOS consequently resulting in increased nitric oxide 
(NO) production in an IL-32-dependent manner. Interestingly, overexpression of 
iNOS actually led to a decreased amount of IL-32, suggesting that NO can attenuate 
IL-32 production during influenza A virus infection creating another negative 
feedback loop (38). Besides iNOS, NO and IL-32 induction by influenza A virus, the 
expression of IL-6 and soluble IL-6 receptor (sIL-6R) is induced upon infection (39). 
The receptor can be upregulated by its own ligand, IL-6; however, it was also shown 
to be induced by IL-32. Silencing of sIL-6R suppressed the expression of IL-6 and IL-
32 showing that induction of these molecules is dependent on sIL-6R expression. 
Moreover, when adding rhuIL-32γ or establishing overexpression of IL-32γ there 
is an inhibition of sIL-6R expression whereas silencing of IL-32 upregulates sIL-6R 
expression. IL-32 therefore showed to be able to downregulate sIL-6R but at the 
same time induce IL-6 creating a proinflammatory state and showing a critical role 
for sIL-6R in acute inflammatory responses to viral infection (39). Thus, IL-32 serves 
as a proinflammatory mediator in Influenza A virus infection and adds to the so 
called cytokine storm contributing to the disease pathogenesis. Figure 2 sumarizes 
the role of IL-32 as a mediator of inflammation as well as its role favouring the 
immunopathogenesis of intracellular infectious pathogens.      
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Figure 2: IL-32 in inflammation. IL-32 induces the production of inflammatory cytokines, including 
TNFα, IL-8, IL-6 and IFNγ. TNFα leads to the induction of IL-32, once produced, IL-32 can also lead to 
the production of TNFα.  In addition, IL-32 can synergize with NOD1 and NOD2 ligands, resulting 
in IL-6 and IL-1β production through a caspase-1-dependent mechanism. The NOD2 receptor is 
engaged by its ligand MDP, driving the activation of NF-kB via RIPK2 signaling. During infections 
caused by H. pylori, IL-32 by itself can amplify through NF-kB and MAPK activation triggering 
proinflammatory cytokines and chemokines, such as CXCL1 and CXCL2. In infections caused by HIV, 
IL-32 induces a Th1 response. Furthermore, IL-32 is aslo involved in immunosuppression through 
induction of IDO and ILT4 molecules. In HBV and HCV infections, IL-32 signals via NF-kB triggering 
additional proinflammatory mediators leading to fibrosis and apopstosis. Lastly, in infections caused 
by Influenza A virus, IL-32 can control the production of COX2-induced PGE2 by negative feedback 
control. The production of NO is also mediated by IL-32. As a negative control, NO inhibits IL-32 
production. Besides NO, IL-32 also induces IL-6 and sIL-6Rα upon Influenza A infection, which is also 
by negative feedback control. 
The role of IL-32 in host defense 
Control of bacterial infections
First description about IL-32 in bacterial infections came from Netea et al. (20) that 
showed the induction of this cytokine by Mycobacterium tuberculosis (Mtb) and 
M. bovis in human monocytes. Production was dependent on IFNγ after caspase-
1-activated IL-18 release. In line with this, few years later Bai et al. (40) showed 
that IL-32 plays a major role in the control of Mtb infection. This effect was first 
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demonstrated in a human THP-1-macrophage cell line in which IL-32 was silenced. 
Silencing of endogenous IL-32 in these cells resulted in a decreased Mtb-induced 
TNFα, IL-1β and IL-8 production. This decrease in the cytokine production favoured 
the proliferation of Mtb in infected macrophages. Moreover, the treatment of 
Mtb-infected macrophages with rhuIL-32γ caused a decrease in the intracellular 
burden of Mtb. One of the mechanisms involved was the induction of macrophage 
apoptosis by rhuIL-32γ, which was dependent on caspase-3 (40), caspase-1 and 
lysosomal cathepsin-mediated pyroptosis (6). The importance of IL-32 in controlling 
Mtb infection was demonstrated in an experimental model of Mtb infection in 
transgenic mouse for human IL-32γ (IL-32γTg). The results showed that the IL-
32γTg mice presented better survival rates compared to the wild type (WT) mice. 
Furthermore, the number of mycobacteria isolated from alveolar macrophages of 
the IL-32γTg mice was lower than that from WT mice (6). 
In 2014, Montoya et al. (41) have identified IL-32γ as a target gene induced by 
IFNγ in an IL-15-dependent manner in human macrophages infected with Mtb. IL-
32γ up-regulated molecules of the vitamin D antimicrobial pathway, cathelicidin 
and β-defensin 2 (DEFB4), which are anitimicrobial peptides that contribute 
to the macrophage microbicidal activity. Besides, IL-32 gene expression was 
evaluated in patients with latent compared to active tuberculosis, patients with 
tuberculosis undergoing chemotherapy and healthy controls. It was shown that IL-
32 is associated with the latent state but not active disease, suggesting IL-32 as a 
correlate of protection against Mtb infection. These studies highlight IL-32 as a key 
mediator in protecting the host by facilitating apoptosis and pyroptosis, inducing 
antimicrobial peptides and thereby decreasing the survival capacity of Mtb.  
Similarly to Mtb infection, IL-32 expression was studied in patients with M. avium 
infection, where IL-32 was detected in airway epithelial cells and lung granulomas. In 
human monocytes, the presence of IL-32 resulted in a decreased number of intracellular 
mycobacteria in the epithelial cells and macrophages. The anti-mycobacterial effect of 
IL-32 was in part due to the increased apoptosis of the infected cells (42). 
Reinforcing the relevance of IL-32 in controlling infections caused by intracellular 
bacteria, Schenk et al. (43, 44) studied this cytokine in cells from patients with 
leprosy, a disease caused by M. leprae. This disease can be divided in a tuberculoid 
form characterized by Th1 immune responses where the microorganism is 
successfully contained within granulomas and the aggressive lepromatous form, 
which is characterized by Th2 immune responses, bacterial dissemination and 
failure of the host to contain the infection. The authors showed that expression 
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of both NOD2 and IL-32 by DCs was high in patients with the tuberculoid form 
in contrast to the low expression in DCs from patients with the lepromatous 
form. Moreover, NOD2 activation induced IL-32-dependent differentiation of 
monocytes into DCs. These DCs can be distinguished from those differentiated 
with granulocyte-macrophage colony stimulating factor (GM-CSF) by the capacity 
to cross-present antigens via MHC class I molecules to CD8+ T lymphocytes. One of 
the most noteworthy observations was that IL-32 restored the capacity of the NOD2 
activation to induce differentiation of DCs from patients with the lepromatous form. 
These findings provide evidence for the potential use of IL-32 and/or IL-32-derived 
DCs as immunotherapy for human infectious diseases. 
Recently, aiming to identify infection-relevant gene expression signatures in non-
tuberculous mycobacterial microorganisms, primary respiratory epithelial cells 
were infected with M. avium or M. abscessuss. Using RNA-seq analysis, the authors 
showed that IL-32 was one of the up-regulated genes among the other cytokine/
chemokine genes in infected cells (45). Collectively, all these studies indicate that 
IL-32 might be one of the targets for therapeutic interventions in infections caused 
by intracellular bacteria such as different mycobaterium species. 
Role in viral infections
The expanding knowledge of IL-32 indicates that it plays a vital role in infections 
caused by viruses as well. High levels of IL-32 were found in serum of patients 
chronically infected with HIV what could be explained by the release of IL-32 
isoforms from apoptotic T cells or secretion of IL-32γ by infected cells. Silencing 
of endogenous IL-32 resulted in increased HIV replication in either HEK293T cells 
or Jurkat T cells, but overexpression of IL-32 did not efficiently decreased viral 
replication (31). Nold et al. (46) further demonstrated in latently HIV-1-infected U1 
macrophages that addition of rhIL32γ reduced viral load via an IFNα-dependent 
pathway. In addition, the authors showed that depletion of IL-32 was related to a 
decrease in Th1 cells and inflammaroty cytokines, which was accompanied by an 
increase of HIV-1 replication.
To further characterize the anti-HIV properties of IL-32, Monteleone et al. (47) 
showed that IL-32 (α and nonα) mRNA levels were higher in PBMCs from HIV-
infected individuals than healthy individuals. Furthermore, IL-32 mRNA levels 
negatively correlated with HIV RNA levels. The authors also demonstrated that the 
treatment of PBMCs with rhuIL-32γ caused an increase in the expression of antiviral 
IFN-induced genes, including myxovirus resistence A (MxA), apolipoprotein B 
mRNA-editing enzyme catalytic APOBEC3G and APOBEC3F. 
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In infections caused by herpes simples virus type 2 (HSV-2) endogenous IL-32 
has been described to be important in preventing cytophatic effects of HSV-2 in 
epithelial cells and therefore limiting viral replication. Antiviral effects are mediated 
by IFNα and MxA production induced by endogenous IL-32. In addition, rhuIL-32γ 
conferred protection to epithelial cells when added before infection. The antiviral 
effects of rhuIL-32γ were partially dependent on IFNα PKR-eIF-2α pathway. It was 
also shown that CD8+ T lymphocytes present in genital mucosa of HSV-2-infected 
patients exhibit high expression of IL-32 associated with viral control (48, 49). 
Recently, Mesquita et al. (50) have shown the effect of IL-32 in viral coinfections. 
PBMCs from patients coinfected with HIV and HSV-2 simultaneously present 
lower levels of IL-32 expression than PBMCs from patients infected only with HIV. 
As treatment of the cells with rhuIL-32γ blocked HIV reactivation the authors 
suggested that HSV-2 infections decreased IL-32 expression, which may contribute 
to an increase of HIV reservoirs. 
Additionally, increased levels of IL-32 were found in serum of patients infected with 
Influenza A virus (18, 36, 37). Li et al. (51) demonstrated the antiviral activity of IL-
32 in influenza A infection. In this study, the antiviral activity of the isoforms α, β, 
d, γ, e and z  of IL-32 was evaluated in human epithelial cells. IL-32γ presented the 
best antiviral effect. These antiviral effects were dependent on NF-kB and CREB 
pathways (51).
IL-32 seems to be important in controlling infections caused by HBV. IL-32 did 
not alter the viral replication in hepatoma cell lines overexpressing IL-32γ or in 
cells treated with rhuIL-32γ after infection with HBV. However, in PBMCs rhuIL-
32γ  induces IFNl1, an antiviral factor, important for controlling HBV replication. 
Moreover, a correlation between high levels of IL-32 and IFNl1 was found in serum 
and liver tissue of patients infected with HBV (52). Figure 3 shows the important role 
of endogenous IL-32 in the control of well-known intracellular pathogens. 
Leishmaniasis: an overview 
Leishmaniasis are vector-borne neglected tropical diseases caused by protozoa 
of the Leishmania genus. These parasites are transmitted to humans by sandflies 
of the genus Lutzomyia in the Americas and Pheblotomus in South-East Asia, East 
Africa, North Africa-Eurasia and Mediterranean basin. Around 1.0 million people 
are annually affected by leishmaniasis around the world and ~30,000 deaths occur 
each year. Leishmaniasis comprise tegumentary (cutaneous (CL)) and mucosal (ML) 
and visceral leishmaniasis (VL), which can be mild, severe or fatal diseases (http://
www.who.int/mediacentre/factsheets/fs375/en/). In the Americas, from southern 
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United States to northern Argentina, American Tegumentary Leishmaniasis (ATL) is 
mainly associated with L. (Viannia) braziliensis, L. (V.) guyanensis, L. (V.) panamensis, 
L. (Leishmania) amazonensis and L. (L.) mexicana. In other parts of the world the 
main species causing tegumentary leishmaniasis are L. (L.) major, L. (L.) aethiopica 
and L. (L.) tropica. For VL, in South America and Mediterranean basin it is caused by 
L. infantum whereas in Asian and African countries it has been associated with L. 
donovani (53).
Figure 3: IL-32 in the control of intracellular infectious pathogens. In case of Mtb infections, 
endogenous IL-32 induces TNFα, IL-1β and IL-8 production. Additionally, IL-32 mediates the induction 
of apoptosis and pyroptosis, which are induced in a caspase-3, cathepsins and caspase-1-dependent 
manner, respectively. In human macrophages infected with Mtb, IL-32 is related with the induction 
of antimicrobial peptides, such as cathelicidin (LL-37) and β-defensin 2. All these mechanisms 
together contribute to the control of infecitons caused by Mtb.  In M. leprae infections, both NOD2 
and IL-32 are important for monocytes differentiation into DCs, which is related with the capacity 
to cross-present antigens to CD8+ T lymphocytes. In infections caused by either M. abscessus or M. 
avium induces IL-32. In M. avium infections, IL-32 increases apoptosis of the infected cells, favouring 
a decrease of intracellular mycobacteria. In HIV infections, IL-32 reduces viral load via IFNα induction. 
In addition, IL-32 is also related to an increase of Th1 cells, inflammatory and antiviral proteins (MxA 
and APOBEC3G/3F, which lead to antiviral activities.  Besides HIV, IL-32 plays a role in the control of 
HSV-2 infections by inducing IFNα and MxA production. In influenza A virus, the antiviral effects are 
dependent on NF-kB and CREB pathways. The control of HBV mediated by IL-32 is dependent of the 
induction of IFNl1. 
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ATL is a skin/mucosal granulomatous disease that manifests as cutaneous localized 
or disseminated ulcers, papules diffusely distributed, mucosal lesions or atypical 
lesions (53-55) . Localized cutaneous leishmaniasis (LCL) is characterized by single 
or multiple ulcers located in expose areas and at the bite of inoculation of the 
parasite. The typical ulcer is painless, of varied size, well delimited with infiltrated 
raised edges (56). Disseminated cutaneous leishmaniasis (DL) is characterized by 
numerous acneiform, papular, nodular and ulcerated skin lesions, distributed in two 
or more body parts (57). Mucosal leishmaniasis (ML) affects nasopharyngeal and 
oral mucosal epithelial barriers, often leading to ulceration and septum perforation 
(53). Diffuse cutaneous leishmaniasis (DCL) is a rare but severe form or the disease 
with multiple non-ulcerated nodular lesions that often affects face, limbs and trunk 
of patients (58). In VL, the clinical manifestation of range from an assymptomatic 
self-resolving phenotype or a progressively severe disorder. The dissemination of 
Leishmania parasites throughout the reticuloendothelial system may be fatal if not 
treated (59). 
Immune response in Leishmania infections
The protozoan Leishmania is a digenetic parasite flagellated form of the parasite, 
called a promastigote, to mammalian hosts, including humans, dogs and rodents. 
Once the promastigotes are injected into the skin via the bite of a sand fly, they 
enter several types of phagocytic cells. Within the phagolysosome of macrophages, 
promastigotes transform to a round non-flagellated replicative form called an 
amastigote (60). Although macrophages are the primary host cell for Leishmania 
parasites, monocytes, dendritic cells (DCs) and neutrophils that are recruited to the 
infection site can become infected and have important and distinct roles in shaping 
the immune response to infection (61, 62).
The Leishmania membrane is composed of complex glycoconjugates identified as: 
small glycoinositolphospholipids (GIPL), lipophosphoglycan (LPG), glycoproteins 
(gp63) and proteophosphoglycans (PPGs). It is noteworthy that the composition 
and size of this molecules can vary not only with species, but also with the 
stage of development of the parasite (63, 64). These molecues are known as the 
main pathogen associated molecular pattern (PAMP) in Leishmania (65). Pattern 
recognition receptors (PRR) are critical for Leishmania parasite recognition by host 
innate immune cells. In case of L. braziliensis (66)  and L. amazonensis (67), their LPG 
can be recognized by Toll-like receptor (TLR) 2 and TLR4, respectively. C-type lectin 
receptors (CLR) dectin-1 and mannose receptor (MMR), complement receptors CR1 
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and CR3, Fc receptors and NLRs receptors have also been reported important for 
Leishmania-host interface (68-70). 
Engagement of Leishmania PAMPs with their corresponding PRRs leads to parasite 
uptake and a cascade of signaling pathways and ultimately to the production 
of cytokines (e.g. TNFα, IL1β, IL-10) (71, 72). Once produced, proinflammatory 
cytokines are important for controlling the Leishmania infection by inducing 
microbicidal molecules, such as reactive oxygen and nitrogen intermediates (ROI, 
RNI), which are crucial for the parasite killing (66, 73). In the other hand, IL-10 acts as 
anti-inflammatory and immunosupressor cytokine (74).  
In addition to the cytokines produced by innate immune cells, IFNγ and 
TNFα produced by Th1 lymphocytes are considered crucial in the initiation of 
protective immunity against Leishmania spp. infections, while IL-4 produced by 
Th2 lymphocytes leads to susceptibility (75). CD8+ cytotoxic T lymphocytes can 
also contribute to IFNγ production in the initial stages of infection. However, 
CD8+ cells-mediated cytotoxicity in tegumentary leishmaniasis can be harmful 
to both Leishmania spp. and infected hosts cells (71, 76). In addition to Th1 cells, 
Th17 lymphocytes produce IL-17A and IL-22 are also likely to be protective in VL 
(77). However, IL-17 mediates macrophage activation and tissue damage in ATL 
(78). In order to balance the immune response, T regulatory cells (T-regs) produce 
regulatory cytokines such as TGF-β and IL-10 that might inhibit tissue damage 
caused by increased inflammatory responses in the infection site (79). 
Importantly, the clinical manifestation of leishmaniasis is dependent upon both the 
parasite species and the host’s immune response. The production of cytokines is 
one the most import events in parasite evolution in human infection because it is 
involved in the lesion development, cure evolution or worsening relapsing forms. 
Although all clinical forms require Th1 responses to cure the disease, an exacerbated 
Th1 and an increased number of CD8+ cells are associate with incresead disease 
severity. By contrast, high number of parasites whitin the lesions of patients is a 
consequence of low levels of Th1 cytokines. Moreover, the release of an excess of 
anti-inflammatory cytokines facilitates parasite growth, and may play an important 
role in the establishment of the infection (60, 74, 76). Figure 4 gives a schematic 
overview of the important players involved in the Leishmania immune response.
28
Figure 4: Overview of the Leishmania immune response. 
Treatment of Leishmaniasis: the challenge 
The treatment of Leishmaniasis patients has been accomplished with the same 
drugs for years, and there is no vaccine to prevent either tegumentary or visceral 
Leishmaniasis (80). The most common treatment is an intramuscular or intravenous 
injection of pentavalent antimonials. This drug is expensive for low and middle-
income countries and requires several injections that are toxic and painful. 
Furthermore, there is emergence of parasite resistance to antimonial drugs. In some 
endemic areas, where the efficacy of pentavalent antimonial is very low it is replaced 
by other more effective drugs such as amphotericin B and miltefosine (81-83). 
Due the lack of an effective strategy to treat patients infected with Leishmania 
spp., alternative methods have been pointed. Attempts to vaccinate individuals 
with whole killed parasites, attenuated live parasites, parasites proteins, subunit 
recombinant vaccines, vectored vaccines and DNA vaccines have had limited 
success (84, 85). Clinical improvement in the treatment of ATL with Bacillus Calmette-
Guérin (BCG), the tuberculosis vaccine, combined with promastigotes antigens of 
Leishmania spp. have been reported previously (86). In addition, it has been shown 
that BCG vaccination in combination with conventional treatment can increase 
circulating NK cells and proinflammatory monocytes, contributing to clinical 
remission of several lesions in a patient with diffuse cutaneous leishmaniasis (DCL) 
caused by L. (L.) amazonensis (87). Similarly, Obaid et al. (88) observed that β-glucan 
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(a cell wall component of Candida albicans) as adjuvant together with Leishmania 
antigens lead to protection against L. (L.) donovani in hamsters. 
Trained innate immunity as a novel treatment 
strategy for the long-term non-specific protection 
against Leishmania spp. infections
Recently, an increasing body of evidence shows that innate immune system has 
adaptive characteristics that involve a heterologous memory of past insults. Both 
experimental models and proof-of-principle clinical trials show that innate immune 
cells, such as monocytes, macrophages and NK-cells can provide protection against 
certain infections in vaccination models independently of lymphocytes (89, 90). 
BCG is known as a classical example, where in addition its specific protective effect 
against tuberculosis, it has been shown to induce protection against secondary 
infections with C. albicans (91), Schistosoma mansoni (92), influenza virus (93) or 
Leishmania spp. infections (87, 94). 
Innate immune cells have the capacity to build a memory of a previous encounter 
with pathogens and thereby develop a increased immunological response upon 
reinfection, for which the term “trained immunity” has been proposed (89). In addition 
to BCG, pathogen associated molecular patterns (PAMPs), such as cell wall component 
β-glucan from Candida albicans, and endogenous stimuli such as oxidized low-density 
lipoprotein (oxLDL) are also known to drive induction of trained immunity (95, 96). 
Sepecifically, it was shown that β-glucan leads to a modulation of the transcriptomic, 
metabolomic and functional properties of the hematopoietic progenitor cascade in 
the bone marrow, in turn generating more myeloid cells with a faster kinetic at the 
expense of the lymphoid lineage (97). Similar studies in mice intravenously injected 
with BCG demonstrated demonstrated the effect of vaccination on remodeling 
myelopoesis, that in turn mediates an improved host defense against mycobacteria 
(98). Since innate immune cells have shown to maintain the innate memory 
phenotype beyond their life-span over a period up to 3 months, these findings 
explain the long-term phenotype detected in trained immunity. 
Mechanistically, the trained phenotype is accompanied by a shift in the intracellular 
metabolism from oxidative phosphorylation towards an increased aerobic glycolysis 
and epigenetic rewiring at the level of histone (99, 100). Recently studies have 
also shown the importance of fatty acids, amino acid metabolism and cholesterol 
synthesis during induction of trained immunity (101, 102). Interestingly, various 
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metabolites generated as a product of these changes in cellular metabolism 
serve as important substrates or cofactors for epigenetic enzymes (writers and 
erasers) linking immunometabolic activation with long-term epigenetic changes 
(103). Modifications of histones can either activate or repress gene transcription, 
depending on the specific lysine residue that is modified and the amount of methyl-
groups that is added. For example, enrichment of trimethylation of lysine 4 residue 
o histone 3 (H3K4me3), H3K4 monomethylation and H3K27 acetylation at the 
promoters and enhancers of proinflammatory cytokines genes have been shown 
to result in increased TNF and IL6 transcription, whereas H3K9me3 H3K27me3 are 
associated with gene repression (91, 95, 104, 105). 
It is likely that trained immunity evolved as a primitive form of immune memory, 
aimed to provied aditional protection of the host against reinfections. However, 
there may also be a bad side to the reprogramming of innate immunity, in which 
increased inflammatory responses towards exogneous or endogenous stimuli 
favouring inflammation and susceptiblity to metabolic and autoinflammatory 
disorders, such as atherosclerosis, gout or diabetes melitus (106). Figure 5, gives an 
overview of the mechanisms underlying the induction of trained innate immunity. 
Figure 5: Overview of the mechanisms underlying the induction of trained innate immunity.
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Aim and general outline of the thesis
This thesis aims to identify novel pathways involved in the host immune response 
against Leishmania parasites and its relations with disease susceptibility and 
clinical outcome. Identification and characterization of these pathways is needed 
in order to identify personalized treatment strategies for leishmaniasis in the near 
future. In addition, the potential treatment options for patients with leishmaniasis 
based on trained immunity is explored. A schematic overview of the thesis is 
shown in figure 6. 
Figure 6: Schematic overview of the thesis. 
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Part I: The role of IL-32 in host defense against 
Leishmania infections 
Chapter 2 demonstrates the role of IL-32 in THP-1-derived macrophages upon 
infections with New World Leishmania species. We investigated whether Leishmania 
spp. can induce splicing of IL-32γ mRNA into IL-32β a less inflammatory isoform. To 
understand the role of IL-32 in Leishmania infections siRNA for IL-32 knockdown or 
plasmids for IL-32 overexpression were applied in a human monocyte/macrophage 
cell line. Furthemore, the importance of IL-32 in induction of microbicidal activity 
and macrophage cell death during infection with L. (V.) braziliensis or L. (L.) 
amazonensis were explored. In Chapter 3, we investigated the expression of IL-32 
in cutaneous lesions of patients infected with L. amazonensis. We explored the role 
of IL-32γ in experimental mouse model for Leishmaniasis caused by L. amazonensis 
and L. braziliensis and its relation with cytokine production. 
Chapter 4 reveals a protective role of IL-32 in an experimental model of Visceral 
Leishmaniasis in mice. We studied whether L. infantum induces IL-32γ expression 
in human PBMCs. Next, we evaluated the role of IL-32γ in control systemic 
infection caused by L. infantum and its relation with granuloma formation in the 
liver, cytokine production and development of T lymphocytes responses during 
experimental visceral Leishmaniasis. 
Chapter 5 identifies genetic variations in IL-32 that influences the host defence 
against New World Leishmania species. We evaluated the functional consequences 
of three different genetic variations in IL32 (rs4786370, rs4349147, rs1555001) for 
innate and adaptive cytokine production. Furthermore, by analyzing a cohort of 
ATL patients and controls, we investigated whether these genetic variations in IL32 
influence the susceptibility to disease and the clinical outcome. The expression of 
important inflammatory mediators in skin lesion fragments from ATL patients was 
correlated with mRNA levels of IL-32 isoforms.  
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Part II: Therapy targets in Leishmaniasis
The second part of this thesis concentrates on possible therapeutic targets which 
could be used for the treatment of patients with Leishmaniasis. In Chapter 6, we 
examined the role of NOD2 receptor in immune responses against L. amazonensis 
and L. braziliensis species. The aim of this study was to assess whether NOD2 was 
involved in innate and adaptive immune response and its role in control infections 
caused by Leishmania spp. 
Chapter 7 shows that β-glucan-induced trained immunity protects against L. 
braziliensis infection with a crucial role for IL-32. We studied  whether the exposure 
of monocytes to β-glucan led to the induction of non-specific protection against 
intracellular infection caused by Leishmania spp. In both human primary cells and a 
murine model of trained immunity, we assessed the effects of β-glucan training in 
monocytes/macrophages. In addition, by assessing genetic variations in IL-1/IL-1R 
and IL-32 genes, we investigated the role of IL-32 and IL-1 signaling for β-glucan-
induced trained immunity. 
In Chapter 8 we showed for the first time that L. braziliensis antigens induces 
rewiring and epigenetic alterations in human monocytes resutling in trained 
immunity. We investigated the effect of antigens of L. braziliensis exposure to primary 
human monocytes by assessing the changes in TNFα production, cellular metabolic 
pathways, and epigenetic enrichment. In addition, non-specific protection to 
secondary infections was examined in vitro as well as in vivo experiments.
Chapter 9 summarizes the findings from each chapter within this thesis and 
gives an outlook to the future and possible applications of the findings presented 
in this thesis. 
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The role of IL-32 in host 
defence against Leishmania 
infections
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Abstract
Background
Interleukin-32 (IL-32) is expressed in lesions of patients with American Tegumentary 
Leishmaniasis (ATL), but its precise role in the disease remains unknown. 
Methodology/Principal Findings
In the present study, silencing and overexpression of IL-32 was performed in 
THP-1-derived macrophages infected with Leishmania (Viannia) braziliensis or 
L. (Leishmania) amazonensis to investigate the role of IL-32 in infection. We report 
that Leishmania species induces IL-32γ, and show that intracellular IL-32γ protein 
production is dependent on endogenous TNFα. Silencing or overexpression of IL-
32 demonstrated that this cytokine is closely related to TNFα and IL-8. Remarkably, 
the infection index was augmented in the absence of IL-32 and decreased in cells 
overexpressing this cytokine. Mechanistically, these effects can be explained by 
nitric oxide cathelicidin and β-defensin 2 production regulated by IL-32. 
Conclusions
Thus, endogenous IL-32 is a crucial cytokine involved in the host defense against 
Leishmania parasites.
45Cytokines and microbicidal molecules regulated by IL-32 in THP-1-derived human
2
Introduction
Interleukin-32 (IL-32) is a predominantly intracellular proinflammatory cytokine 
[1] that can be expressed in nine different isoforms (IL-32α, IL-32β, IL-32γ, IL-32δ, 
IL-32ε, IL-32ζ, IL-32η, IL-32θ and IL-32σ) [2]. This cytokine can induce production 
of tumor necrosis factor alpha (TNFα), IL-8, IL-6, and IL-1β in THP-1 and RAW264.7 
macrophages cell lines [3,4], with IL-32γ being the most active isoform [5]. 
Induction of IL-32α and IL-32γ during Mycobacterium tuberculosis (MTB) infection 
mediates TNFα, IL-6, IL-1β production and macrophage apoptosis that is involved 
in protection against MTB [6,7]. In addition, IL-32/vitamin D/antimicrobial peptides 
axis control MTB infection [8]. IL-32 is associated with strong Th1 immune response, 
controlling M. leprae infection [9]. In viral infections, induction of IL-32 is associated 
with the control of viral replication [10–12], but also with inflammation and tissue 
lesion [13–16]. In protozoan infections, IL-32 has been identified in lesions of 
patients with American Tegumentary Leishmaniasis (ATL) [17].
ATL is a vector-borne disease caused by Leishmania parasites. In general, L. (Viannia) 
braziliensis cause localized cutaneous (LCL) and oral/ nasal mucosal lesions (ML). LCL 
can cure spontaneously or after treatment. By contrast ML does not spontaneously 
heal and recurrence is frequent after treatment. In addition to these clinical forms, 
L. (Leishmania) amazonensis can cause diffuse cutaneous leishmaniasis (DCL), which 
it is not cured even after treatment [18–20]. A moderate or strong Th1 response is 
present in infections caused by L. (V.) braziliensis whereas patients infected with 
L. (L.) amazonensis present a less potent Th1-type response or can be anergic [21]. 
The strong Th1-type immune response is important for controlling the infection 
but also causes inflammation and pathology [22,23]. Th1-type cytokines (IFNγ 
and TNFα)  activate infected monocytes or macrophages to secrete microbicidal 
molecules such as oxygen and nitrogen reactive species, which are crucial for the 
parasite killing [24–28]. During Leishmania infection, macrophages can produce 
proinflammatory cytokines (TNFα, IL-1β, IL-8) and regulatory (IL-10, IL-1Ra) 
molecules [29–31]. Thus a balance between pro- and anti-inflammatory mediators 
during the immune responses is critical to control inflammatory diseases [32,33]. 
The mechanisms responsible for persistence of the parasite and immunopathology 
of leishmaniasis remain unclear. We previously reported that IL-32γ is expressed 
in cutaneous and mucosal lesions of patients with ATL caused by Leishmania 
(Viannia) species and also that L. (V.) braziliensis induces IL-32γ in peripheral blood 
mononuclear cells (PBMC) [17]. Here, we investigated whether distinct isoforms of 
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IL-32 can be induced by L. (V.) braziliensis and L. (L.) amazonensis, and whether IL-
32 can regulate cytokine and microbicidal activity of human macrophages infected 
with these two New World Leishmania species. 
Methods
THP-1 cell line and Leishmania cultures 
THP-1 cell line was obtained from ATCC (Manassas, VA). Cells were cultured in RPMI-
1640 medium (Gibco - Life Technologies) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS; Gibco - Life Technologies), 10 mM of pyruvate, 10 mM 
L-glutamine, 100 U/mL of penicillin and 100 μg/mL streptomycin (Sigma - Aldrich). 
L. (L.) amazonensis (IFLA/BR/67/PH8) reference strain and MHOM/BR/2003/IMG 
L. (V.) braziliensis, a clinical isolate obtained from cutaneous lesion of LCL patient 
(Leishbank IPTSP/UFG) [34], were used. Promastigotes forms were cultured in 
Grace’s Insect Medium, (Gibco - Life Technologies) supplemented with heat-
inactivated 20% FBS (Sigma - Aldrich) and 100 U/mL of penicillin/streptomycin 
(Sigma - Aldrich) at 26 °C. Parasites of L. (L.) amazonensis from stationary phase 
(6th - 7th day) of growth were used to infect macrophages derived from THP-1 cells. 
For L. (V.) braziliensis, parasites were collected from stationary phase (6th - 7th day) 
of growth and metacyclic promastigotes were negatively selected using Bauhinia 
purpurea lectin according to the protocol described by [35]. Parasites were washed 
three times with sterile phosphate-buffered saline (PBS) pH 7.4 (1,000 g, 10 min, 
10 ºC). The suspensions were diluted into 0.4% formaldehyde in PBS for parasite 
quantification by hemocytometer.
THP-1-derived macrophages and stimulation
A previously described protocol [36] was used for THP-1 cell differentiation into 
macrophages with some alterations. According to the type of experiment, cell 
numbers were adapted to cultures with or without cover slides. Briefly, cells were 
cultured with phorbol myristate acetate (PMA, Sigma-Aldrich) at 100 ng/mL. After 
48 h (37°C, 5% CO2), cells were gently washed with warm medium and incubated 
for an additional 48 h. Medium was replenished and cells were incubated for a 
further 24 h. Parasites (at multiplicity of infection (MOI) ~ 5:1) of both Leishmania 
species were added into the THP-1-derived macrophage cultures and 100 ng/mL of 
E. coli LPS (O111:B4 Sigma-Aldrich) was used as a control. This commercial LPS was 
further purified based on [37]. In some experiments, THP-1-derived macrophages 
were preincubated for 1 h in the absence or presence of neutralizing antibodies to 
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TNFα (5 μg/mL, Adalimumab) or IgG control (5 μg/mL). After 4 h, non-internalized 
parasites were washed out, medium was replaced and cultures were incubated for 
indicated times. 
Confocal microscopy 
After THP-1-derived macrophage infection (2 x 105 cells/0.5 mL, grown 
over coverslips in 24-wells plates; MOI: 5:1; 24 h), cells were fixed with 4% 
paraformaldehyde and blocked/permeabilized with 0.1% saponin, 10% FBS, 5% 
goat serum and 5% human serum solution (block solution). Primary antibodies to 
IL-32 (rabbit polyclonal antibody 5 μg/mL; Abcam;) and to LAMP1 (mouse H4B4, 
IgG1; 1/2 culture supernatants; to identify lysosomal proteins and parasitophorous 
vacuoles); secondary antibodies - Alexa Fluor 594 goat anti-rabbit IgG (H+L), 1/200, 
to detect IL-32 (Molecular Probes) and anti-mouse IgG (whole molecule) F(ab)´2 
fragment of sheep antibody-Cy3 conjugate, 1/200, to detect LAMP2 (Sigma-Aldrich); 
and control antibodies were all in block solution. A solution of 4´,6-diamidino-2-
phenylindole (DAPI; 10 μg/mL; Invitrogen, Life Technologies) was used to stain 
nucleus/DNA, and fluorescent mounting medium (Dako) was used to prepare the 
coverslips for confocal microscopy. Images were acquired in a Leica TCS SP5 II 
confocal microscope. 
Silencing and overexpression of IL-32 by siRNA or plasmid 
THP-1 cells (15 x 106 cells/15 mL) were differentiated into macrophages (75 cm2 - 
tissue culture flask; Corner) for 5 days, as described above. 2.5 x 106 cells/800 µL were 
electroporated by using Amaxa Nucleofector technology (Lonza, Basel) according 
with the protocol described in reference [38]. For knockdown of IL-32, 1 μg of ON-
TARGETplus SMARTpool siRNA (S1 Table) per transfection was used or 1 μg of ON-
TARGETplus SMARTpool control siRNA (Dharmacon Inc). For IL-32 overexpression, 
0.5 μg of pCDNA3 plasmid expressing human IL-32γ  or egfp was used as a control. 
Transfected cells (3 x 105/100 µL) were plated on to flat-bottom 96-well plates 
(Costar) with or without 6 mm coverslips and 100 µL of transfection medium were 
added. Twenty-four hours post-transfection, the medium was replaced and 1.5 x 106 
parasites of either Leishmania species were added to the cultures. After 4 h and 24 h, 
supernatants were collected and stored at -20°C until cytokine measurement; after 
4 h, 24 h or 48 h the cell monolayers were collected by adding 200 µL of TRIzol and 
stored at -80 °C until mRNA extraction. After incubation, coverslips were collected 
to measure macrophage infection index. We performed comparable experiments to 
determine transfection (egfp) efficiency and this was around 30%. It is important 
to notice that according to the protocol used for silencing and overexpression [38], 
the general protocol described above needed alterations. After derivation with 
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PMA, cells were transfected and they rested 24 h in medium containing 5% and 
20% of human serum for silencing and overexpression, respectively. In addition, to 
keep cells adhered additional PMA was added to the cultures (2.5 ng/mL). Thus, the 
results are comparable among them only in each set of experiments in the same 
conditions (WT cells vs transfected cells). 
mRNA expression by quantitative real-time PCR (qPCR) 
RNA isolation was carried out based on the method reported by [39]. RNA 
was precipitated with isopropanol and washed with 75% ethanol followed by 
reconstitution in RNAse-free water. Subsequently, RNA was reverse transcribed into 
cDNA by using iScript (Bio-Rad, Hercules, CA, USA). Diluted cDNA was used for qPCR 
analysisys that was done by using the StepOnePlus sequence detection systems 
(Applied Biosystems, Foster City, CA, USA) with SYBR Green Mastermix (Applied 
Biosystems). Primer sequences (S2 Table) for IL-32 were previously developed by 
[3,40] whereas other primer sequences (TNFα, IL-1β, IL-8, IL-1Ra, IL-10, inducible 
nitric oxide synthase [iNOS], cathelicidin) were obtained from Harvard Primerbank 
database. Primers were purchased from Biolegio. The mRNA analysis was done with 
the 2^dCt x 1000 method and normalized against the housekeeping gene GAPDH. 
Assessment of Leishmania-induced mediators
Human TNFα, IL-8, IL-1β, IL1-Ra, IL-10 and LL-37 (cathelicidin) were determined in 
culture supernatants using commercial Enzyme-Linked Immunosorbent Assay 
(ELISA) kits (Sanquin, R&D Systems and Hycult biotech). Intracellular IL-32 protein 
was measured in cell lysates collected with Triton-X100 by using an IL-32 ELISA (R&D 
Systems). Nitric Oxide (NO) production was determined in culture supernatants 
with Griess reagent to detect nitrite (Sigma-Aldrich). Cell death was monitored by 
measuring the release of lactate dehydrogenase (LDH) in the supernatants by using 
a Cytotox 96 kit (Promega).
Evaluation of Macrophage infection 
After incubation, the coverslips were collected, fixed and stained with Giemsa 
(Merck Millipore) and analyzed under a light microscope (1000x) to determine 
the infection index. Three hundred cells were analysed and the percentage of 
infected cells and the mean number of intracellular parasites per infected cell 
were determined. Infection index = percentage of infected cells × mean number of 
parasites per infected cell. 
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Statistical Analysis 
Data represent mean ± SEM (standard error of the mean). All data were evaluated by 
OneWay ANOVA/Bonferroni test using GraphPad Prism v.6 software (San Diego, CA, 
USA). Level of significance was established at p < 0.05.
Results 
Leishmania-induced intracellular IL-32γ production is dependent on 
TNFα
We detected a significant induction of IL-32γ, but not IL-32β or IL-32α for both L. (L.) 
amazonensis or L. (V.) braziliensis infection (24 h; Fig 1A). L. (L.) amazonensis induced 
higher IL-32γ expression than L. (V.) braziliensis (Fig 1A). IL-32γ time course showed 
that IL-32γ mRNA started to increase after 4 h and achieved a peak at 24 h (S1A Fig 
- left panel). It is known that IL-32γ mRNA can be spliced into IL-32β and IL-32α [3]. 
Here we showed that in THP-1 cultures Leishmania, in contrast to LPS, only induced 
IL-32γ (Fig 1A and S1A Fig – right panel). The intracellular IL-32 protein levels (Fig 
1B), paralleling changes in mRNA expression, were higher in L. (L.) amazonensis than 
in L. (V.) braziliensis-infected macrophages. 
Both L. (L.) amazonensis and L. (V.) braziliensis induced significant amounts of TNFα, 
IL-8, IL-1Ra and IL-10. Time course production of these cytokines showed that 24 
h was the best cutoff point to establish relationship between these cytokines and 
IL-32 production (S2 Fig). TNFα levels were increased after 24 h of infection with 
both species (Fig 1C) and were higher than TNFα produced after 4 h, whereas LPS–
induced TNFα production declined from 4 h to 24 h (S1B Fig). Remarkably, only L. 
(V.) braziliensis induced a major increase in IL-1β production. L. (L.) amazonensis 
induced considerably higher levels of TNFα, IL-1Ra and IL-10 than L. (V.) braziliensis 
(Fig 1C). 
Since Leishmania-induced IL-32 and TNFα showed similar time course production 
(increase from 4 h to 24 h), to explore the influence of Leishmania-induced TNFα 
in the production of IL-32, TNFα was efficiently blocked using specific antibodies 
during Leishmania species infection (Fig 1D, left panel), leading to a significant 
reduction in intracellular IL-32 production (Fig 1D, right panel). Comparable results 
were obtained when LPS was used to induce TNFα (Fig 1D, left panel) and IL-32 
(Fig 1D, right panel). Increased intracellular IL-32γ concentrations are associated 
with cell death [41]. However we observed LDH concentrations remained stable 
following Leishmania infection (S1C Fig).
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Figure 1. Leishmania induces IL-32γ expression in a TNFα-dependent manner. PMA-differentiated 
THP-1 cells (1 x 106 cells/mL) were infected with promastigote forms (5 x 106 parasites) in the growth 
stationary phase of L. (L.) amazonensis (L. amaz), metacyclic promastigote forms (5 x 106 parasites) of 
L. (V.) braziliensis (L. braz) or LPS (100 ng/mL) as a positive control during 4 h. Cells were washed to 
remove non-internalized parasites and incubated for 24 h. (A), mRNA expression of isoforms α, β and 
γ of IL-32 was determined by quantitative real-time PCR. (B), Intracellular IL-32 protein levels were 
determined by ELISA in cell lysates. (C), TNFα, IL-8, IL-1β, IL-1Ra, IL-10 productions were determined 
by ELISA in culture supernatants. (D), Antibodies to TNFα (anti-TNFα, 5 μg/ml) or isotype control 
(5 μg/mL) were added 30 min before addition of LPS (100 ng/mL) or Leishmania sp. TNFα levels (left 
panel) and intracellular IL-32 (right panel) were determined by ELISA in supernatants and cell lysates, 
respectively. Values are expressed as means ± SEM of three independent experiments. *p < 0.05 
(Medium vs LPS, L. amaz, L. braz); #p < 0.05 (L. amaz, L. braz).
Next we investigated the cellular distribution of IL-32 after Leishmania species 
infection. In Fig. 2A is depicted general staining for IL-32 in uninfected or Leishmania-
infected cells. As showed in Fig. 2B IL-32 localizes to both the cytoplasm and nucleus 
of macrophages. In some preparations, IL-32 co-localized with lysosomes, however co-
localization with Leishmania containing parasitophorous vacuoles was rare (Fig. 2C).
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Figure 2. Intracellular distribution of IL-32 after Leishmania species infection.  PMA-
differentiated THP-1 cells (2 x 105 cells/0.5 mL) were infected with promastigote forms (10 x 105 
parasites) in stationary phase of growth of L. (L.) amazonensis or metacyclic promastigote forms 
(10 x 105 parasites) of L. (V.) braziliensis during 4 h. Afterwards, cells were washed to remove non-
internalized parasites and incubated for 24 h. Cells were stained for IL-32 (rabbit polyclonal antibody; 
red), lysosomal-associated membrane protein, LAMP1 (mouse monoclonal antibody; green) and 
dapi (blue) for confocal microscopy. Yellow colour indicates colocalization of IL-32 and LAMP1. In 
(A), in the eight first images, bar = 20 μm; two inferior images, bar = 10 μm (L. (V.) braziliensis). (B), 
L. (L.) amazonensis, white arrow heads indicate parasites present in LAMP1+-parasitophorous 
vacuoles; bar = 10 μm; (C), L. (V.) braziliensis, white arrow heads indicate colocalization of IL-32 and 
LAMP1 in a LAMP1+-parasitophorous vacuole containing one amastigote (blue), bar = 1 μm; images 
were took from (A) (left bottom, dashed white squares).
52
Figure 3. Decrease of cytokine production after IL-32 silencing in THP-1-derived macrophages 
infected with Leishmania species. PMA-differentiated THP-1 cells (2.5 x 106 cells/800 µL) were 
electroporated by using Amaxa Nucleofector Technology with IL-32 siRNA (for IL-32 knockdown) 
and control siRNA according to the protocol described in [38]. The final concentration per well was 
3 x 105 cells/100 µL. After 24 h of transfection, cells were infected with promastigote forms (1.5 x 106 
parasites) in the growth stationary phase of L. (L.) amazonensis (L. amaz) or metacyclic promastigote 
forms (1.5 x 106 parasites) of L. (V.) braziliensis (L. braz). After 4 h, non-internalized parasites were 
washed out and cells were incubated for 24 h. (A), mRNA expression of IL-32γ isoform and all 
isoforms were determined by quantitative real-time PCR. mRNA expression and protein levels of 
TNFα and IL-8, (B); IL-1β and IL-1Ra, (C); and IL-10, (D) were determined by quantitative real-time PCR 
and ELISA in supernatants, respectively. Values are expressed as means ± SEM of three independent 
experiments. *p < 0.05 (Control SiRNA vs IL-32 SiRNA); #p < 0.05 (L. amaz, L. braz). 
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Silencing or overexpression shows that IL-32γ regulates cytokine 
production induced by Leishmania species. 
We investigated whether endogenous IL-32 is directly involved in the enhanced 
production of pro- and anti-inflammatory cytokines observed after Leishmania 
infection. To verify whether the transfection procedure may interfere in the capacity 
of THP-1-derived macrophages to produce cytokines, cells without transfection (WT 
THP-1) were also investigated. IL-32 mRNA expression (all IL-32 isoforms and IL-32γ) 
was silenced by RNA interference (Fig 3A). Silencing of endogenous IL-32γ decreased 
TNFα mRNA expression at 24 h (p < 0.05), but not TNFα protein levels (Fig 3B). In 
addition, after 4 h neither the TNFα mRNA nor the protein was significantly affected 
by silencing of IL-32 (S3A Fig). Both IL-8 mRNA and IL-8 protein were strongly 
reduced after infection with either Leishmania species when IL-32 was silenced (Fig 
3B). Interestingly, when IL-32 expression was silenced, the levels of induced IL-1β 
and IL-1Ra mRNA and protein expression induced by L. (V.) braziliensis were not 
altered (Fig 3C).  By contrast, IL-1Ra mRNA and IL-1Ra protein were decreased after 
infection with L. (L.) amazonensis and silencing of IL-32 (Fig 3C). No differences were 
observed for IL-10 mRNA expression and protein production for both Leishmania 
species in IL-32 knockdown cells (Fig 3D). 
Overexpression of IL-32γ (Fig 4A) resulted in significant increases in TNFα and IL-8 
mRNA expression and protein production after infection with either Leishmania 
species in comparison with egfp transfected control cells (Fig 4B). The presence of 
high levels of IL-32γ caused an impressive increase of TNFα mRNA fast after 4 h of 
incubation without significant alteration in protein levels (S3C Fig). In accordance 
with IL-32γ silencing results, no differences in IL-1β levels were observed whereas 
increased IL-1Ra mRNA and protein expression was detected only after infection 
with L. (L.) amazonensis (Fig 4C). No differences were found between the two 
Leishmania species on IL-10 mRNA expression and proteins levels (Fig 4D). 
IL-32γ regulates nitric oxide and cathelicidin production, microbicidal 
molecules that can control Leishmania species infection
To examine if endogenous IL-32γ controls Leismania species infection, IL-32 was 
silenced in THP-1-derived macrophages prior to infection. To verify whether 
the transfection procedure may interfere with the capacity of THP-1-derived 
macrophages uptake of Leishmania, cells without transfection (WT THP-1) were also 
investigated. A significant increase in the percentage of macrophages infected with 
either L. (L.) amazonensis or L. (V.) braziliensis was observed after 4 h, 24 h and 48 h 
in the absence of IL-32 (Figs 5A and 5B). However, no differences were observed in 
the number of parasites per infected cell (Figs 5A and 5B). The infection index with 
54
both Leishmania species (4 h; 24 h) was increased in IL-32 knockdown cells (Figs 
5A and 5B). Because silencing of IL-32 is a transitory process, we checked for IL-32 
expression 48 h after infection. Indeed IL-32 silencing was reversed at this time (S4 
Fig), potentially explaining the results at this time point of infection. 
Figure 4. Increased cytokine production after overexpression of IL-32 in human THP-1-derived 
macrophages infected with Leishmania species. PMA-differentiated THP-1 cells (2.5 x 106 cells/800 
µL) were electroporated by using Amaxa Nucleofector Technology with IL-32 plasmid (for IL-32 
overexpression) and egfp plasmid (as a control) according to the protocol described in [38]. The 
final concentration per well was 3 x 105 cells/100 µL. After 24 h of transfection, cells were infected 
with promastigote forms (1.5 x 106 parasites) in the growth stationary phase of L. (L.) amazonensis 
(L. amaz), metacyclic promastigote forms (1.5 x 106 parasites) of L. (V.) braziliensis (L. braz). After 4 
h cells were washed and incubated for 24 h. A, mRNA expression of IL-32γ isoform and all IL-32 
isoforms was determined by quantitative real-time PCR. mRNA expression and protein levels of 
TNFα and IL-8 (B),  IL-1β and IL-1Ra (C), and IL-10 (D) were determined by quantitative real-time PCR 
and ELISA in supernatants, respectively. Values are expressed as means ± SEM of three independent 
experiments. *p < 0.05 (egpf plasmid vs IL-32γ plasmid); #p < 0.05 (L. amaz, L. braz).
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Fig 5C shows a significant decrease of iNOS and nitrite production after 24 h of 
infection with both Leishmania species in cells silenced for IL-32 compared to 
control cells. In addition, cathelicidin and β-defensin 2 mRNA expression as well as 
antimicrobial peptide LL-37 concentration were strongly reduced in THP-1-derived 
macrophages depleted of IL-32 (Fig 5D and 5E). 
Figure 5. Silencing of IL-32 in human THP-1-derived macrophages increases Leishmania species 
infection. PMA-differentiated THP-1 cells (2.5 x 106 cells/800 µL) were electroporated by using Amaxa 
Nucleofector Technology with IL-32 siRNA (for knockdown IL-32) and control siRNA according with 
protocol described by [38]. The final concentration of cells per well were 3 x 105 cells/100 µL. After 
24 h of transfection, cells were infected with promastigotes forms (1.5 x 106 parasites) in the growth 
stationary phase of L. (L.) amazonensis (L. amaz), metacyclic promastigote forms (1.5 x 106 parasites) 
of L.(V.) braziliensis (L. braz). After 4 h, cells were washed to remove non-internalized parasites and 
incubated for 24 h or 48 h. Cells were stained and percentage of infected macrophages, number of 
parasites per infected cells, and infection index were evaluated. In A, infection with L. amazonensis; 
B, infection with L. braziliensis. iNOS (C - left panel), cathelidicin (D - left panel) and β-defensin 2 (E) 
mRNA expression were determined by quantitative real-time PCR (24 h). Production of nitrite (C - 
right panel) and LL-37 (D - right panel) was determined by Griess reagent and ELISA in supernatants, 
respectively (24 h). Values are expressed as means ± SEM of three independent experiments. *p < 
0.05 (Control SiRNA vs IL-32 SiRNA).
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Figure 6. Decreased Leishmania species infection and increased leishmanicidal molecules after IL-
32 overexpression in human THP-1-derived macrophages. PMA-differentiated THP-1 cells (2.5 x 106 
cells/800 µL) were electroporated by using Amaxa Nucleofector Technology with IL-32 plasmid (for 
IL-32 overexpression) and egfp plasmid (as a control)(32). The final concentration of cells per well 
were 3 x 105 cells/100 µL. After 24 h of transfection, cells were infected with promastigote forms 
(1.5 x 106 parasites) in the growth stationary phase of L. (L.) amazonensis (L. amaz) or metacyclic 
promastigote forms (1.5 x 106 parasites) of L. (V.) braziliensis (L. braz). After 4 h, non-internalized 
parasites were washed out and cells were incubated for 24 h or 48 h. Cells were stained and 
percentage of infected macrophages, number of parasites per infected cells, and infection index 
were evaluated. A, L. amazonensis; B, and L. braziliensis. iNOS (C - left panel) and cathelidicin (D - left 
panel) and β-defensin 2 (E) mRNA expression were determined by quantitative real-time PCR (24 h). 
Nitrite production (C - right panel) and LL-37 production (D – right panel) were determined by Griess 
reagent and ELISA in supernatants, respectively (24 h). Values are expressed as means ± SEM of three 
independent experiments. *p < 0.05 (egpf plasmid vs IL-32γ plasmid).
In IL-32γ overexpressing cells, we observed a significant decrease in the percentage 
of infected cells and infection index after 4 h and 24 h with both L. (L.) amazonensis 
and L. (V.) braziliensis (Figs 6A and 6B). No differences were observed in the 
number of parasites per L. (L.) amazonensis-infected cell. In contrast, a reduction 
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in the number of L. (V.) braziliensis parasites per infected cell after 4 h of infection 
was detected in IL-32γ-overexpressing cells (Fig 6B). In parallel, we observed a 
significant increase of iNOS mRNA expression and nitrite production after 24 h of 
infection with both Leishmania species in IL-32γ-transfected cells (Fig 6C). Moreover 
cathelicidin and β-defensin 2 mRNA expression as well as LL-37 peptide production 
were strongly increased when IL-32γ was overexpressed, especially in infection with 
L. (V.) braziliensis (Fig 6D and 6E).
Discussion
The present study demonstrates the important role that endogenous IL-32γ plays 
in regulating cytokines and microbicidal molecules induced by L. (L.) amazonensis 
or L. (V.) braziliensis in THP-1-derived macrophages. Only IL-32γ mRNA was induced 
by parasites while splicing of IL-32γ into IL-32β and IL-32α was observed after LPS 
stimulation. In fact, these data are in accordance with previous results for LPS [7,42] 
and with our study showing that only IL-32γ can be detected in cutaneous and 
mucosal lesions of patients infected with L. (Viannia) species and in PBMCs cultured 
with L. (V.) braziliensis amastigotes [17]. 
Here, results indicate that L. (L.) amazonensis induces higher levels of IL-32γ mRNA 
and IL-32 protein than L. (V.) braziliensis. IL-32 is intracellularly expressed, as detected 
in cell lysates and confocal microscopy. It has been demonstrated that IL-32β can 
be driven towards cell membrane in U937 human monocytic cell line during cell 
activation [43]. In our hands, no specific IL-32 cell localization was detected in THP-
1-derived macrophages during Leishmania species infection and it is not localized 
to parasite vacuoles in order to exert its biological functions.   
In this study, TNFα production was higher in macrophages infected with L. 
(L.) amazonenis than L. (V.) braziliensis. This result could not be ascribed to LPS 
contamination (S5 Fig). Further, production of chemokine IL-8 was increased by both 
Leishmania species. We were unable to detect IL-1β production in L. (L.) amazonenis-
infected THP-1 macrophages. In accordance, Shio et al. [44] demonstrated that L. (L.) 
mexicana, another species belonging to the same subgenus of L. (L.) amazonensis, 
has the ability to inhibit NLRP3 inflammasome activation and subsequently 
reduces IL-1β  secretion in PMA-differentiated THP-1 cells. In addition, in mouse 
macrophages IL-1β is not induced by L. (L.) amazonensis; however, in vivo IL-1β is 
important to murine infection control [29].  In contrast to L. (L.) amazonensis, the 
present study showed that besides TNFα induction, L. (V.) braziliensis induced IL-1β 
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and induced lower levels of IL-1Ra and IL-10 than L. (L.) amazonensis. This suggested 
a trend to more inflammatory profile in L. (V.) braziliensis than in L. (L.) amazonensis 
infection. The production of higher amounts of IL-1Ra and IL-10 in L. (L.) amazonensis-
infected macrophages could contribute to balancing the inflammatory process. It is 
known that macrophage has the ability to produce inflammatory cytokines that is 
accompanied by an anti-inflammatory cytokine profile contributing to homeostasis 
of the immune response [45]. In the case of Leishmania infection the suppression 
of immune response can also lead to less inflammatory lesions or even to an 
anergic state in patients with severe cases of DCL caused by L. (L.) amazonensis. Less 
inflammatory properties of L. (L.) amazonensis in comparison with L. (V.) braziliensis 
have been described in mice [46] and human beings [21]. Thus, although in in 
vitro model presented here, L. (L.) amazonensis induced higher levels of IL-32γ and 
TNFα than L. (V.) braziliensis in human macrophages, the higher production of IL-10 
and IL-1Ra induced by L. (L.) amazonensis can be responsible by further control of 
inflammatory process and immunosuppression in in vivo infections caused by this 
species. Nevertheless, we did not perform experiments to evaluate whether IL-10 
or IL-1Ra can suppress the production of IL-32γ or TNFα induced by Leishmania. In 
fact, there is no report about the control of IL-32 production by anti-inflammatory 
cytokines. This point remains to be investigated. 
One important point to be addressed is that, as reported above [21,47,48], it 
has been described that L. (V.) braziliensis tends to lead a T-cell hypersensitivity 
pole (strong production of IFNγ and TNFα) in patients with ML whereas L. (L.) 
amazonensis can lead to a T-cell hyposensitivity pole in patients with diffuse 
cutaneous leishmaniasis. However, both species can cause localized cutaneous 
leishmaniasis without clinical differences in lesions or immune responses [21] and 
there is no report about simultaneous comparison between cytokine productions 
by human macrophages infected with these two species. In human monocytes/
macrophages from healthy donors the TNFα production after stimulation with L. 
(V.) braziliensis is low unless IFNγ has been added [49,50]. In mouse models, L. (L.) 
braziliensis is more inflammatory than L. (L.) amazonensis [47,51], but lesions caused 
by this latter species are bigger than those caused by L. (V.) braziliensis  [46,52]. In 
addition, in mice L. (V.) braziliensis did not cause ML. Thus, it could be a surprise that 
L. (L.) amazonensis is inducing higher production of IL-32γ and TNFα in human THP-
1 macrophages than L. (V.) braziliensis, but this could depend on the macrophage 
origin or activation status. It is noteworthy that human beings have IL-32 while mice 
lack this gene what can generate different responses when comparing macrophages 
from humans or mice. 
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Previously, we had demonstrated [53] that TNFα is a potent inducer of IL-32 in human 
synovial fibroblasts. Indeed, we now show that IL-32 protein production induced by 
Leishmania species and by LPS is also dependent on TNFα. On the other hand, IL-32γ 
upregulates the production of proinflammatory cytokines such as TNFα, IL-1β and 
IL-8 [3]. We then reasoned that IL-32γ could be responsible for cytokine regulation 
during Leishmania sp infection. Heinhuis et al. [41] demonstrated that IL-32γ is 
involved in cell death processes, and for this reason the influence of overexpression 
of IL-32 in THP-1 cells was evaluated only for 24 h, since after this time point, the 
increase of IL-32 inside the cells can lead to the cell death. After infection with both 
Leishmania species, TNFα and IL-8 were down regulated in THP-1 cells depleted of 
IL-32γ while overexpression of IL-32γ caused a strong increase in the production of 
these cytokines. The high levels of TNFα induced after IL-32γ overexpression in L. (L.) 
amazonensis infection are particularly noteworthy. Data from silencing (no effects on 
mRNA TNFα levels after 4 h) and from overexpression of IL-32 (increase of mRNA TNFα) 
suggest that the amount of IL-32γ can be a critical factor to increase transcription of 
TNFα. TNFα induction capacity was one of the first properties described for IL-32 [4]. 
Moreover, IL-32γ overexpression in THP-1 cells causes an increase in TNFα, IL-6 and 
IL-8 production [53] in accordance with our results. Heinhuis et al. [53] demonstrated 
that in cells overexpressing intracellular IL-32γ there is an enhanced TNFα mRNA 
stability, which explains higher TNFα levels than in control cells. In fact, IL-32γ seems 
to be required to control TNFα mRNA stability since in our hands silencing of IL-32γ 
decreased TNFα mRNA (24 h) whereas after overexpression of IL-32γ both TNFα mRNA 
(4 h) and TNFα protein were increased (24 h) in comparison to control cells. These data 
further suggest that IL-32γ can influence post-transcriptional mechanisms to increase 
TNFα during Leishmania species infection. We have previously reported increased 
expression of TNFα in lesions of ML patients infected with L. (Viannia) species and 
described a positive correlation between levels of TNFα and IL-32 [17], which is in 
agreement with these current data. 
L. (V.) braziliensis-induced IL-1β and IL-1Ra as well as IL-10 induced by both Leishmania 
species were not affected by the up or down regulation of IL-32γ.  That IL-32γ had 
no effect on IL-1β production was unexpected since silencing of IL-32 in THP-1 cells 
reduced TNFα, IL-8 and IL-1β after infection with MTB [6]. The negative regulator of 
IL-1β, IL-1Ra was induced by L. (V.) brazilienis, however this induction was not affected 
by IL-32γ levels, thus suggesting that IL-32γ is dispensable for IL-1β production but 
can enhance the effects of IL-1β during L. (V.) braziliensis infection. By contrast, L. 
(L.) amazonensis does not induce IL-1β and the induction of IL-1Ra by this parasite 
species was upregulated by IL-32γ, suggesting that if IL-1β is induced in vivo it can be 
controlled by IL-1Ra in an IL-32γ-dependent manner. In accordance, the induction of 
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IL-1Ra by IL-32γ was described in PBMCs [45] and our data suggest that Leishmania 
parasites can partially subvert IL-32γ pro-inflammatory property by increasing IL-1Ra. 
Infected THP-1-derived macrophages inhibit Leishmania species growth but do not 
eliminate them, at least until 48 h of culture. Cells depleted of IL-32 exhibited an 
increase in macrophage infection index after Leishmania species infection, which was 
reversed when IL-32γ was overexpressed. These effects were related to alterations in 
the percentage of infected cells and not to the number of parasites per cell.  These 
results suggested that IL-32 is important to control infections caused by L. (L.) 
amazonensis and L. (V.) braziliensis in human macrophages. Therefore, we evaluated 
microbicidal molecules known to be involved in Leishmania control [30,54,55] 
as possible targets of IL-32γ. Our data demonstrate that IL-32γ is linked with the 
induction of iNOS, cathelicidin and β-defensin 2 expression and consequently NO, 
LL-37 peptide, and β-defensin 2 release during Leishmania species infection. These 
molecules were induced by IL-32 in influenza virus [48] and MTB infection [8]. 
NO is a classical leishmanicidal molecule in mouse macrophages [30] but human 
macrophages produce low levels of NO. Nevertheless, in some reports this was 
enough to contribute for Leishmania killing [56–58]. Cathelicidin plays a role in the 
control of lesions caused by L. (L.) amazonensis and prevents parasite dissemination 
in mice [59]. Thus, while in mice NO and cathelicidin are important molecules for anti-
Leishmania macrophage activity in the absence of IL-32, in human cells anti-microbial 
peptides dependent on IL-32γ can contribute to control Leishmania infection. 
In our experiments, low levels of microbicidal molecules were detected in uninfected 
macrophages, which decreased after IL-32 silencing (Fig. 5). These results suggested 
that PMA used to differentiate THP-1 cells into macrophages can induce low levels of 
IL-32 that, in turn, contribute to induction of iNOS/NO and antimicrobial peptides. In 
fact, PMA can induce iNOS [60] and IL-32 [36] in THP-1 cells, thus both can contribute 
to increase Leishmania-induced microbicidal molecules. 
Cathelicidin induction could be related to the IL-1Ra production, as described by Choi 
et al. [61]. They reported that LL-37 or IL-32γ enhanced human macrophage IL-1Ra 
production and subsequently led to the suppression of proinflammatory cytokines 
induced by IL-32γ as a possible negative feedback mechanism. According to our data, 
since IL-32γ is linked to IL-1Ra and LL-37 production after L. (L.) amazonensis infection, 
we suggest that IL-1Ra may indeed play a role in the balance of the inflammatory 
state caused by L. amazonensis suggesting a mechanism of feedback dependent on 
IL-32γ/LL-37/IL-1Ra. 
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In addition to the role of IL-32 in the production of microbicidal molecules we 
observed that after 4 h of infection the percentage of infected macrophages was 
inversely associated with IL-32 expression (Fig. 5, Fig. 6). As this is a short time for 
parasite proliferation, data suggest that IL-32 can modulate the uptake of the 
parasites. As it was shown before that IL-32 can induce differentiation of monocytes 
into macrophages increasing the phagocytosis capacity [62], we are now investigating 
whether IL-32 can control the phagocytosis process of Leishmania sp.
Our study was focused in understanding the role of IL-32 in innate immune response 
by evaluating human macrophage functions. However it is also known that IL-32 can 
drive the acquired immune response by inducing the differentiation of monocytes 
into dendritic cells. IL-32-matured and activated dendritic cells induce T helper (Th) 
lymphocyte differentiation into Th1 and Th17 cells [63,64], which are important cells 
to control leishmaniasis [65]. The role of IL-32-matured and activated dendritic cells 
must be further investigated in the context of Leishmania sp infections.
In summary, we demonstrate that Leishmania species induce IL-32γ, and suggest that 
these parasites can inhibit the IL-32γ splicing into the less pro-inflammatory isoforms 
IL-32β and IL-32α. Furthermore, we demonstrated that during L. (V.) braziliensis and L. 
(L.) amazonensis infection IL-32γ was differentially associated with the production of 
pro and anti-inflammatory mediators. In addition, IL-32γ upregulates the induction 
of microbicidal molecules, which may contribute to control Leishmania species 
infections (S6 Fig). The results suggest that IL-32γ is a crucial intracellular cytokine 
for the regulation of macrophage functions during Leishmania species infection that 
can result in different consequences of clinical manifestations of leishmaniasis caused 
by L. (V.) braziliensis and L. (L.) amazonensis. Next steps will include primary human 
macrophages to better understand the role of IL-32 in human leishmaniasis. Our 
current knowledge concerning the role of IL-32 in ATL might be useful and contribute 
to the development of new therapies.
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Supplemental Data
S1 Table. ON-TARGETplus Human IL-32 siRNA SMARTpool sequence.
S2 Table. Primers sequence.
Target sequence 1: AGACAGUGGCGGCUUAUUA 
 
Target sequence 2: AGAAAGAGAUGGAUUACGG 
 
Target sequence 3: CGAAGGUCCUCUCUGAUGA 
 
Target sequence 4: GAGCUCACUCCUCUACUUG 
  
 
Supplementary Table 1 
ON-TARGETplus Human IL-32 siRNA SMARTpool sequence 
	GAPDH FW primer: 5’-AGG-GGA-GAT-TCA-GTG-TGG-TG-3’ 
GAPDH RV primer: 5’-CGA-CCA-CTT-TGT-CAA-GCT-CA-3’ 
 
IL-32all FW primer: 5'-AGGACGTGGACAGGTGATGTC-3'  
IL-32all RV primer: 5'-GTCTCCAGGTAGCCCTCTTTGA-3' 
 
IL-32γ FW primer: 5’-AGGCCCGAATGGTAATGCT-3’ 
IL-32γ RV primer: 5’-CCACAGTGTCCTCAGTGTCACA-3’ 
 
TNF-α FW primer: 5’-CCTCTCTCTAATCAGCCCTCTG-3’ 
TNF-α RV primer: 5’-GAGGACCTGGGAGTAGATGAG-3’ 
 
IL-8 FW primer: 5’-ACTGAGAGTGATTGAGAGTGGAC-3’ 
IL-8 RV primer: 5’-AACCCTCTGCACCCAGTTTTC-3’ 
 
IL-1β FW primer: 5’-CAGCTACGAATCTCCGACCAC-3’ 
IL-1β RV primer: 5’-GGCAGGGAACCAGCATCTTC-3’ 
 
IL-1Ra FW primer: 5’-GCCTCCGCAGTCACCTAAT-3’ 
IL-1Ra RV primer: 5’-TCCCAGATTCTGAAGGCTTG-3’ 
 
IL-10 FW primer: 5’-CAACCTGCCTAACATGCTTCG-3’ 
IL-10 RV primer: 5’-TCATCTCAGACAAGGCTTGGC-3’ 
 
iNOS FW primer: 5’-GCGCAGACATGATCGCCATA-3’ 
iNOS RV primer: 5’-CCTCACCGAACTCACCAGC-3’ 
 
 
Cathelicidin FW primer: 5’-TGCCCAGGTCCTCAGCTAC-3’ 
Cathelicidin RV primer: 5’-GTGACTGCTGTGTCGTCCT-3’ 
 
β-defensin 2 FW primer: 5’-GGT GTT TTT GGT GGT ATA GGC G-3’ 
β-defensin 2 RV primer: 5’-AGG GCA AAA GAC TGG ATG ACA-3’ 
Supplementary Table 2 
Primers sequence  
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Supplemental Figure 1. PMA-differentiated THP-1 cells (1x106 cells/mL) were infected with 
promastigote forms (5x106 parasites) in stationary phase of growth of L. (L.) amazonensis (L. amaz), 
metacyclic promastigote forms (5x106 parasites) of L. (V.) braziliensis (L. braz) or LPS (100 ng/mL) as 
a positive control during 4 h. Non-internalized parasites were washed out and cells were incubated 
for 24 h or 48 h. (A), Time course production of IL-32γ after 4 h, 24 h and 48 h (left panel); Distribution 
of mRNA expression of isoforms of IL-32 after 24 h (right panel); determined by quantitative real-
time PCR. (B), TNFα cytokine production in 4 h-culture supernatant, by ELISA. (C), LDH levels were 
determined by Cytotox 96 assay in supernatants after 24 h.  Values are expressed as means ± SEM of 
three independent experiments. *p < 0.05 (Medium vs LPS, L. amaz, L. braz).
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Supplemental Figure 3. PMA-differentiated THP-1 cells (2.5x106 cells/800 µL) were electroporated 
by using Amaxa Nucleofector Technology with IL-32 siRNA (for IL-32 knockdown) and control siRNA 
and IL-32 plasmid (for IL-32 overexpression) and egfp plasmid (as a control)(32) according with 
protocol described in [2]. The final concentration of cells per well were 3x105 cells/100 µL. After 
24 h of transfection, cells were infected with promastigote forms (1.5x106 parasites) in growth 
stationary phase of L. (L.) amazonensis (L. amaz) or metacyclic promastigote forms (1.5x106 parasites) 
of L. (V.) braziliensis (L. braz). Afterwards, non-internalized parasites were washed out and cells were 
incubated for 24 h. After 4 h (A and C) and 24 h (B and D) incubation, mRNA expression and protein 
levels of TNFα were determined by quantitative real-time PCR and ELISA, respectively. Values are 
expressed as means ± SEM of three independent experiments. *p < 0.05 (Control SiRNA vs IL-32 
SiRNA); (egpf plasmid vs IL-32γ plasmid); #p < 0.05 (L. amaz, L. braz). 
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Supplemental Figure 4. PMA-differentiated THP-1 cells (2.5x106 cells/800 µL) were electroporated 
by using Amaxa Nucleofector Technology with IL-32 siRNA (for IL-32 knockdown) and control 
siRNA according with protocol described in [2]. The final concentration of cells per well were 
3x105 cells/100 µL. After 24 h of transfection, cells were infected with promastigote forms (1.5x106 
parasites) in growth stationary phase of L. (L.) amazonensis (L. amaz) or metacyclic promastigote 
forms (1.5x106 parasites) of L. (V.) braziliensis (L. braz). Afterwards, non-internalized parasites were 
washed out and cells were incubated for 48 h. mRNA expression of Il-32 all (left) and γ isoform of 
IL-32 (right) were determined by quantitative real-time PCR. Values are expressed as means ± SEM of 
three independent experiments. 
Supplemental Figure 5. Evaluation of LPS contamination in parasite cultures. PMA-differentiated 
THP-1 cells (2 x 105 cells/mL) were pre-treated with polymyxin B (5 μg/mL) for 30 min and infected with 
promastigote forms (1 x 106 parasites) in the growth stationary phase and metacyclic promastigote 
forms (1 x 106 parasites) of L. (V.) braziliensis (L. braz). After 4 hours supernatants were collected and 
cells were washed to remove non-internalized parasites and incubated for 24, 48 h. TNFa protein 
levels were determined by ELISA in supernatants. Values are expressed as means ± SEM of three 
independent experiments. *p < 0.05 (Medium vs L. amaz, L. braz); #p < 0.05 (L. amaz vs L. braz).
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Supplemental Figure 6. An overwiew of cytokines and microbicidal molecules induced by 
Leishmania species in PMA-differentiated human THP-1 cells. IL-32γ and IL-8 are induced by L. 
(L.) amazonensis and L. (V.) braziliensis at similar levels. L. (L.) amazonensis induces higher levels of 
TNFα, IL-10 and IL-1Ra than L. (V.) braziliensis, which induces higher levels of IL-1β. TNFα and IL-8 
production is mediated by IL-32γ  in infections caused by both species whereas IL-1Ra production 
is only dependent on IL-32γ in L. (L.) amazonensis infection. In addition, L. (V.) braziliensis–induced 
IL-1β is not dependent on IL-32γ as well as production of IL-10 induced by both parasite species. 
Considering microbicidal molecules IL-32γ contributes similarly for their production in cells infected 
with both Leishmania species. The differential control of cytokines induced after L. (L.) amazonensis 
and L. (V.) braziliensis infections by IL-32γ can contribute for different clinical outcomes of disease 
caused by theses parasites. 
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Aos meus tios e primos,
Uma coisa boa na vida são nossos tios. 
Graças a eles temos os nossos primos. 
Obrigada sempre pelo carinho de todos vocês. 
Adoro vocês! 
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Abstract
Background: Interleukin 32 (IL-32) is a pro-inflammatory cytokine induced in 
patients with American tegumentary leishmaniasis (ATL) caused by Leishmania 
braziliensis. Here, we investigated whether IL-32 is also expressed in patient lesions 
caused by L. amazonensis. In addition, we evaluated experimental L. amazonensis 
and L. braziliensis infections in C57BL/6 transgenic mice for human IL-32γ (IL-32γTg) 
in comparison with wild-type (WT) mice that do not express the IL-32 gene.
Results: Human cutaneous lesions caused by L. amazonensis express higher levels 
of IL-32 than healthy control skin. In mice, the presence of IL-32γ promoted the 
control of cutaneous lesions caused by L. braziliensis, but not lesions caused by 
L. amazonensis in an ear dermis infection model. In addition, IL-32γTg mice displayed 
less tissue parasitism and inflammation in IL-32γTg than WT mice during the healing 
phase of L. braziliensis infection. Production of antigen-specific pro-inflammatory 
cytokines was higher in IL-32γTg mice than in WT mice during L. braziliensis infection 
but not during L. amazonensis infection.
Conclusions: Human cutaneous lesions caused by L. amazonensis express high 
levels of IL-32. In mice, the presence of IL-32γ contributes to the lesion healing 
caused by L. braziliensis but not by L. amazonensis. Data suggest that despite the 
ability for both species to induce IL-32 in humans, the connections between this 
cytokine and other immune players induced by related species of parasites can lead 
to distinct outcomes of the murine infections. 
Keywords: Leishmania amazonensis, Leishmania braziliensis, Cutaneous 
leishmaniasis, IL-32, Cytokines, Mouse model
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Introduction
American tegumentary leishmaniasis (ATL) is an infectious disease caused by 
Leishmania protozoan, affecting the skin, oral or nasal mucosa. Brazil is one of 
10 countries that together account for 70–75% of the cases of tegumentary 
leishmaniasis in the world [1]. Leishmania amazonensis and Leishmania braziliensis 
are the main species that cause ATL in Brazil. L. amazonensis is associated with the 
development of localized or diffuse skin lesions whereas L. braziliensis is associated 
with localized cutaneous or mucosal lesions [2-4].
In general, humans or mice infected with L. braziliensis present a stronger cellular 
immune response against the parasites than human or mice infected with 
L. amazonensis [5, 6]. L. braziliensis infections cause small cutaneous lesions that 
regress after a few weeks in C57BL/6 mice. In these mice, it has been demonstrated 
that the IL-12-IFN-γ/TNF-α-NO axis controls the parasite infection [7-9]. By contrast, 
L. amazonensis generates chronic and non-healing infection in C57BL/6 mice with a 
deficient Th1 cell response [5, 10] 
IL-32 is a cytokine expressed by several human cells, including NK cells, monocytes/
macrophages, T lymphocytes, epithelial cells, endothelial cells, fibroblasts and 
hepatocytes. IL-32 is predominantly expressed intracellularly and can induce the 
production of TNF-α, IL-8 and IL-1β [11]. To date, there are nine isoforms of human 
IL-32 and the highest biological activity has been attributed to IL-32γ [12]. IL-32 is 
associated with the control or immunopathology of numerous infectious diseases, 
such as tuberculosis, HIV/AIDS, leprosy and hepatitis [13] likewise in dermatological 
diseases [14, 15].  
Although rodents do not naturally produce IL-32, recombinant IL-32 (rIL-32) can 
activate mouse cells [11]. In addition, injection of rIL-32γ into the knee joints of mice 
leads to arthritis partially mediated by induction of TNF-α [16]. Thus, the use of an 
experimental animal model to study the role of IL-32 in inflammatory and infectious 
diseases is made possible by IL-32 humanized transgenic mice. 
We previously described that cutaneous and mucosal lesions of patients with ATL 
caused by L. braziliensis exhibit increased IL-32 expression compared to healthy 
tissues [17]. Here, we investigated the expression of IL-32 in cutaneous lesions of 
patients infected with L. amazonensis, and the role of IL-32γ in experimental mouse 
infections caused by L. amazonensis and L. braziliensis.
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Methods
Patient and control samples
Patients diagnosed with cutaneous leishmaniasis according to Oliveira et al. [8] and 
control healthy individuals were submitted to biopsy procedure to obtain fragments 
from lesions and healthy skin, after signing the consent form.
Immunohistochemical (IHC) analysis for IL-32
Biopsy fragments were obtained from cutaneous lesions to identify Leishmania 
species by polymerase chain reaction (PCR) as previously described [8], confirming 
all samples positive for L. amazonensis. Samples of healthy skin (n = 8) and a 
fragment of lesions from patients (n = 5) were used for IHC analysis for IL-32 using 
rabbit polyclonal antibodies to human IL-32 (Abcam Inc., Cambridge, UK), according 
to Galdino et al. [17]. The tissue expression (epithelium and dermis) of IL-32 was 
classified as follows: 0, absence of labelled cells; 1, 1 to 25% of labelled cells; 2, 26 to 
50% of labelled cells; 3, 51 to 75% of labelled cells; 4, 76 to 100% of labelled cells). 
All sections were blindly analyzed using a light microscope (magnification of 400×). 
Animals and parasites
Transgenic mice for human IL-32 were developed by Choi et al. [18] and donated 
to our group by Dr Charles Dinarello (University of Colorado, Denver, USA). Six 
to 8 week old C57BL/6 WT and IL-32γTg mice were used in the experiments. All 
procedures were followed in accordance with the guidelines and legislation on 
ethics research. 
Leishmania (L.) amazonensis (MHOM/BR/1973/M2269) and L. (V.) braziliensis (MHOM/
BR/2003/IMG) strains were obtained from patients with localized cutaneous lesions 
[19, 20]. L. braziliensis strain was obtained and identified by our group, as described 
by Dorta et al. [19]. Briefly, lesion fragments were macerated in phosphate-buffered 
saline (PBS) and cultured in Grace’s Insect Medium (Gibco, Life Technologies, 
Carlsbad, USA) supplemented with heat-inactivated 20% fetal bovine serum (FBS, 
Sigma-Aldrich, St. Louis, USA) and 100 U/ml of penicillin/streptomycin (Sigma-
Aldrich) at 26 °C. The identification of the species was performed by PCR-RFLP, 
according to Volpini et al. [21]. Leishmania amazonensis strain was identified and 
donated to us by Mortara et al. [20].
Leishmania amazonensis and L. braziliensis promastigote forms were cultured 
in Grace’s insect medium supplemented as described above. Parasites of either 
L. amazonensis or L. braziliensis from stationary phase (6th day) of growth were 
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washed three times with sterile PBS, pH 7.4 (1,000× g, 10 min, 10 °C), suspended in 
PBS and quantified by hemocytometer after fixation with PBS/0.1% formaldehyde. 
Parasite lysates were obtained by 5 freeze-thaw cycles in liquid nitrogen and 37 °C 
water bath followed by protein quantification using the Pierce BCA protein assay 
(ThermoFisher, Rochester, USA ). 
Infection, disease progression and histopathological analysis
Animals were inoculated (1 × 105 promastigotes/10 μl of PBS) into the dermis of the 
left ear. Three independent experiments were performed, with three animals per 
group in each experiment. Lesion size was measured weekly using a digital caliper. 
Lesion size is described as the difference between the thickness of the infected ear 
and the thickness of the uninfected ear [22]. Tissue parasitism was evaluated in the 
infected ear, draining lymph node (submandibular) and spleen by limiting dilution 
assay. The results were expressed as the negative logarithm of the parasite titer [23]. 
Paraformaldehyde fixed-ear tissue was embedded in paraffin to be processed for 
histopathological analysis after haematoxylin and eosin (H&E) staining. The cellular 
infiltrate evidenced in the inflammatory process was considered [24-26]. 
Cytokine production
Lesion-draining submandibular lymph node cells from uninfected and infected 
mice were macerated and maintained in RMPI 1640 medium (Sigma-Aldrich) 
supplemented with 10% FBS (Gibco), 1 M HEPES (Sigma-Aldrich), 2 mM glutamine 
(Sigma-Aldrich), 100 U/ml penicillin (Sigma-Aldrich) and 100 µg/ml streptomycin 
(Sigma-Aldrich). Viable cells were quantified using a hemocytometer by dye 
exclusion with Trypan blue 0.1% in PBS. Lymph node cells (5 × 105 cells/ml) were 
stimulated with antigen from L. amazonensis or L. braziliensis (50 µg/ml) for 24 
h or 72 h, at 37 °C and 5% CO2. TNF-α and IL-10 were evaluated in the culture 
supernatants by commercial enzyme-linked immunosorbent assay (ELISA) kits 
(R&D Systems, Minneapolis, USA), according to the manufacturer’s protocol. IFN-γ 
was evaluated by ELISA using monoclonal antibodies obtained from hybridoma 
cultures, according to [27]. All cultures and measurements were done in duplicates.
Statistical analysis
Data are expressed as means ± standard deviations or median and individual values 
and compared using Student’s t or Mann-Whitney U tests, respectively. Analyses 
were performed using Prism software version 6.0 (GraphPad, San Diego, CA, USA). 
Significance was established as P < 0.05.
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Results
Expression of IL-32 in lesions of patients with ATL caused by 
L. amazonensis
We previously demonstrated that IL-32 is highly expressed in cutaneous and 
mucosal lesions of patients with ATL infected with Leishmania (Viannia) spp., mainly 
L. braziliensis. In addition, amastigote forms of L. braziliensis were able to induce IL-
32β in human peripheral blood mononuclear cells [17]. Here, we demonstrate that 
in cutaneous lesions caused by L. amazonensis infection IL-32 protein expression 
was also increased when compared to healthy skin specimens [U = 7.5, P = 0.0412 
(epithelium) and U = 0.0, P = 0.0008 (inflammatory infiltrate)]. IL-32 was detected 
both in the epithelium and in the inflammatory infiltrate (Fig. 1a, b). 
Figure 1. Expression of IL-32 in American tegumentary leishmaniasis lesions caused by 
L. amazonensis. a Fragments of lesions from ATL patients infected with L. amazonensis and skin from 
healthy controls were included in paraffin and submitted to immunohistochemistry for IL-32. The 
reaction was revealed with 3,3’-Diaminobenzidine and Meyer’s hematoxylin used to counterstain. b 
Evaluation of IL-32 expression score was determined according to the percentage of cells expressing 
IL-32. The scores represent: 0 (absence of stained cells), 1 (1–25% of stained cells), 2 (26–50% stained 
cells), 3 (51–75% stained cells), and 4 (76–100% stained cells). *P < 0.05 (Mann-Whitney test)
The role of IL-32 in experimental lesions caused by L. amazonensis or 
L. braziliensis
To understand the precise role of IL-32 in ATL, we infected human IL-32γTg and WT 
mice with either L. amazonensis or L. braziliensis. IL-32γTg mice showed a delayed 
development of ear lesions caused by L. amazonensis (until week 3); however, the 
size of the lesions were similar to WT mice in later stages of infection (Fig. 2a, c). 
In contrast, mice infected with L. braziliensis demonstrated a significant increase in 
the lesion size on the 3rd week of infection (t(14) = 2.23316, P = 0.042), as well as a 
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reduction of lesion size from week 6 post-infection in IL-32γTg mice compared to 
WT mice (Fig. 2b, c) [t(14)  = 3.29151, P = 0.0053 (6 weeks); t(14)  = 2.16645, P = 0.048 
(7 weeks); t(14)  = 2.82843, P = 0.013 (8 weeks); t(14)  = 2.37595, P = 0.032 (9 weeks)]. 
We observed that L. amazonensis-infected IL-32γTg mice showed higher lesional 
parasite load on week 3 of infection compared to WT animals (t(14) = 2.52036, 
P = 0.024). Despite this initial favoring of parasitism in IL-32γTg animals, the growth 
of L. amazonensis in later stages of infection was controlled, whereas parasites grew 
exponentially in WT mice (Fig. 2d). Although IL-32γ was not able to reduce the 
L. amazonensis infection in the skin, we observed that IL-32γ is important for parasite 
dissemination because IL-32γTg mice harbored lower numbers of L. amazonensis 
parasites in draining lymph nodes (t(6) = 3, P = 0.024) and spleens (t(14) = 2.46598, P = 
0.027) compared with WT mice in 9 weeks (Fig. 2e). During L. braziliensis infection, 
we observed a strong reduction of parasite burden in IL-32γTg mice [t(14) = 3.68751, 
P = 0.0024 (week 6) and t(14) = 3.12076, P = 0.0075 (week 9)] (Fig. 2f ). We did not 
observe L. braziliensis dissemination until the end of the experiments. As expected, 
WT and IL-32γTg mice exhibited similar histological profiles of lesional inflammatory 
infiltrates after L. amazonensis infection. In contrast, the inflammatory infiltrate was 
remarkably reduced on weeks 6 and 9 post-infection in L. braziliensis-infected IL-
32γTg mice compared to WT mice. Despite this, both WT and IL-32γTg mice showed 
a reduction of inflammatory infiltrate at the final stage of infection (9 weeks) when 
comparing the histopathological aspects on 3 or 6 weeks (Fig. 3). 
IL-32γ induces inflammatory cytokines in experimental infections 
caused by L. braziliensis in contrast to L. amazonensis
Lesion-draining submandibular lymph node cells from infected mice were 
stimulated ex vivo with lysates of L. amazonensis or L. braziliensis promastigotes for 
24 h, or 72 h and cytokines were measured in culture supernatants. No difference 
in the production of IFN-γ, TNF-α and IL-10 was observed between WT and IL-32γTg 
animals infected with L. amazonensis on weeks 3, 6 or 9 post-infection. In contrast, 
lymph node cells from L. braziliensis-infected IL-32γTg animals showed higher 
cytokine production after antigen-specific stimulation than cells from WT mice 
(weeks 3 and 6; Fig. 4) [t(51) = 3.22153, P = 0.0022 (IFN-γ, 3 weeks); t(54) = 4.87909, P < 
0.0001 (TNF-α, 6 weeks); t(14) = 2.92794, P = 0.011 (IL-10, 6 weeks)].
83IL-32γ promotes the healing of murine cutaneous lesions
3Figu
re
 
3.
 
H
is
to
pa
th
ol
og
ic
al
 
pr
ofi
le
s 
of
 e
ar
 l
es
io
ns
 c
au
se
d 
by
 
L.
 a
m
az
on
en
si
s 
an
d 
L.
 b
ra
zi
lie
ns
is
 
in
 
w
ild
-t
yp
e 
an
d 
IL
-3
2γ
Tg
 
m
ic
e.
 
Fr
ag
m
en
ts
 o
f 
ea
rs
 f
ro
m
 C
57
BL
/6
 
W
T 
an
d 
IL
-3
2γ
Tg
 m
ic
e 
un
in
fe
ct
ed
 
(a
bo
ve
) 
or
 
in
fe
ct
ed
 
w
ith
 
L.
 
am
az
on
en
si
s 
(le
ft
) 
or
 L
. b
ra
zi
lie
ns
is
 
(r
ig
ht
) 
fo
r 
3,
 6
 a
nd
 9
 w
ee
ks
 w
er
e 
fix
ed
 a
nd
 s
ta
in
ed
 b
y 
he
m
at
ox
yl
in
 
&
 e
os
in
, 
fo
r 
an
al
ys
is
 u
nd
er
 a
 l
ig
ht
 
m
ic
ro
sc
op
e 
(1
00
×
 m
ag
ni
fic
at
io
n)
. 
A
 m
on
on
uc
le
ar
 c
el
l 
in
fla
m
m
at
or
y 
in
fil
tr
at
e 
w
as
 
ob
se
rv
ed
 
in
 
th
e 
de
rm
is
 
th
at
 
w
as
 
pr
og
re
ss
iv
e 
in
 
L.
 
am
az
on
en
si
s-
in
fe
ct
ed
 
an
d 
re
gr
es
si
ve
 in
 L
. b
ra
zi
lie
ns
is
-in
fe
ct
ed
 
m
ic
e.
 S
ca
le
-b
ar
s:
 1
00
 µ
m
84
Figure 4. IL-32 amplifies the production of inflammatory cytokines induced by L. braziliensis during 
murine ear dermis infection. Lesion-draining submandibular lymph node cells were stimulated with 
specific antigens from L. amazonensis or L. braziliensis for 24 h (TNF-α) or 72 h (IFN-γ and IL-10). The 
production of (a) IFN-γ, (b) TNF-α and (b) IL-10 was evaluated by ELISA in culture supernatants. The 
results represent the mean ± standard deviation of 8 animals per group. *P < 0.05, (WT × IL-32γTg, 
Student’s t-test)
Discussion
The present study demonstrated that in addition to L. braziliensis [17], L. amazonensis 
induces a strong IL-32 expression in human cutaneous lesions. Furthermore, we 
showed that human IL-32γ was able to support the healing of skin lesions in L. 
braziliensis-infected mice, which is in contrast to L. amazonensis caused skin lesions. 
Based on pro-inflammatory properties of IL-32γ [11, 13] we hypothesize that IL-32γ 
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could increase the immune response against L. amazonensis and lead to improved 
healing of the lesions. Although IL-32γ inhibited the lesional parasite load, IL-32γ 
did not increase the production of pro-inflammatory cytokines or improved healing. 
It is well-known that L. amazonensis strongly modulates the host immune response 
against this parasite [5, 10, 18, 28]. These experimental results, together with the 
observation that IL-32 is highly expressed in cutaneous lesions of L. amazonensis-
infected patients, suggest that even in the presence of IL-32 the parasites and lesion 
are persistent. 
Although it is known that C57BL/6 mice are relatively resistant to L. braziliensis 
infection [5], we observed that the pro-inflammatory response during 
L. braziliensis infection was strengthened by IL-32γ without a significant increase of 
immunopathology. In addition, IL-32γ played an important role in controlling the 
parasite load, favoring the healing of the skin lesion. Thus, in cutaneous murine 
lesions caused by L. braziliensis that is restricted to skin and draining lymph node, 
the pro-inflammatory properties of IL-32γ help the control of the infection. However, 
in L. amazonensis, which spreads beyond the cutaneous lesions to other tissues 
and suppress cytokine production, IL-32γ contributes to the control of parasite 
dissemination but not for skin lesion healing. Differential expression of IL-32γ in 
the tissues during these two infections could explain the results besides intrinsic 
parasite factors that can interfere with the role of IL-32γ. The results underscore the 
need of unravelling the molecular mechanisms used by L. amazonensis parasites to 
subvert the antileishmanial effect of IL-32γ in skin observed against L. braziliensis 
infection.
It is important to highlight that murine models of leishmaniasis are not a reliable 
landscape of the immune responses against Leishmania parasites because mice 
do not produce IL-32. However, murine cells respond to human IL-32 [12]. Some 
important microbicidal mechanisms are dependent on IL-32, and therefore these 
latter mechanisms are lost in mice [29]. In this way, this IL-32γTg mouse model is very 
important to reveal novel mechanisms that control or lead to immunopathogenesis 
in leishmaniasis.
Conclusions
IL-32γ is an important player in the control of L. braziliensis cutaneous infections 
in contrast to L. amazonensis-mediated infections, at least in ear dermis infection 
model. IL-32γ might be a novel target in strategies to control leishmaniasis caused 
by L. braziliensis.
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To my friends, 
“Close friends are truly life’s treasures. 
Sometimes they know us better than we know 
ourselves. With gentle honesty, they are there to 
guide and support us, to share our laughter and 
our tears. Their presence reminds us that we are 
never really alone.”
- Vincent Van Gogh
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Abstract
Visceral Leishmaniasis (VL) is a chronic parasitic disease caused by Leishmania 
infantum in the Americas. During VL, several proinflammatory cytokines are 
produced in spleen, liver and bone marrow. However, the role of IL-32 has not been 
explored in this disease. IL-32 can induce production of proinflammatory cytokines 
in innate immune cells and polarize the adaptive immune response. Herein, we 
discovered that L. infantum antigens induced mainly mRNA expression of the IL-
32γ isoform, but also induced low levels of IL-32β transcript in human peripheral 
blood mononuclear cells. Furthermore, infection of human IL-32γ transgenic mice 
(IL-32γTg) with L. infantum promastigote forms increased IL-32γ expression in the 
spleen and liver. Interestingly, IL-32γTg mice harbored less parasitism in the spleen 
and liver as compared to wild-type (WT) mice. In addition, IL-32γTg mice showed 
increased granuloma formation in the liver as compared to WT mice. The protection 
against VL was associated with increased production of nitric oxide (NO), IFN-γ, IL-
17A and TNF-α by splenic cells re-stimulated ex vivo with L. infantum antigens. In 
parallel, there was an increase in the number of Th1 and Th17 T cells in the spleens 
of IL-32γTg mice infected with L. infantum. IL-32γ induction of IFN-γ and IL-17A 
expression was found to be essential for NO production by splenic cells of infected 
animals. These data indicate that IL-32γ potentiates Th1/Th17 immune response 
during experimental VL, thus contributing to the control of L. infantum infection. 
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Introduction
Visceral leishmaniasis (VL) is a chronic, debilitating disease caused by Leishmania 
spp. transmitted by sand flies. It is estimated that there are 400,000 new cases of 
VL annually, with about 30,000 deaths (1). VL is caused by Leishmania donovani 
in Asia, India and East Africa, and by Leishmania infantum in the Americas and in 
the Middle East, Central Asia and China (2, 3). Brazil, together with India, Nepal, 
Bangladesh, Sudan and Ethiopia, accounts for 90% of VL cases worldwide (2). 
The transmission of L. infantum is zoonotic, in which humans are accidental hosts 
and dogs are the main peridomestic reservoirs (1, 4). The clinical manifestations 
of VL range from an asymptomatic self-resolving phenotype to a progressively 
severe disorder characterized by fever, cachexia, weight loss, anemia, leukopenia, 
thrombocytopenia, hypergammaglobulinemia, and hepatosplenomegaly, and may 
be fatal if left untreated (5, 6). 
In general, protection against VL is dependent on Th1 lymphocyte responses 
and interferon gamma (IFNγ) production (7–9), which activates macrophages to 
produce leishmanicidal molecules, such as nitric oxide (NO) (10). In addition to Th1 
cells, Th17 lymphocytes produce interleukin 17A (IL-17A) and are also likely to be 
protective in VL. IL-17A acts synergistically with IFNγ to increase NO production 
by murine macrophages infected with L. infantum (11–13). On the other hand, 
Th2 and T regulatory cell (Treg) cytokines – especially IL-10 – are associated with 
susceptibility and progression of VL (14–17). 
Interleukin 32 (IL-32) is an intracellular cytokine produced by immune and non-
immune cells, which induces the production of proinflammatory cytokines and 
chemokines, such as TNF-α, IL-6, IL-8 and IL-1β, via activation of p38 mitogen-
activated protein kinase (MAPK) and NFkB (18–20). IL-32 can polarize the acquired 
immune response to the Th1 and Th17 profiles by enhancing antigen presentation 
and IL-12 and IL-6 induction (21). There are nine known IL-32 isoforms generated 
by the alternative splicing of IL-32γ, which is the most biologically active isoform 
(19, 22). IL-32 has been associated with the immunopathology and/or protection of 
numerous infectious diseases, such as those caused by Mycobacterium tuberculosis, 
M. avium, human immunodeficiency virus (HIV), influenza A,  and hepatitis B virus 
(23–28). 
Although rodents do not present any gene homologous to IL-32, murine cells are 
able to respond to this cytokine (29, 30). Based on this, transgenic mice expressing 
human IL-32γ gene (IL-32γTg) were generated and has been successfully used in 
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studies on the role of IL-32 in in vivo infections (31–33). We recently showed that 
IL-32 expression increases in IL-32γTg mice or humans infected with parasites that 
cause cutaneous leishmaniasis (33–35). Importantly, IL-32 was associated with 
the production of pro-inflammatory cytokines and leishmanicidal molecules such 
as NO and antimicrobial peptides, during the infection of human macrophages 
with Leishmania amazonensis or Leishmania braziliensis (35). In addition, IL-32 
contributed to control L. amazonensis dissemination from cutaneous lesions to the 
spleens in the IL-32γTg mice (33). Due to aforementioned properties of IL-32 and 
the fact that IL-32 is highly expressed in liver and spleen of IL-32γTg mice (36), we 
investigated the effect of IL-32 over-expression in a murine model of VL induced by 
infection with L. infantum.
Methods
Ethics Statement
The human sample study was approved by Commission on Human Research - 
CMO Arnhem-Nijmegen (NL32357.091.10). Buffy coats from healthy donors were 
obtained after written informed consent (Sanquin Blood Bank, Nijmegen, the 
Netherlands).  Donor samples were kept anonymous and the use of the samples 
received IRB approval. All animal procedures were followed in accordance with the 
guidelines and legislation on ethics of the Brazilian Society of Science in Laboratory 
Animals (SBCAL) and National Council of Control of Animal Experimentation 
(CONCEA) and approved by the Committee on Ethics in the Use of Animals/CEUA-
PRPI-UFG, protocol no. 042/16. 
IL-32 expression in human peripheral blood mononuclear cells (PBMCs) 
upon exposure to L. infantum antigens. 
Peripheral blood mononuclear cells (PBMCs) were obtained from blood samples 
after overlaying on density gradient (Ficoll-Paque, Pharmacia Biotech, Piscataway, 
NJ, USA), as previously described (74, 75). PBMCs were cultured in RPMI 1640 
medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% FCS (Gibco, 
Life Technologies, São Paulo, SP, Brazil), 2 mM L-glutamine, 11 mM sodium 
bicarbonate, 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma-Aldrich), 
referred as complete medium. 5 x 105 PBMCs were cultured in absence or presence 
of total L. infantum antigen (50 µg/mL) for 4 h, 24 h and 48 h, at 37oC, 5% CO2. After 
stimulation cells were lysed with PBS/0.5% Triton-X 100 (Sigma-Aldrich) containing 
protease inhibitor cocktail (Sigma-Aldrich) for measuring IL-32 protein by ELISA 
(R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s protocol 
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(detection limit 31 pg/mL). In addition, expression of IL-32 mRNA was also evaluated 
as described below. 
IL-32 mRNA expression by quantitative real-time PCR (qPCR) 
RNA isolation was performed as described before (76). Briefly, mRNA was transcribed 
into cDNA using iScript (Bio-Rad, Hercules, CA, USA). cDNA was used for qPCR 
analysis by using the StepOnePlus sequence detection systems (Applied Biosystem, 
Foster City, CA, USA) with SYBR Green Mastermix (Applied Biosystems). The primer 
sequences for IL-32 (Biolegio, Nijmegen, The Netherlands) used here are presented 
in Table S1, as previously described (77). The mRNA analysis was performed with 
the 2^dCt x 1000 method and normalized against the housekeeping gene GAPDH 
(human samples – PBMCs lysates) or 18S (mice samples – BMDMs or spleen and liver 
lysates).
Animals and parasites
IL-32γTg mice were generated by Choi et al. (36) using C57BL/6 mouse strain, 
donated by Dr. Charles Dinarello (University of Colorado Denver, USA), and 
maintained at the animal facility of Federal University of Goiás/IPTSP, Brazil. 6 to 8 
weeks old-C57BL/6 wild-type (WT) and IL-32γTg mice were used in the experiments. 
L. (L.) infantum (MHOM/BR/74/PP/75) was cultured in Grace’s Insect Medium (Gibco-
Life Technologies) supplemented with heat-inactivated 20% Fetal Calf Serum (FCS, 
Gibco-Life Technologies), 0.2 mM L-glutamine (Sigma-Aldrich) and 100 U/mL of 
penicillin/streptomycin (Sigma-Aldrich) at 26°C. Promastigotes in stationary phase 
(5th day) of growth were washed three times with sterile phosphate-buffered 
saline (PBS), pH 7.4 (1,000 g, 10 min, 10 ºC), suspended in PBS and quantified 
by hemocytometer after dilution in PBS/0.1% formaldehyde. Total antigen of 
L. infantum promastigotes was obtained as previously described (33).
In vivo infection and evaluation of parasitism and tissue lesions
WT and IL-32γTg mice were injected intraperitoneally (i.p.) with 107 promastigotes 
in the stationary phase of growth. After 15, 30, 45 and 60 days of infection, the 
animals were euthanized for collection and weighing of the organs and evaluation 
of parasitism in the spleen and liver by the limiting dilution (78, 79). The percentage 
of splenomegaly and hepatomegaly were obtained by the equation: (organ weight/
total animal weight) x 100.
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Paraformaldehyde fixed-spleen and liver tissues were embedded in paraffin 
for histopathological analysis. After staining with Hematoxylin-Eosin, the 
histopathological aspects of spleen and liver and granuloma formation in 
liver sections were evaluated under light microscopy. The number and area of 
granulomas were quantified in 10 consecutive fields by using ImageJ software. 
Mouse spleen cell cultures 
Spleen cells from 30 day-infected mice were cultured at 5 × 106 cells/mL in RPMI 
1640 complete medium and stimulated with 50 µg/mL of L. infantum antigen or 
5 µg/mL Concanavalin A (ConA, Sigma-Aldrich) for 24 h or 72 h at 37 ºC/5% CO2. 
In some experiments, the cells were stimulated for 72 h with L. infantum antigen 
or ConA in the presence of neutralizing monoclonal antibodies to IFN-γ (clone 
XMG1.2) or to TNFα (clone MP6-XT3). Moreover, Th17/IL-17A-pharmacological 
inhibitor digoxin (10 µM; Sigma-Aldrich) (37) was used. Normal rat IgG was used as 
isotype control and DMSO as digoxin control.
Preparation of tissue homogenates
To measure cytokine concentrations in the organs, tissue samples were harvested, 
weighed, and macerated in 0.5 mL of PBS/0.1% Triton-X 100 (Sigma-Aldrich) added 
with protease inhibitor cocktail (Sigma-Aldrich) to cytokine measurement or in 0.5 
mL of Trizol for RNA isolation as described above.
Mouse cytokine and nitrite measurements
Murine IL-17, TNFα and IL-10 were evaluated by commercial Enzyme-Linked 
Immunosorbent Assay (ELISA) kits (R&D Systems), according to the manufacturer’s 
protocol (Detection limit 39pg/mL for IL-17A and 78pg/mL for TNFα and IL-10). IFNγ 
was evaluated by ELISA using monoclonal antibodies obtained from hybridoma 
cultures, according to (80) and its dection lilmit was 39 pg/mL. Nitrite concentration 
was evaluated by the Griess method to evaluate NO production in the cultures (81). 
Human IL-32 was evaluated by ELISA (R&D Systems) from cell lysates, according to 
the manufacturer’s protocol, as described above for human cells.
Flow cytometry and lymphocyte proliferation assays.
Spleens and livers from 30 day-infected mice were harvested and macerated to 
obtain single cell suspensions. For cell surface marker analysis, cells were fixed, 
washed, and stained with anti-mouse CD3 FITC (145-2C11 clone), anti-mouse CD4 
PE (GK1.5 clone), anti-mouse CD8 PerCP-Cyanine5.5 (53-6.7 clone) or their respective 
isotype control (all from eBioscience, San Diego, CA, USA). For intracellular cytokine 
analysis, spleen cells were cultured in the presence of 50 µg/mL of L. infantum 
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antigen for 72 h. Brefeldin A (10 µg/mL, eBioscience) was added to the culture and 
incubated for additional 6 h. The cells were washed with FACS buffer (eBioscience) 
and stained with anti-mouse CD4 PE (GK1.5 clone, eBioscience) antibody, washed 
and fixed with 100 µL of intracellular Fixation Buffer (eBioscience) and permeabilized 
with Permeabilization Buffer (eBioscience). The cells were subsequently stained 
with anti-mouse IFNγ Alexa Fluor 488 (XMG1.2 clone, eBioscience) and anti-mouse 
IL-17A APC (eBio17B7 clone, eBioscience). The CD4+ Th cells were gated individually 
for determining the population of IFNγ- or IL-17A-producing cells. 
Antigen-specific proliferation analysis was performed by carboxyfluorescein 
succinimidyl ester (CFSE) method, as described before (82). Briefly, spleen cells (5 x 
106 cells/mL) were incubated with 5 µM CFSE (Sigma-Aldrich) at 25 ºC, for 5 minutes. 
The cells were washed in PBS, resuspended in RPMI 1640 complete medium and 
incubated at 37 ºC/5% CO2 for 4 days in the presence of 50 µg/mL of L. infantum 
antigen or ConA 5 µg/mL.  The cells were then collected and analyzed by flow 
cytometry.
All experiments were performed in BD Accuri™ C6 Flow cytometry (BD Bioscience, 
San Jose, CA, USA) and data were analyzed using FlowJo software (Tree Star, 
Ashland, OR, USA).
L. infantum infection of mouse bone marrow-derived macrophages 
(BMDMs) and measurement of microbicidal activity and NO
BMDMs were obtained as described before (83). BMDMs (1 x 106 cells/mL) were 
cultured in RPMI 1640 complete medium and infected with stationary phase- 
L. infantum promastigotes (MOI 5:1) for 3 h. After, they were washed for removing 
non-internalized parasites, and incubated with complete medium, in the 
absence or presence of murine recombinant IFNγ (10 ng/mL; Sigma-Aldrich) and 
lipopolysaccharide (LPS 1 µg/mL; Sigma-Aldrich). After 3 h and 48 h, at 37 ºC/5% 
CO2, coverslips were collected; cells were fixed in methanol (Labsynth, Diadema, 
SP, Brazil) and stained by Giemsa (Merck KGaA, Darmstadt, Germany). Under light 
microscopy, the percentage of macrophages containing internalized parasites and 
the number of parasites per infected cell were evaluated. At least 200 cells were 
counted. Supernatants were collected for nitrite measurement as described above.
Statistical analysis
Data were expressed as mean ± standard errors of the mean (SEM) and Student’s 
t test, one-way or two-way ANOVA analysis with Bonferroni’s post-test were used. 
Median with interquartile range and Mann–Whitney U test were used for data with 
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nonparametric distribution. Prism 6.0 software (GraphPad Software, La Jolla, CA, 
USA) was used and p < 0.05 was considered significant. 
Results 
Leishmania infantum induces IL-32γ expression in human PBMC.
We have demonstrated that L. amazonensis and L. braziliensis, which cause 
cutaneous leishmaniasis, induce expression of IL-32γ in human PBMCs (33–35). 
To assess whether L. infantum also induces IL-32 expression, human PBMCs were 
incubated with L. infantum antigens. IL-32 protein levels were significantly increased 
in cell lysates of PBMCs stimulated with L. infantum for 24 h and 48 h as compared 
to unstimulated cells (p < 0.05; Fig. 1A). The IL-32γ mRNA appeared 4 h after the 
stimulus and was maintained at high levels for up to 48 h (Fig. 1B). Interestingly, 
IL-32β mRNA expression was only detected after 24 h stimulation of the PBMC with 
L. infantum (Fig. 1C). IL-32α isoform was not detected at any of the aforementioned 
incubation times. Comparatively, L. infantum was able to induce higher levels of IL-
32γ than IL-32β (Fig. 1D). The level of IL-32γ mRNA induced by L. infantum was at 
levels comparable to the induction of this isoform by LPS and higher than those 
induced by L. braziliensis (Fig. S1). 
IL-32γ control systemic infection caused by L. infantum.
After demonstrating that L. infantum can upregulate both mRNA and protein 
expression of IL-32, we examined the role of this cytokine in an murine model of VL. To 
investigate whether IL-32γ could modulate VL-associated immunopathogenesis, WT 
and IL-32γTg mice were infected with stationary phase- L. infantum promastigotes. 
It was observed that L. infantum infection increased IL-32 production in both the 
spleen and liver of IL-32γTg mice (Fig. 2A). As was observed in human PBMCs, L. 
infantum induced predominantly the IL-32γ isoform in the spleen and liver of IL-
32γTg mice (Fig. 2B). The peak of IL-32γ mRNA expression and IL-32 production was 
on day 45 post infection (p.i.) in the spleen and at day 30 p.i. in the liver (Fig. 2A and 
2B). IL-32β mRNA was only expressed on the 45th day p.i. in both organs (Fig. 2B). 
IL-32γTg mice had fewer parasites in both the spleen and liver as compared to WT 
mice over the course of the 60-day infection period (Fig. 2C and Fig. S2). Despite the 
lower tissue parasitism, IL-32γTg mice exhibited earlier and greater increase in the 
weights of the spleen and liver than WT mice (15 and 30 days after infection). 
However, during the late phase of infection (45 and 60 days p.i.), there were no 
significant differences in relative weights of the spleen and liver between IL-32γTg 
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and WT mice (Fig. 2D and 2E). These data suggest that endogenous IL-32γ is 
important for the control of tissue parasitism during experimental VL.
Figure 1. L. infantum induces expression of IL-32γ in human PBMCs. PBMCs (5 x 106/mL) from 
healthy donors were cultured with total antigen of L. infantum (50 µg/mL) for 4 h, 24 h or 48 h. 
RPMI represents unstimulated cells. (A) IL-32 production was assessed by ELISA in the cell lysates. (B) 
Expression of IL-32γ mRNA by real-time qPCR. (C) Expression of the IL-32β isoform by real-time qPCR. 
(D) Comparison between the relative expressions of the γ and β isoforms of IL-32. Data represent 
median with interquartile range (n = 6 donors). A-C, *p < 0.05 compared to the control in each time, 
by Mann-Whitney U test; In D, *p < 0.05 (IL-32γ vs IL-32β), by Mann-Whitney U test.
IL-32γ increases granuloma formation in the liver during murine 
experimental visceral leishmaniasis.
VL is characterized by granulomatous lesions in the viscera, located mainly in the 
spleen and liver, caused by a chronic inflammatory process induced by the parasites. 
Therefore, since we showed that IL-32γ decreases the parasite load in these organs, 
we investigated the association of IL-32 expression with histopathological 
alterations, triggered by the host immune response to the parasite. Infection with L. 
infantum led to loss of lymphoid architecture of the spleen with predominance of 
red pulp cells, including an increase in the number of megakaryocytes. These 
findings were similar in the spleens of the L. infantum infected–WT or –IL-32γTg 
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mice (Fig. S3). However, we observed a considerable increase in the number of liver 
granulomas in the IL-32γTg mice compared to WT mice (Fig. 3A and 3B). In addition, 
we observed that the hepatic granulomas of L. infantum infected IL-32γTg mice 
occupied larger areas in the liver than the hepatic granulomas of WT mice (Fig. 3C). 
We also observed the presence of larger necrotic areas in the infected IL-32γTg liver 
compared to that seen in the WT mice (Fig. 3A). No differences were found in the 
histopathological aspects of liver and spleen between uninfected IL-32γTg and WT 
mice (Fig. 3A and Fig. S3). Thus, histopathological analyses indicated that IL-32γ 
promoted the formation of larger and more necrotic hepatic granulomas during 
murine L. infantum infection. 
Figure 3. IL-32γ increases hepatic granuloma formation during experimental infection with 
L. infantum. WT and IL-32γTg mice were infected i.p. with 1 x 107 L. infantum promastigotes for 30 
days and fragments of spleen and liver were prepared for histopathological analysis (Hematoxylin-
Eosin staining) under a light microscope. (A) Representative photomicrography of the liver of 
uninfected or infected WT and IL-32γTg mice. The left and middle panels present 100x magnification 
and right panels present 400x magnification. Black arrows indicate granulomas and asterisks 
necrotic areas. (B) Number of hepatic granulomas from 30 day-infected WT and IL-32γTg mice per 10 
fields. (C) Total area of hepatic granulomas in 10 fields. In B and C, the data represent the median and 
individual values of 8 animals, from 3 independent experiments. *p < 0.05 by Mann–Whitney test.
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IL-32γ induces proinflammatory cytokines during experimental 
visceral leishmaniasis.
After 30 days of in vivo infection with L. infantum, the splenic cells of the IL-32γTg 
mice produced significantly higher levels of IFNγ, IL-17A, TNFα and IL-10 following 
ex vivo stimulation with total L. infantum antigen. In WT splenic cell cultures, only 
IFNγ was induced by lysates of L. infantum compared to non-stimulated condition 
(Fig. 4A to 4D). Exposure of splenic cell culture to ConA modestly induced IFNγ 
production in cells from both infected WT or IL-32γTg mice as well as IL-10 in 
WT cultures (Fig. 4A to 4D). In addition, IFNγ, IL-17A, TNFα and IL-10 were found 
in higher levels in both splenic and liver lysates of infected IL-32γTg mice than in 
infected WT mice (Fig. 4E to 4H). In IL-32γTg mice, a positive correlation was found 
between the tissue levels of IL-32 versus TNFα or IL-10 levels in the spleen (Fig. S4). 
All evaluated cytokines were detected at higher levels in liver than in the spleen 
(normalized for tissue weight) from IL-32γTg mice. In addition, the levels of IL-32 in 
the liver significantly correlated with IFNγ, IL-17A or IL-10 levels after infection with 
L. infantum (Fig. S4B). These data indicate that IL-32γ favors a mixed Th1 and Th17 
profile during experimental VL in mice. 
Th1 and Th17 lymphocytes are increased in IL-32γ transgenic mouse 
infected with L. infantum
Since the presence of IL-32γ induced both Th1 and Th17 associated cytokines 
during the experimental VL, we investigated whether IL-32γ increased both Th1- 
and Th17-T cell numbers after L. infantum infection. IL-32γTg mice infected with 
L. infantum for 30 days possessed a higher percentage of T helper lymphocytes 
(CD3+CD4+) in the spleens than infected WT mice (Fig. 5A) whereas there was no 
difference in the percentage of cytotoxic T cells (CD3+CD8+) between the groups 
(Fig. 5B). Although there was a large production of proinflammatory cytokines in 
the liver of IL-32γTg mice, we did not observe differences between the percentage 
of CD4+ or CD8+ T cells present in the livers of WT and IL-32γTg mice (Fig. 5A and 
5B). Antigen-specific proliferation of Th lymphocytes was assessed by CFSE dilution 
method (Fig. S5). CD4+ T cells from the spleens of infected-IL-32γTg mice displayed 
higher antigen-specific proliferation than those from infected WT mice (Fig. 5C) 
whereas similar level of proliferation was obtained after polyclonal activation of T 
lymphocytes from IL-32γTg and WT mice with ConA (Fig. 5C). In addition, 30 day-
infected IL-32γTg mice exhibited a higher percentage of IFNγ-producing CD4+ T cells 
(Fig. 5D) and IL-17A-producing CD4+ T cells (Fig. 5E) in the spleens than infected WT 
mice. Together, these data indicate that IL-32γ upregulates Th1 and Th17 associated 
immune responses during experimental VL.
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Figure 5. IL-32γ increases generation of Th1 and Th17 cells during mouse infection with 
L. infantum. WT and IL-32γTg mice were infected i.p. with 1 x 107 L. infantum promastigotes for 30 
days. Spleen and liver cells were labeled with anti-CD3 FITC, anti-CD4 PE and anti-CD8 PerCP-Cy5.5 
and analyzed by flow cytometry. Percentage of (A) T CD3+CD4+ and (B) T CD3+CD8+ lymphocytes in 
spleen and liver from 30 days-infected WT and IL-32γTg mice. (C) Splenic cells were labeled with 5 
µM CFSE and stimulated with total L. infantum antigen (50 µg/mL) or ConA (5 µg/mL) for 4 days. The 
cells were labeled with anti-CD4 FITC for flow cytometric analysis of proliferation of CD4+ T cells. 
(D and E) The splenic cells (5 x 106 cells/mL) from infected WT and IL-32γTg mice were stimulated 
with 50 µg/mL of total L. infantum antigen for 72 h. Cells were treated with Brefeldin A (10 µg/mL) 
for additional 6 h and the cells stained with anti-CD4 PE. Intracellular cytokines were assessed with 
anti-IFNγ AF488 or anti-IL-17A APC. The data show representative contour plots of IFNγ+CD4+ or 
IL-17A+CD4+ T cells on the left side, and mean ± SEM of 6 animals per group from 2 independent 
experiments, on the right side. *p < 0.05, by Student’s t test.
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Figure 6.  Splenic cells from IL-32γTg mice infected with L. infantum produced greater amounts 
of NO after stimulation with L. infantum antigen ex vivo. (A) WT and IL-32γTg mice were infected 
i.p. with 1 x 107 L. infantum promastigotes. After 30 days, the splenic cells (5 x 106 cells/mL) were 
ex vivo stimulated with L. infantum antigen (50 µg/mL) or ConA (5 µg/mL) for 72 h. Nitric oxide 
production was evaluated by the Griess method in culture supernatants. (B) Correlation between 
the levels of IL-32 in the spleen and nitrite concentration in the supernatant of the splenic cell 
culture. (C) BMDMs from IL-32γTg mice were infected with L. infantum (MOI 5:1) for 3 h or 24 h and 
IL-32 mRNA was analysed by real-time qPCR. (D) BMDMs from WT or IL-32γTg mice were infected 
with L. infantum (MOI 5:1) for 3 h. Cells were washed for removing non-internalized parasites and 
cultured for additional 48 h in the absence or presence of IFNγ (10 ng/mL) alone or IFNγ (10 ng/
mL) + LPS (1 µg/mL). NO was evaluated by Griess method in 48 h-culture supernatant. (E) The 
percentage of infected macrophages and (F) number of parasites per infected cell were evaluated 
under light microscopy. In A, the data show mean ± SEM of 9 animals per group from 3 independent 
experiments. *p < 0.05, by Student’s t test. In B, the data show the individual values of 9 animals and 
linear regression curve. r and p values from Pearson correlation test. In C-F, data represent mean ± 
SEM of 3 independent experiments performed in duplicate.
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Increased nitric oxide production in IL-32γTg mice is dependent on 
IFNγ and IL-17A.
Since NO is one of the major molecules involved in the killing of Leishmania spp. 
in mice (10), we evaluated NO production – as measured by the level of nitrite, the 
metabolite of NO – in splenic cell culture supernatant from 30 day-infected IL-32γTg 
mice stimulated with L. infantum antigen ex vivo. Increased NO production was 
observed by splenic cells from infected IL-32γTg mice after incubation with total L. 
infantum antigen compared to WT mice. ConA stimulus did not significantly induce 
differences in NO production between the splenic cells from WT and IL-32γTg 
mice (Fig. 6A). Nitrite levels in the splenic cell cultures activated with L. infantum 
antigens were positively correlated with IL-32 levels present in the spleens of 
infected-IL-32γTg mice (Fig. 6B). Although infection with L. infantum induced IL-32γ 
mRNA in BMDMs from IL-32γTg mice (Fig. 6C), BMDMs from WT and IL-32γTg mice 
produced similar NO levels after in vitro infection with L. infantum promastigotes 
and stimulation with IFNγ alone or with IFNγ/LPS (Fig. 6D). In fact, there was no 
significant difference between the percentage of infected macrophages (Fig. 6E) or 
between the number of amastigotes per macrophage (Fig. 6F) from WT and IL-32γTg 
mice (Fig. 6E). These findings indicate that the protective effect of IL-32γ during 
experimental VL is not solely due to phenotypic alterations in the macrophage 
themselves of the IL-32γTg mice.  
Since WT and IL-32γTg BMDMs produced NO in similar levels, we reasoned that the 
increased L. infantum antigen-specific NO production observed in IL-32γTg spleen 
cells was secondary to the increased Th1/Th17 cytokines induced by IL-32γ.  Splenic 
cells from 30 day-infected WT and IL-32γTg mice were then incubated with total 
antigen of L. infantum in the absence or presence of neutralizing antibody to IFNγ 
or to TNFα, or a pharmacological inhibitor of Th17 cell differentiation and IL-17A 
production in vivo and in vitro (digoxin) (37, 38). Neutralization of IFNγ or Th17/
IL-17A inhibition significantly reduced the antigen-specific NO production by IL-
32γTg splenic cells. Simultaneous inhibition of IFNγ and IL-17A further increased 
this NO inhibition (p < 0.05, Fig. 7). In WT mice, only neutralization of IFNγ reduced 
NO production. TNFα neutralization had no significant effect on NO production by 
splenic cells from both groups of mice (Fig. 7). 
Taken together, these data demonstrate that IL-32γ can induce antigen-specific 
NO production during murine VL by increasing the production of IFNγ and IL-17A. 
In fact, we observed that IFNγ and IL-17A levels were positively correlated with 
NO production in the spleen cell cultures from IL-32γTg mice. On the other hand, 
there was no significant correlation between IFNγ or IL-17A and nitrite levels in the 
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cultures from WT mice. There was no correlation between TNFα and nitrite levels in 
both animal groups (Fig. S6).
Thus, the protective effect of IL-32γ against murine VL appears to be dependent on 
the activation of an axis comprised of IL-32γ, Th1/IFNγ, Th17/IL-17A, and 
macrophage/NO components.
Figure 7. Increased NO production in splenic cells from IL-32γTg mice infected with L. infantum 
is dependent on IFNγ and IL-17. WT and IL-32γTg mice were infected i.p. with 1 x 107 L. infantum 
promastigotes for 30 days. The spleens were removed and splenocytes (5 x 106 cells/mL) were 
stimulated ex vivo with L. infantum antigen (50 µg/mL) in the absence or presence of rat IgG isotype 
control, anti-IFNγ or anti-TNFα (5 mg/mL) antibodies and/or DMSO or digoxin (10 mM) for 72 h. NO 
production was evaluated by measuring nitrite concentrations in the supernatant of the WT and 
IL-32γTg splenic cells. The data show the mean ± SEM of 6 animals per group from 2 independent 
experiments. *p < 0.05, by one-way ANOVA, with Bonferroni’s post-test.
Discussion
In this study, we showed that L. infantum induces mainly the IL-32γ isoform and 
to a lesser extent IL-32β in PBMCs from healthy individuals. Our previous studies 
demonstrated enhanced expression of IL-32γ in human American Tegumentary 
Leishmaniasis (ATL) lesions and also in human PBMCs and macrophages after 
stimulation with L. braziliensis or L. amazonensis (33–35). We report here that L. 
infantum induces even higher levels of IL-32γ in human PBMCs than other Leishmania 
spp. or Candida albicans. We found that Leishmania protozoans are potent inducers 
of IL-32 expression, and L. infantum was the most potent inducer of IL-32. These data 
prompted us to investigate the role of IL-32γ in a murine model of VL.
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The present study demonstrated that transgenic mice that constitutively express 
human IL-32γ also displayed increased induction of IL-32 in both the spleen and 
liver with L. infantum infection, with peaked IL-32γ levels occurring 30 and 45 p.i. 
This result was unexpected, since the IL-32γ gene was driven by the chicken β-actin 
promoter. Although a constitutive expression of this gene is expected, different 
tissues and organs differentially expressed IL-32 (36). The 5’flanking region of the 
β-actin gene promoter contains various cis-regulatory elements including highly 
conserved CCAAT and TATA binding domains, present in the promoter region of 
β-actin found in rodents, humans, and chicken (39, 40).  Indeed, several evidences 
have shown that β-actin can be induced by innumerable biological agents, 
proinflammatory cytokines and cell proliferation. Furthermore, it is known that 
age and tissue type influence the expression of β-actin (41–44). It is already known 
that different cell types differentially express β-actin, which may explain, at least 
partially, the differences in the expression of IL-32 in different organs. As we further 
showed that L. infantum infection increased inflammatory infiltrate in both spleen 
and liver, the increase in cellularity after infection may also explain the increased 
production of IL-32. 
Of biological significance, the IL-32γTg mice were more resistant to L. infantum 
infection than WT mice with reduced parasitism in the spleen and liver. It is likely 
that the relatively high expression of IL-32γ around 30 days of infection contributed 
to the hepatomegaly and splenomegaly. Indeed, the liver was involved earlier in 
IL-32γTg mice than in WT mice, characterized in the former by an increase in the 
number, size, and necrosis of the granulomas, which likely accounted for the 
transient hepatomegaly. The hepatomegaly regressed from day 45 p.i. in both 
group of animals, but the splenomegaly was still significant in WT mice. The results 
of this study are in agreement with previous reports, which demonstrated that 
C57BL/6 mice develop VL after L. infantum infection and control the parasite after 
60-80 days of infection (12, 45, 46). C57BL/6 mice that developed splenomegaly 
and hepatomegaly after L. infantum infection have improved control of parasitism 
(12, 45) possibly because of a tissue increase of a host-protective inflammatory 
response.  Our data demonstrated that IL-32γ increased hepato- and splenomegaly 
and mice were even more resistant to L. infantum infection compared to WT mice, 
indicating the salutary effect of IL-32 in controlling VL.
The formation of granulomas is important to limit L. infantum infection, which 
can further lead to the killing of the parasites when associated with a strong Th1 
immune response (47–49). Our data showed that IL-32γ favors the development of 
both Th1 and Th17 lymphocytic profiles. There was an increase of proinflammatory 
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cytokines such as IFNγ, TNFα and IL-17A during experimental VL in IL-32γTg mice. 
These data are also consistent with results showing that C57BL/6 mice displayed 
both host-protective Th1 and Th17 responses against L. donovani and L. infantum 
(12, 50). Interestingly, in our study, the Th1 and Th17 responses were improved in 
IL-32γTg mice as demonstrated by the increase of IFNγ and IL-17A in tissue lysates 
as well as after specific-antigen ex vivo stimulation of spleen cell cultures.  These 
findings are supported by studies showing the induction of Th17 and IL-17A by 
L. infantum and L. donovani, respectively (12, 51) . Thus, IL-17 emerges to be an 
important host-protective cytokine during VL. We showed here that IL-32γ induces 
a strong Th1 and Th17 responses against L. infantum. Moreover, IL-32γ appears to 
reduce immunosuppression caused by this Leishmania sp. infection.
One of the mechanisms by which IL-32γ induces both Th1 and Th17 responses 
might be the improvement of dendritic cells maturation and subsequent enhanced 
production of IL-12 and IL-6 by dendritic cells in a PLC/JNK/NF-κB-dependent 
mechanism (21). A previous study showed that IL-32 knockdown resulted in 
drastic reduction of Th1 cytokines by human PBMCs (52). Indeed, proinflammatory 
cytokines such as TNFα and IFNγ induce IL-32 and, in turn, IL-32 induces the 
production of these cytokines in a feedback loop that amplifies the inflammatory 
response (19, 53). IL-17A is also an inducer of IL-32 in rheumatoid arthritis, a disease 
in which there is a loop involving TNFα, IL-32 and IL-17A (54).  Thus, in the present 
VL mouse model, IL-32γ, IFNγ and IL-17A are important players in coordinating the 
immune response against L. infantum parasites.
The limitation of Leishmania growth is mainly dependent on the production of 
NO in mice, which is dependent on Th1 cytokines (55). We have demonstrated 
that IL-32γ induces NO production in splenic cells of infected IL-32γTg mice and 
IL-32 levels strongly correlated with nitrite levels. Indeed, our results indicate that 
the high production of IL-32γ-induced IFNγ and IL-17A appear to be essential for 
NO production and likely contributed to the parasite control during VL. In fact, 
inhibition of IL-17-producing cells indicated that Th17 cells enhanced the ability 
of Th1 cells and macrophages to produce NO. Moreover, the correlation between 
NO and IFNγ or IL-17A production is especially strong in IL-32γTg mice. We have 
demonstrated that IL-32γ is associated with NO production by human macrophages 
infected with L. amazonensis and L. braziliensis (35). Although WT and IL-32γTg 
isolated macrophages produced similar amounts of NO to infection with L. infantum, 
our results indicated that both Th1 and Th17 increases in IL-32γTg mice can induce 
even more NO production by splenic macrophages during VL.
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The role of Th1/IFNγ production on NO production and control of parasitism in 
VL is well established (10, 56, 57); however the role of IL-17A in leishmaniasis is 
controversial (58). Terrazas et al. demonstrated that IL-17A promotes susceptibility 
to experimental VL, since IL-17A-deficient mice showed less parasitism in the 
spleen and liver than control mice (51). Conversely, it was recently shown that IL-
17A synergized with IFNγ to augment NO induction and is essential for resistance in 
experimental VL (12, 13, 46, 59) and other infectious diseases (60, 61). Significantly, 
the Th17 response and IL-17A production are associated with protection in patients 
with VL (11, 62). Indeed, Th1 and Th17 are important for induction of iNOS/NO 
and increased resistance of dogs to VL (63). In human cutaneous leishmaniasis, 
Novoa et al showed a protective role of IL-17 in patients infected with L. braziliensis 
(64). However, Th17 is associated with pathology and disease severity in mice 
and human models of cutaneous leishmaniasis, especially due to an increase in 
neutrophil recruitment, which is associated with tissue damage without the benefit 
of controlling parasite replication (65–68). Thus, despite the controversy, most 
previous studies demonstrate that IL-17A contribute to the protective response 
against VL. It is important to note that a Th17 response alone does not protect 
patients with VL and the Th1 response appears to be essential in protection against 
human VL even in the presence of high amounts of IL-17A (69). 
IL-32γ splicing is important because different IL-32 isoforms may have different 
functions during immune responses (22, 70). IL-32β is especially known to induce 
the production of IL-10 (70, 71). We evaluated three main isoforms of IL-32 and 
only IL32γ and IL-32β were detected during L. infantum infection, corroborating 
our previous hypothesis that Leishmania spp. can inhibit IL-32γ splicing (34, 35). 
Here, we have detected the expression of IL-32β during the experimental VL, but 
the levels of mRNA for this isoform were very low relative to IL-32γ. Therefore, it is 
difficult to ascribe the higher levels of IL-10 in L. infantum-infected IL-32γTg mice 
versus WT mice solely to an increase of IL-32β during infection.
Although we have shown that IL-32γ is increased in human PBMCs in the presence 
of L. infantum, the role of this cytokine in human infection remains unknown. Mice 
present lower inflammatory process than human beings and they are susceptible 
to L. infantum infection (6), thus we hypothesized that the expression of IL-32 could 
contribute to better control of the parasites by increasing the host-protective 
inflammatory response. In fact, we showed that there is an improved response 
to the parasite but not healing as occurs in non-treated VL patients. Together 
with other pro-inflammatory cytokines such as IFNγ, TNFα and IL-17A, IL-32γ 
contributes to the control of the parasitic infection but it also likely participates in 
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the immunopathology of the disease (6, 72). In human VL there is a large mixture 
of pro- and anti-inflammatory factors (6), but the network of their interactions is 
poorly understood. Our data highlight the relevance of future studies to investigate 
how the expression of IL-32 varies with clinical course of the disease in humans.
In conclusion, the present study shows that IL-32γ is important in inducing an 
adaptive immune response profile during murine VL and that IL-32γ contributes 
to the control of L. infantum. These results  support  the need to evaluate IL-32 
in human VL where Th1 and Th17 cells are important to control this infection. 
Humanized mouse models allow a more relevant characterization of host immune 
response to human infections and herein we demonstrated that human IL-32 is an 
important contributor to the host-immune response to leishmaniasis. Furthermore, 
the role of IL-32 in improving both Th1 and Th17 responses during VL places IL-32 as 
a target to augment in future VL vaccine and adjuvant developments. Augmenting 
IL-32 expression in future leishmania vaccine development – with IL-32 functioning 
as an adjuvant itself and/or induced by more traditional adjuvants – has the 
potential to improve existing vaccines against leishmaniasis (73). 
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Supplemental Data
Table S1. Primers sequence
human GAPDH
FW primer: 5’-AGG-GGA-GAT-TCA-GTG-TGG-TG-3’
RV primer: 5’-CGA-CCA-CTT-TGT-CAA-GCT-CA-3’
murine 18S
FW primer: 5’-GTAACCCGTTGAACCCCATT-3’
RV primer: 5’-CCATCCAATCGGTAGTAGCG-3’
human IL-32g
FW primer: 5’-AGGCCCGAATGGTAATGCT-3’
RV primer: 5’-CCACAGTGTCCTCAGTGTCACA-3’
human IL-32b
FW primer: 5’-CAGTGGAGCTGGGTCATCTCA-3’
RV primer: 5’-GGGCCTTCAGCTTCTTCATGTCATCA-3’ 
human IL-32a
FW primer: 5’-GCTGGAGGACGACTTCAAAGA-3’
RV primer: 5’-GGGCTCCGTAGGACTTGTCA-3’
Supplemental Figure 1. Induction of IL-32γ by different stimuli and pathogens in human 
PBMCs. PBMCs (1 x 106/mL) from healthy donors were cultured with LPS (10 ng/mL), poly:IC (50 
µg/mL), 50 µg/mL of total antigen of L. infantum, L. amazonensis (IFLA/BR/67/PH8) or L. braziliensis 
(MHOM/BR/2003/IMG) or heat-killed Candida albicans  (1 × 107 cells/mL) ATCC MYA-3573 (UC 820). 
Expression of IL-32γ isoform was evaluated by qPCR. Data represent mean ± SEM of 6 donors. *p < 
0.05, by Mann-Whitney, compared to control. #p < 0.05, by Mann-Whitney, as indicated.
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Supplemental Figure 2. IL-32γ promotes the control of experimental infection with L. infantum. 
WT and IL-32gTg mice were infected i.p. with 1 x 107 L. infantum promastigotes, for 15, 30, 45 and 60 
days. Parasite burden was evaluated by limiting dilution and normalized by mg of tissue. (A) Parasite 
burden in Spleen. (B) Parasite burden in liver. The data show mean ± SEM of 9 animals per group, 
divided into 3 independent experiments. *p < 0.05 by Student’s t test.
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Supplemental Figure 3. Histopathological aspects of the spleen in WT and IL-32gTg mice 
infected with L. infantum. WT and IL-32gTg mice were infected i.p. with 1 x 107 L. infantum 
promastigotes. After 30 days, fragments of spleen were fixed and stained by Hematoxylin-Eosin 
for analysis under a light microscope. The upper panels show photomicrographs of uninfected WT 
and IL-32gTg spleens (40x magnification). The lower panels show photomicrographs of WT and IL-
32gTg of L. infantum-infected spleens, showing loss of architecture tissue and hyperplasia of red 
pulp in both animals (left panels: 40x magnification; right panels: 100x magnification; inserts: 400x 
magnification). The red arrows show megakaryocytes. 
121Human IL-32g plays a protective role in an experimental model of visceral leishmaniasis
4
Supplemental Figure 4. Positive correlation between IL-32 production with other cytokines in 
the spleen and liver of L. infantum-infected IL-32gTg mice. Spleen and liver of infected WT and 
IL-32gTg mice were mechanically disrupted in PBS/0.1% Triton X-100 in the presence of protease 
inhibitor cocktail and cytokine production was assessed by ELISA. (A) Correlation between the 
production of IL-32 and other cytokines in the spleen. (B) Correlation between the production of 
IL-32 and other cytokines in liver. The data present the individual values of 9 animals and linear 
regression curve. The r and p values were obtained after Pearson’s correlation test.
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Supplemental Figure 5. Gate strategy for CFSE-labeled T CD4+ cells proliferation analysis. 
Splenocytes were labeled with 5 µM CFSE and stimulated with 50 µg/mL of L. infantum antigen or 
Concanavalin A (5 µg/mL) for 4 days. The cells were stained with anti-CD4 PE for flow cytometry 
analysis of proliferation in CD4+ cells gate.
Supplemental Figure 6. Correlation between cytokine and NO levels produced by spleen 
cells from infected WT and IL-32gTg mice. WT and IL-32gTg mice were infected i.p. with 1 x 107 L. 
infantum promastigotes for 30 days. The spleen was removed and homogenized. Erythrocytes were 
lysed and splenocytes were stimulated with L. infantum antigen (50 µg/mL) or ConA (5 µg/mL) for 
24 h (for TNF-α) or 72 h. Cytokine production were evaluated by ELISA. (A-C) Correlation between 
the production of cytokines and NO in IL-32gTg mice. (D-F) Correlation between the production 
of cytokines and NO in WT mice. The data present the individual values of 9 animals and linear 
regression curve. The r and p values by Pearson’s correlation test.
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Supplemental Figure 6. Correlation between cytokine and NO levels produced by spleen 
cells from infected WT and IL-32gTg mice. WT and IL-32gTg mice were infected i.p. with 1 x 107 L. 
infantum promastigotes for 30 days. The spleen was removed and homogenized. Erythrocytes were 
lysed and splenocytes were stimulated with L. infantum antigen (50 µg/mL) or ConA (5 µg/mL) for 
24 h (for TNF-α) or 72 h. Cytokine production were evaluated by ELISA. (A-C) Correlation between 
the production of cytokines and NO in IL-32gTg mice. (D-F) Correlation between the production 
of cytokines and NO in WT mice. The data present the individual values of 9 animals and linear 
regression curve. The r and p values by Pearson’s correlation test.
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Aos meus grandes amigos de Goiás, 
O bem que me fizeram, nunca hei de esquecer. 
Obrigada pela torcida de que tudo desse certo. 
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Abstract
Interleukin-32 (IL)-32 is a novel inflammatory mediator that has been described 
to be important in the immunopathogenesis and control of infections caused by 
Leishmania parasites. By performing experiments with primary human cells in vitro, 
we demonstrate that the expression of IL-32 isoforms is dependent on the time 
exposed to L. amazonensis and L. braziliensis antigens, and that the early induction 
of IL-32γ is mediated by PRRs NOD2, TLR4 and Dectin-1. Moreover, for the first 
time we show the functional consequences of three different genetic variations in 
IL32 (rs4786370, rs4349147, rs1555001) modulating IL-32γ expression, influencing 
innate and adaptive cytokine production after Leishmania exposure. Using a 
Brazilian cohort of 107 American Tegumentary Leishmaniasis (ATL) patients and a 
control cohort of 245 healthy individuals, the IL32 rs4786370 genetic variant was 
associated with protection against ATL, whereas the IL32 rs4349147 was associated 
with susceptibility to the development of different clinical forms of Leishmaniasis. 
Lastly, we show that IL-32γ is mainly associated with the expression of IL-1α, IFNγ, 
IL-17 and IL-22 mRNA in lesion fragments of ATL patients. These novel insights may 
help improve therapeutic strategies and eventually lead to benefits for patients 
suffering from Leishmania infections. 
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Introduction
American Tegumentary Leishmaniasis (ATL) is a chronic inflammatory disease 
caused by protozoa of the genus Leishmania. In Brazil, it is caused by species that 
belong to Leishmania (Viannia) and Leishmania (Leishmania) subgenus, which can 
lead to different clinical manifestations. The localized cutaneous leishmaniasis (LCL) 
is one of the most frequent and mild forms of disease, which can cure spontaneously 
in a minority of the Leishmaniasis infected patients. However, the other forms of ATL 
including mucosal leishmaniasis (ML), disseminated leishmaniasis (DL), and diffuse 
cutaneous lesions (DCL) are more difficult to treat, and relapses are highly frequent 
(1, 2).
Importantly, the clinical manifestation of leishmaniasis is dependent upon both 
the parasite species and the host’s immune response. For example, Leishmania 
(V.) braziliensis and Leishmania (L.) amazonensis primarily cause LCL, which is 
characterized by one or few ulcers in the skin with elevated borders, appearing 
mainly in exposed areas, like upper limbs, lower limbs and face. Among the severe 
cases, L.  braziliensis causes ML affecting primarily the nasopharyngeal and oral 
mucosal epithelial barriers, often leading to ulceration and septum perforation. 
DL is characterized by more than ten papular and ulcerated lesions spread on at 
least two non-contiguous areas of the patient’s body (3, 4). DCL is a rare but severe 
form of the disease caused by L. amazonensis characterized by the presence of non-
ulcerative disseminated nodules that often affects face, limbs and trunk of patients 
(5, 6). 
Upon inoculation of Leishmania spp. by a sand fly into the host skin, cellular and 
molecular events can influence the development of the disease. Innate immune 
cells are important during early stages of infection. Dendritic cells (DC), natural killer 
(NK) cells, neutrophils, and macrophages are fundamental for the host response 
to the parasite (7, 8). Additionally, pattern recognition receptors (PRR) are critical 
for Leishmania parasite recognition by host immune cells. The major pathogen 
associated molecular pattern (PAMP) in Leishmania is lipophosphoglycan (LPG) (9). 
In case of L. braziliensis (10)  and L. amazonensis (11), their LPG can be recognized 
by Toll-like receptor (TLR) 2 and TLR4, respectively. C-type lectin receptors (CLR) 
dectin-1 and mannose receptor (MR), complement receptors CR1 and CR3, Fc 
receptors and NOD-like receptor (NLR) have also been reported important for 
Leishmania-host interface (12-14).
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In addition to its well-described function in parasite control, IFNγ has been 
associated with immunopathology in ATL. Furthermore, TNFα, IL-1β, IL-17 and CD8+ 
T lymphocytes have also been implicated in promoting pathology in Leishmaniasis. 
(15-18). Contrary to inflammatory cytokines, IL-10 can regulate some of these 
immunopathologic responses (19, 20). Moreover, other members of the IL-10 family 
have been identified as key players in the wound healing process (21, 22). IL-22 is 
one of the members of this family, which has been pointed as an important factor to 
limit Leishmania-induced immunopathology (23).
IL-32 is another cytokine that has been described to be involved in the 
immunopathogenesis of inflammatory diseases and control of intracellular 
pathogens. IL-32 is mainly produced by immune cells, but it is additionally expressed 
in non-immune cells including epithelial and endothelial cells (24-28). IL-32 mRNA 
can be processed by alternative splicing, generating several different isoforms. 
The isoforms are generated from the pre-mRNA for IL-32γ, which in respect to 
inflammation is the most active isoform. In the context of human diseases, the most 
studied isoforms are IL-32α, IL-32β and IL-32γ (29, 30). On the functional level, IL-32γ 
amplifies inflammatory signaling induced by TNFα and synergizes with PRRs for the 
induction of IL-1β and IL-6 (31, 32). Through these mechanisms, IL-32 drives innate 
immune cells to generate Th1 and Th17 cellular responses (33). From a molecular 
perspective, IL-32 can inhibit proinflammatory cytokine mRNA decay influencing 
the activation of transcription factors (26). Furthermore, IL-32γ inhibits Hepatitis 
B virus activities at the transcriptional level through a non-cytokine function in 
hepatocytes (34).  
We previously described the expression of IL-32 in epithelial, endothelial and 
mononuclear cells in lesions from patients with LCL and ML (35).  In fact, IL-32 has 
also been implicated as a key player in controlling parasite load in infections caused 
by L. braziliensis or L. amazonensis in both the IL-32γ-transgenic mouse model and 
human cells (36, 37).  To date, it is not precisely known how IL-32 isoforms contribute 
to host defense against Leishmania infections. In the current study, we confirmed 
that IL32 mRNA and protein are expressed in human PBMCs stimulated with 
L. amazonensis or L. braziliensis. We further evaluated the functional consequences 
of three different genetic variations in IL32 (rs4786370, rs4349147, rs1555001) for 
innate and adaptive cytokine production. Furthermore, by analyzing a cohort of 
107 ATL patients and 245 controls, we evaluated whether these genetic variations 
in IL32 influence the susceptibility to disease and the clinical outcome. Finally, the 
expression of important inflammatory mediators in lesion fragments from ATL 
patients was correlated with mRNA levels of IL-32 isoforms.  
130
Methods
Patients, controls and tissues samples
All patients were diagnosed with cutaneous (n = 68) or mucosal (n = 38) ATL in 
Annuar Auad Tropical Disease Hospital, in Goiânia, Goiás, West Central region of 
Brazil.  To be included in the study, besides a leishmaniasis lesion, patients had at least 
one exam indicating the presence of parasites were included. Among the technical 
procedures used for the diagnosis, polymerase chain reaction (PCR) for Leishmania 
genus, histopathological exam with immunohistochemistry for amastigotes forms 
(IHC), indirect immunofluorescence (IFI), and Montenegro’s skin test (MST) were 
used (Table 1) (38). Skin biopsy fragments of 56 ATL patients with cutaneous and 
mucosal lesions were obtained. All the fragments were tested for parasite DNA using 
a polymerase chain reaction (PCR-RFLP) described by (39), and presented positive 
result for Leishmania Viannia subgenus.  For gene expression evaluation, one lesion 
fragment was stored in TRIzol reagent (Invitrogen, USA). To access genetic variations, 
patients were asked to provide blood. For the controls (n = 245), blood from healthy 
individuals was obtained at the blood bank of the Goiano Institute of Oncology and 
Hematology (INGOH), in Goiânia, Goiás. All procedures were approved by Ethics 
Committee of Hospital das Clínicas and Hospital Anuar Auad, Goiânia, Goiás, Brazil 
and informed consent was signed by all patients and controls. 
Table 1.
Characteristics of ATL patients#
  LCL* ML$ DL&
Male 53/68 26/38  -
Female 15/68 (12/38) 1  ± 0
Age (Years) 43.7 ± 14.2 56.4  ±  15.0 41 ± 0
Number of lesions 2.0  ±  1.7  - 20 ± 0
MST (mm)@ 11.6  ±  6.7 25.2  ±  15.7  -
Positive diagnostic test results % (positive/total tested)
PCR^ 80.9 (17/21) 100 (8/8) -
IHC+ 75.0 (33/44) 62.5 (10/16) -
IFI¶   62.0 (18/29) 68.1 (15/22) Positive
MST@   48.3 (15/31)  73.3 (11/15)  -
#
One hundred and seven ATL patients who were assisted at Hospital de Doenças Tropicais Anuar Auad (Goiânia - Goiás, West Central, 
Brazil), 68 with *LCL (Localized Cutaneous Leishmaniasis), 38 with 
$
ML (Mucosal leishmaniasis) and 1 with DL& (Disseminated 
Leishmaniasis). ^PCR: polymerase chain reaction for Leishmania genus, +IHC: histopathological exam with immunohistochemistry 
for amastigotes,  @ MST: Montenegro skin test; ¶IFI: indirect immunofluorescence; 72 patients were from West Central region of Brazil 
(including 25 with ML and 1 with DL); 16 from North (including 4 with ML) and 1 from North East.
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Leishmania cultures and lysates 
L. amazonensis (IFLA/BR/67/PH8) reference strain and MHOM/BR/2003/IMG 
L. braziliensis, a strain from Leishbank IPTSP/UFG, were used. Promastigote 
forms were cultured in Grace’s insect medium (Gibco, Life Technologies, USA) 
supplemented with 20% of heat-inactivated fetal bovine serum (FBS, Gibco), 100 U/
mL of penicillin/streptomycin (Sigma-Aldrich), at 26°C. Stationary-phase parasites 
were obtained on the 6th day of growth and washed three times with phosphate-
buffered saline (PBS; 1000 x g, 10 min 10°C). Parasite lysates were obtained by 5 
freeze-thaw cycles of promastigotes in the presence of protease inhibitors (Protease 
inhibitor cocktail, Sigma-Aldrich), in liquid nitrogen followed by thawing in a water 
bath at 37°C. Protein quantification was performed using the Pierce BCA protein 
assay kit (ThermoFisher Scientific, USA).
Isolation of peripheral blood mononuclear cells (PBMC) from healthy 
controls and treatments
Peripheral  blood mononuclear cells (PBMCs) were  isolated from buffy coats 
obtained after informed consent of healthy volunteers (Sanquin BloodBank, 
Nijmegen) and from EDTA tubes of homozygous individuals for the NOD2 3020insC 
mutation, presenting Crohn’s disease. PBMCs were obtained by Ficoll-Paque 
density gradient cell isolation (GE healthcare, UK), as previously described (12)
(40).  Cells were resuspended in RPMI 1640 culture medium (Roswell Park Memorial 
Institute medium; Invitrogen, USA) supplemented with 50 mg/mL gentamicin, 2 
mM glutamax (Gibco), and 1 mM pyruvate (Gibco) and quantified. In brief, PBMC 
stimulations with lysates of both L. amazonensis or L. braziliensis (50 mg/mL) were 
performed with 5 x 105 cells/well in round-bottom 96-wells plates for either 24 h or 
7 days in the presence of culture medium with 10% human pool serum at 37°C and 
5% CO2. In addition, PBMCs were stimulated during 24 h with LPG (10 mg/mL) from L. 
amazonensis or L. braziliensis. In some experiments, PBMCs were pre-incubated for 
1 h, at 37°C, and 5% CO2 with either Bartonella quintana LPS (5 mg/mL) (40) for TLR4 
blocking or with laminarin (100 mg/mL; Sigma-Aldrich) as antagonist of Dectin-1. 
After the stimulation period, supernatants and cells were stored in either 200 mL of 
TRIzol (Invitrogen) at -80°C until RNA extraction or in 100 mL of 0.5 % TritonX-100 
(Sigma-Aldrich) for intracellular IL-32 measurement.
Genetic Analysis in the 200FG cohort
Genetic variation was assessed in the IL-32 gene in healthy individuals of Western 
European descent from the 200FG cohort (41), www.functionalgenomicproject.
com). The volunteers were between 23 and 73 years old and consisted of 77% 
males and 23% females. PBMCs were isolated as described above. After 24 h and 7 
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days, supernatants were collected and cytokines were measured by enzyme-linked 
immunosorbent assay (ELISA) as described below. 
Transcriptional Analysis
Previously published microarray data of normal skin samples (n=10), early (n=8) 
and late (n=17) LCL lesion samples were obtained form the publicly available 
National Center for Biotechnology Information (NCBI) Gene Expression Omnibus 
(GEO) database (accession number GSE55664). The expression of selected genes in 
normal skin verus L. braziliensis lesions were represented in a heatmap presented 
as dendograms shown as a tree, representing the distance between variables. 
Unsupervised hierarchical clustering of selected genes was performed using the 
R package hclust with Spearman correlation and presented using the R package 
‘corrplot’. 
Quantitative PCR 
RNA was isolated from PBMCs and ATL patient’s lesions stored in TRIzol as previously 
described (42). cDNA was made using the iScript kit (Bio-Rad). Primer pairs for the 
IL32 isoforms are described elsewhere (36). IL-1β, IL-1α, IL-22, IL-17 and IFNγ primers 
sequences were designed specifically for each transcript using Primer Express 3.0 
software (DeNovo Software, Glendale, CA, USA). Primers were produced by Sigma-
Aldrich. Diluted cDNA was used for qPCR that was done by using the StepOnePlus 
qPCR system (Applied Biosystems, Foster City, CA, USA) with SYBR Green Mastermix 
(Applied Biosystems). Fold change and relative expression were calculated with 
the 2^-ddCT and 2^-dCT  methods, respectively and normalized against the 
housekeeping gene B2M.  
Enzyme-linked immunosorbent assay (ELISA)
Cytokine production was determined in 24 h supernatants using commercial ELISA 
kits (R&D Systems) for human TNFa, IL-6 and IL-1b. Supernatants of the 7 days 
stimulation were used to measure IFNg, IL-17A and IL-22. IL-32 was determined 
intracellularly with Triton X-100-cell lysates after 24 h and 7 days using commercial 
ELISA kit (R&D Systems). 
Isolation of genomic DNA and genetic assessment of IL32 variations in 
ATL patients and controls
DNA was isolated from venous blood of ATL patients and healthy controls using 
the illustra blood genomicPrep Mini Spin Kit (GE Healthcare, Little Chalfont, UK), 
according to the manufacturer’s protocol. SNPs in IL32 were selected based on 
previously published functional effects on protein function and/or gene expression 
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and characteristics are described in detail in Supplementary Table 1 (43, 44). 
Genotyping of ATL patients and controls was performed by TaqMan® SNP assays 
(Suppl Table 1) (Applied Biosystems), according to the manufacturer’s protocol on 
the StepOnePlus qPCR system (Applied Biosystems). Quality control was performed 
by the incorporation of positive and negative controls and duplication of random 
samples across different plates.
Statistical Analysis
All statistical analyses and graphs of cytokine concentrations and mRNA expression 
in the in vitro PBMC stimulation assays were performed and created using GraphPad 
Prism 6.00 software (GraphPad Software, San Diego, CA, USA). Data are shown as 
mean ± SEM. Results were stratified by genotype, and differences in cytokine 
production between genotypes were analyzed by Mann–Whitney U test, otherwise 
in each figure, the applied statistical test is indicated in the figure legend. The 
difference in genotype frequencies between the patients and the control group 
was analyzed in a dominant and a recessive model using logistic regression. No 
correction for multiple testing was performed. The effect of the genotypes on 
ATL susceptibility was estimated by calculating odds ratios (ORs) and their 95% 
confidence intervals using the same statistical methods. We also performed Fisher 
test analysis to determine whether clinical manifestations of ATL were associated 
with one of the IL32 genotypes. Analyses were conducted using the statistical 
computing evrionment, R (v3.5.0). Overall, statistical tests P-values of < 0.05 were 
considered to be statistically significant.
Results 
Differential IL-32 isoform expression is dependent on duration of 
exposure to Leishmania antigens
To investigate whether Leishmania species can induce different isoforms of IL32 in 
PBMCs from healthy individuals in a time-dependent manner, we evaluated IL32 
mRNA expression. Both L. amazonensis and L. braziliensis induced IL-32γ and IL-
32β expression in PBMCs after incubation for 24 h (Figure 1A and B). On the other 
hand, after 7 days of Leishmania-antigen stimulation, the IL-32β and IL-32α were 
the main isoforms expressed (Figure 1C and D). The production of intracellular IL-
32 protein by PBMCs upon exposure to antigens from both Leishmania species was 
enhanced compared to unstimulated cells at both time points (Figure 1E and F). 
However, we observed a 5-fold increase in intracellular IL-32 between 7 days and 24 
h of incubation (Figure 1E, 1F). 
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Figure 1: IL-32 isoform gene expression as well intracellular IL-32 protein were measured in PBMCs 
stimulated with lysates (50 mg/ mL) of  L. amazonenis and L. braziliensis for (A-B-E) 24 hours and 
(C-D-G) 7 days. IL-32 isoform gene expression as well intracellular IL-32 protein were also measured 
in PBMCs stimulated with LPG (10 mg/ mL) of  L. amazonenis and L. braziliensis for (I-J-K)) 24 hours. 
The data shown are the mean ± SEM of fold change in IL-32 expression induced by Leishmania spp. 
normalized to RPMI control (dotted line). n = 6.  *p < 0.05 (RPMI vs Leishmania spp., Wilcoxon test).
Early induction of IL-32γ is mediated by NOD2, TLR4 and Dectin-1
In order to evaluate which are the receptors involved in early IL-32 induction by 
Leishmania spp. in PBMCs, we further assessed whether genetic variations in PRRs 
could affect the expression of IL-32γ expression. Supplemental Figure 1A shows a 
reduction of IL-32γ mRNA expression in PBMCs isolated from individuals carrying a 
heterozygous frame shift SNP in the NOD2 receptor (rs2066847), when compared to 
the individuals without the SNP (Wt) after 24 h of exposure to L. amazonensis 
antigens. Exploring TLR2 and TLR4, we observed that a missense SNP in TLR4 
(rs4986791), but not in TLR2 (rs5743708), modulates IL-32γ mRNA expression upon 
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L. amazonensis exposure. In addition, we investigated the role of C-type lectin 
receptors, more specifically Dectin-1 (CLEC7A rs16910526 SNP) and Mannose 
receptor (CD206 rs1926736 SNP) role in IL-32γ induction. Supplemental Figure 1B 
shows that a nonsense SNP in CLEC7A might influence IL-32γ mRNA expression, 
since one individual carrying the CC genotype presented lower IL-32γ mRNA 
expression compared to individuals bearing AA and AC genotypes. This effect was 
seen for both species of Leishmania. No effect on IL32γ mRNA expression was 
observed for individuals carrying different genotypes for a missense SNP in CD206 
(rs1926736). 
Figure 2: IL-32γ gene expression was measured in PBMCs from healthy controls carrying no 
mutation in NOD2 (n=6) and from individuals carrying a mutation in NOD2 receptor (3020insC) (n=3) 
after 24 hours exposure with lysates (50 mg/ mL) of  L. amazonenis and L. braziliensis (A-B). IL-32γ 
gene expression measured in PBMCs from healthy individuals (n=6)  pre-incubated 1 hour in the 
presence of Bartonella quintana LPS (Bart LPS - 5 mg/mL) and with laminarin (100 mg/mL) followed 
by stimulation with lysates of  L. amazonenis and L. braziliensis (B-C). The data shown are the mean ± 
SEM, n = 6.  *p < 0.05 (Leishmania spp. vs  Leishmania spp. in the presence of  Bart LPS or laminarin, 
Wilcoxon test).
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The influence of NOD2, TLR4 and Dectin-1 signaling on IL-32γ induction upon 
Leishmania spp. exposure was further validated using biological assays. PBMCs 
isolated from patients carrying a frameshift mutation in NOD2 expressed lower 
levels of IL-32γ mRNA than healthy individuals after L. amazonensis stimulation 
(Figure 2A). In addition, when TLR4 was blocked with Bartonella quintana LPS (TLR4 
antagonist (40) there was a significant reduction in Leishmania spp.-induced IL32γ 
mRNA expression (Figure 2B). Next, using laminarin as a Dectin-1 antagonist, we 
observed a significant reduction in IL32γ mRNA expression after exposure to both 
species of Leishmania. (Figure 2C). 
Genetic variations in IL-32 gene influence cytokine production upon 
Leishmania exposure
To further investigate the relevance of IL-32 for Leishmania-induced cytokine 
production, we used functional genomics searching for SNPs within IL32 that alter 
gene expression. Therefore, we assessed the response of PBMCs isolated from 200 
healthy volunteers (200FG cohort) stimulated with L. amazonensis or L. braziliensis. 
Figure 3A showed that a CC genotype of the promoter SNP (rs4786370) trends to 
have higher mRNA IL-32γ expression after L. amazonensis exposure compared 
to the TT/CT genotypes. No major differences were observed after L. braziliensis 
stimulation. In addition, the effect of a SNP (rs4349147) located in a distal regulatory 
(enhancer) region of IL32 was examined. Figure 3B showed that individuals bearing 
the AA genotypes expressed lower levels of L. amazonensis-induced IL32γ  mRNA 
than those bearing GG/GA genotypes.  Again, no differences were observed for 
L. braziliensis. In addition, the effect of an intronic SNP (rs1555001) on IL32 gene 
expression was investigated. Indeed AA genotypes expressed lower levels of IL-32γ 
mRNA compared to the TT/AT genotypes after exposure to both Leishmania species 
(Figure 3C). 
Since genetic variation in the IL32 gene clearly modulates IL32γ expression, we 
investigated whether these genetic variations influence both innate and adaptive 
cytokine production in human PBMCs cultured in the presence of L. amazonensis or 
L. braziliensis antigens. Therefore, we analyzed PBMCs isolated from healthy 
volunteers of the 200FG cohort with or without those SNPs in the IL32 gene. The 
classical innate cytokines TNFα, IL-6 and IL-1β were evaluated after 24 h of PBMC 
stimulation (early IL-32γ production). No significant differences were observed in 
any of the examined cytokines within the genotypes of the IL-32 promoter SNP after 
both Leishmania spp. exposure (Figure 4A). In contrast, a lower TNFα, IL-6 and IL-1β 
production was observed in the group of individuals with the AA genotypes of the 
enhancer SNP in IL-32 than in PBMCs from individuals bearing the GG/GA genotypes 
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after L. amazonensis stimulation. Moreover, for L. braziliensis antigen stimulation, a 
reduction in IL-1β production was observed in cells from individuals carrying the 
AA genotype of the same SNP compared to the GG/GA genotypes. No significant 
differences were observed in L. braziliensis-induced TNFα and IL-6 production 
(Figure 4B). 
Figure 3: PBMCs from healthy donors from the 200FG cohort were stimulated with lysates (50 
mg/ mL) of L. amazonenis and L. braziliensis for 24 hours. The invidivuals were stratified according 
with different genotypes of (A) IL-32 rs4786370, (B) rs4349147 and (C) rs1555001 and  IL-32γ gene 
expression was determined. The data shown are the mean ± SEM of fold change in IL-32γ expression 
induced by Leishmania spp. normalized to RPMI control. 
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Figure 4: PBMCs from healthy donors from the 200FG cohort were stimulated with lysates (50 mg/ 
mL) of L. amazonenis and L. braziliensis for 24 hours. Cytokine levels of  TNFα, IL-6 and IL-1β  were 
measured.  Cytokine levels were stratified for the different genotypes for (A) IL-32 rs4786370 (TT/
CT n= 139; CC n= 25), (B) rs4349147 (GG/GA n= 140; AA n= 23), (C) rs1555001 (TT/AT n= 146; AA 
n= 17). Dotted line represent the basal level of cytokine production in the RPMI control. The data 
shown are the mean ± SEM, *p < 0.05 (TT/CT vs CC; GG/GA vs AA; TT/AT vs AA, respectively, Mann-
Whitney U test). 
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Figure 5: PBMCs from healthy donors from the 200FG cohort were stimulated with lysates (50 mg/ 
mL) of L. amazonenis and L. braziliensis for 7 days. Levels of  IFNγ, IL-17 and IL-22 were measured 
by ELISA. Cytokine levels were stratified for the different genotypes for (A) IL-32 rs4786370 (TT/CT 
n= 139; CC n= 25), (B) rs4349147 (GG/GA n= 140; AA n= 23), (C) rs1555001 (TT/AT n= 146; AA n= 17). 
Dotted line represent the basal level of cytokine production in the RPMI control. The data shown 
are the mean ± SEM, *p < 0.05 (TT/CT vs CC; GG/GA vs AA; TT/AT vs AA, respectively, Mann-Whitney 
U test). 
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For the intronic SNP of IL32, significant lower TNFα and IL-1β production was 
observed in the PBMC cultures of individuals carrying the AA genotype than in 
those of individuals bearing TT/AT genotypes after stimulation with either species of 
Leishmania. No differences in IL-6 production were observed between the genotypes 
(Fig. 4C). Subsequently, production of the T-cell-derived cytokines IFNγ, IL-17 and IL-
22 were determined after 7 days of PBMCs cultured with Leishmania antigens. Figure 
5A shows a higher IL-22 production in the cultures of PBMCs from individuals with CC 
genotype than those with TT/CT genotypes of the IL-32 promoter SNP (rs4786370) 
after L. amazonensis stimulation. No differences were observed neither in IFNγ nor 
in IL-17 production when comparing these genotypes. In addition, for the enhancer 
SNP (rs4349147), IL-22 production was lower in the AA genotype than the GG/
GA genotypes after exposure to both Leishmania species (Figure 5B). In line with 
previous SNP data, no differences were observed in IFNγ neither in IL-17 production. 
Interestingly, for the intronic SNP (rs1555001), the production of IFNγ, IL-17 and IL-22 
was lower in the cells with AA genotype, which is associated with low levels of  IL-32γ 
expression after L. amazonensis stimulation (Figure 5C). Similar results were noted for 
IFNγ and IL-22 production when PBMCs were stimulated with L. braziliensis. Strikingly, 
L. braziliensis was not capable to induce IL-17 production in the PBMC cultures, in 
contrast to L. amazonensis (Figure 5). 
Association of IL-32 genetic variations with susceptibility to 
Leishmania infection.  
The observation that IL-32 is induced in PBMCs upon stimulation with Leishmania 
spp. and that genetic variations in the IL-32 gene affect IL-32γ expression, and 
thereby the production of proinflammatory cytokines, led us to the hypothesis 
that IL32 SNPs could affect susceptibility to ATL. A Brazilian cohort of 107 ATL 
patients and a control cohort of 245 healthy individuals were genotyped for IL32 
rs4786370 and rs1555001 genetic variations (Table 2). Different models of genetic 
variations were tested, including comparison of frequencies of all three genotypes, 
a dominant model (comparison of frequencies between homozygous wild-type 
versus heterozygous + homozygous for the allelic variant), and a recessive model 
(comparison of frequencies between homozygous wild-type + heterozygous versus 
homozygous for the allelic variant). For the IL32 rs4786370 variant, the frequency 
of the CC genotype was significantly higher in controls than in patients (P = 0.02). 
No differences within genotype frequencies were observed for the IL32 rs1555001 
variant between patients and controls (Table 2). Dominant model analyses resulted 
in no significant different distribution for the IL32 rs4786370 variant. However, 
when a recessive model was assumed (CC versus CT + TT), significant difference 
was observed in the distribution of the homozygous for the variant allele in 
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patients and controls, where patients were less often homozygous (CC) than 
controls.  These results pointed towards an increased frequency of the variant in 
the cohort of controls, arguing for a decreased risk to develop ATL in the presence 
of homozygous CC genotype (P=4.00E-03, OR = 0.35 [95% Cl, 0.17 - 0.72]). No 
significant associations with susceptibility for both dominant and recessive model 
analysis were observed in patients and controls carrying both IL-32 rs1555001 and 
IL-32 rs4349147 variations (Table 2). 
Association between IL32 genetic variations and ATL clinical 
manifestations
To assess whether the IL32 genetic variation influences clinical manifestations of 
ATL, patients were stratified according to the clinical forms, including LCL, ML and 
DL and compared among the different IL32 genotypes. No statistically significant 
differences were observed within the frequencies of the genotypes for either IL-
32 rs4786370 and rs1555001variations and the clinical outcome of the patients 
(Table 3). However, a significant association was observed for the IL-32 rs4349147 
genotypes, with the G allele overrepresented in the group of patients with LCL, 
whereas the A allele is overrepresented in the  group of ML patients (P = 0.002). 
These results suggest that the A allele is associated with susceptibility to develop 
the more severe form of the disease.  
IL-32γ expression is strongly associated with proinflammatory 
cytokines in ATL skin lesions.
To unravel whether IL32 expression in skin lesions of LCL patients is associated 
to genes linked to skin inflammation and host defense, we analyzed the gene 
expression profile of L. braziliensis infected skin in comparion to normal skin. The 
mRNA of the proinflammatory cytokines IL-32, TNF, IL1Α, IL1B, IFNG, IL-17A and IL-
22, the chemokines CXCL1, CXCL5, CXCL9, as well the metalloproteinases MMP25, 
MMP9, MMP10, MMP3 and immune receptors TLR4, TLR2, NOD1, NOD2,  ITGAM, 
CLEC7A, MRC1 were mainly expressed in L. braziliensis lesions (Figure 6A). Next, we 
evaluated whether all these genes were correlated to each other in LCL skin lesions 
(Figure 6B, blue: positive; red: negative correlations). A strong positive correlation 
was observed between functionally related genes, such as IL32 and IL22, which is 
adjacent to a another cluster of CLEC4E, IL6, IL1RN, IL1A, MMP10, MMP9 genes which 
are also positively correlated. 
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Table 2.
Difference in genotype frequencies between LTA patients and controls, and the effect of IL32 genotypes on ATL  
susceptibility
Genotype Patients (%) Controls (%) Odds ratio (95% confidence interval) P-value 
rs4786370
TT 37 (35%) 82 (34%) 1.00 (Reference)
CT 60 (56%) 108 (44%) 1.23 (0.72 - 2.10) 0.44a
CC 10 (9%) 55 (22%) 0.40 (0.16 - 0.91) 0.02a
Total 107 245
Dominant model
TT 37 (35%) 82 (34%) 0.95 (0.58 - 1.53) 0.83b
CT + CC 70 (65%) 163 (66%)
Total 107 245
Recessive model
CC 10 (9%) 55 (22%) 0.35 (0.17 - 0.72) 4.00E-03b
CT + TT 97 ( 91%) 190 (78%)
Total 107 245
rs1555001
TT 51 (48%) 132(53%) 1.00 (Reference)
AT 49 (46%) 96 (39%) 1.31 (0.80 - 2.17) 0.27a
AA 7 (6%) 20 (8%) 0.90 (0.30 - 2.40) 1a
Total 107 248
Dominant model 
TT 51 (48%) 132(53%) 1.24 (0.79 - 1.96) 0.33b
AT + AA 56 ( 52%) 116 (47%)
Total 107 248
Recessive model 
AA 7 (6%) 20 (8%)  0.79 (0.32 - 1.94) 0.62b
AT + TT 100 (94%) 228 (92%)
Total 107 248
rs4349147
GG 57 (54%) 97(49%) 1.00 (Reference)
GA 41 (39%) 79 (39%) 1.13 (0.66 - 1.92) 0.70a
AA 7 (7%) 24 (12%) 2.0 (0.77 - 5.87) 0.14a
Total 105 200
Dominant model 
GG 57 (54%) 97(49%) 0.79 (0.49 - 1.27) 0.33b
GA + AA 48 (46%) 103 (51%)
Total 105 200
Recessive model 
AA 7 (7%) 24 (12%)  0.52 (0.21 - 1.25) 0.14b
GA + GG 98 (93%) 176 (88%)
Total 105 200
a Fisher test; b Logistic regression.
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Figure 6: Gene expression in normal skin and LCL patients. (A) Heatmap showing the expression 
of selected genes in normal skin verus L. braziliensis lesions. Columns represent individual patients 
and rows represent individual genes, colored to indicate expression levels based on a Z-score. 
Dendograms are shown as a tree, representing the distance between variables. (B) Correlation plot 
shows the positive (blue) or negative (red) correlations of all genes expressen in L. braziliensis lesions 
with color intensity reflecting the strength of the correlation. Correlation of IL-32γ with (C) IL-1β, (D) 
IL-1α, (E) IFNγ, (F) IL-17 and (G) IL22 gene expression in skin biopsies of ATL patients determined by 
qPCR. The data shown are log2 of Relative expression adjusted for beta-2 microglobulin expression 
(n=56); *p < 0.05 (IL-32γ vs IL-1β  Spearman r= 0.06112; IL-32γ vs IL-1α  Spearman r= 0.5435; IL-32γ vs 
IFNγ a  Spearman r= 0.3906; IL-32γ vs IL-17 Spearman r= 0.7419; IL-32γ vs IL-22 Spearman r= 0.6519). 
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Since we demonstrate that genetic variations in IL32 influence proinflammatory 
cytokine production in PBMCs stimulated with Leishmania spp. (Figure 4, Figure 5), 
we were prompted to validate whether IL-32γ expression is associated with innate 
(IL-1β, IL-1α) and adaptive cytokines (IFNγ, IL-17 and IL-22) in lesion fragments 
of  our cohort of ATL patients. A significantly positive correlation between IL-32γ 
expression and IL-1α (Figure 6D), IFNγ, and IL-17 (Figure 6E and F) was apparent. Of 
great relevance for host defense, a strong correlation was found between IL-32γ and 
IL-22 (r2 = 0.8930, p < 0.0001) (Figure 6G) expressions in ATL lesions.  Remarkably, 
no significant correlation was observed for IL-32γ and IL-1β expression (Figure 6C). 
Table 3.  
Summary of genotype–phenotype association within the ATL patient group
rs4786370 TT (%) CT (%) CC (%) Total P-value 
LCL 23 (61%) 39 (66%) 6 (60%) 68 0.33
LM 15 (39%) 20 (34%) 3 (30%) 38
DL 0 (0%) 0 1 (10%) 1
rs1555001 TT (%) AT (%) AA (%)    
LCL 35 (67%) 29 (60%) 4 (57%) 68 0.71
LM 16 (31%) 19 (40%) 3 (43%) 38
DL 1 (2%) 0 (0%) 0 (0%) 1
rs4349147 GG (%) GA (%) AA (%)    
LCL 35 (61%) 27 (68%) 3 (43%) 65 0.002
LM 21 (37%) 13 (32%) 4 (57%) 38
DL 1 (2%) 0 (0%) 0 (0%) 1
a Calculated by Fisher test.
Discussion 
In the present study, we demonstrated that both L. amazonensis and L. braziliensis 
induce IL-32 expression in primary human PBMCs. Of interest, L. amazonensis is a 
stronger inducer of both IL32γ mRNA and protein than L. braziliensis at least during 
the first 24 h of PBMC stimulation with Leishmania spp. antigens. Intriguingly, when 
PBMCs were exposed to both  Leishmania species for 7 days, enhanced splicing of 
IL32γ  mRNA occurred with an increase in IL32α and IL32β isoforms expression, 
resulting in a high amount of IL-32 in the cells. The induction of both IL-32 mRNA 
and protein reveals to be dependent on several PRRs, namely NOD2, TLR4 and 
Dectin-1. We showed that genetic variants of the IL32 gene influenced IL32γ mRNA 
expression. Moreover, we could demonstrate that these investigated genetic 
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variations influenced the  production of innate and acquired Leishmania-induced 
cytokine production by primary human PBMCs. Of high interest, our data suggest 
that the IL32 SNP (rs4786370) is associated with susceptibility to ATL. In addition, 
the IL32 SNP (rs4349147) was associated with the clinical outcome of ATL patients, 
being more frequent among ML than LCL patients. Lastly, here we demonstrated 
that the IL-32γ  mRNA expression in lesions of ATL patients was positively correlated 
with the expression of several proinflammatory cytokines, such as IL1α, IFNγ, IL17, 
and IL22. In addition,  IL32α  mRNA expression was positively correlated with IL1α, 
and IL17 mRNA expression whereas IL32β mRNA expression was associated with 
IL17 and IL22 mRNA expression.
In the present study, it was shown that promastigote antigens are able to induce 
early expression of IL32γ in human PBMCs. The results obtained in this study 
indicate that amastigote (35) as well as promastigote forms (36) are both inducers 
of early IL32γ expression. In addition, promastigote antigens from L. amazonensis 
were able to induce higher levels of IL32γ  than L. braziliensis in PBMCs, confirming 
the previous results obtained with THP-1 macrophages (36).  In contrast, after 7 days 
of exposure to both Leishmania species, human PBMCs predominantly expressed 
IL32α and IL32β mRNA (Figure 1C and D). It is likely that IL32γ mRNA will be spliced 
during long term Leishmania exposure. In parallel with the elevated mRNA levels 
of IL32 isoforms at days 1 and 7, enhanced intracellular protein expression of IL-32 
was observed. Interestingly, the highest concentrations were seen after 7 days of 
exposure to Leishmania spp. (Figure 1G). 
Although it was reported previously that Leishmania spp. can induced IL-32 in 
human cells and it is positively associated with cytokine production in vitro and in 
vivo (35, 36), which receptor is involved in this process is unknown. Using a functional 
genomics approach, we were able to identify the receptors that are important for 
Leishmania spp. mediated induction of IL32γ, the most inflammatory isoform of 
IL-32. Functional genomics revealed to be a powerful approach to identify novel 
pathways in infectious diseases, such as candidemia, tuberculosis and Lyme disease 
(45, 46). In line with previous reports, we could show that TLR4 and NOD2 receptors 
are involved in the recognition of Leishmania and induction of IL32γ (12, 47). Apart 
of TLR4 and NOD2, Dectin-1 was identified as the PRR for the induction of IL-32γ. 
Several C-type lectins, such as MR and Mincle have been described as recognition 
receptors for Leishmania (48-50). It is unlikely that MR is involved in the induction 
of IL32γ since there were no SNPs identified that modulated the IL-32γ expression 
(Suppl. Figure 1B). It would be of high interest to evaluate whether mincle plays a 
role in Leishmania induction of IL32γ. 
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To demonstrate the role of IL-32 in Leishmania-induced cytokine production by 
primary cells, we described genetic variations within IL32 that alter IL32γ mRNA 
expression and proinflammatory cytokines produced by cells from innate and 
acquired immunity; thus, we have shown that depending on the Leishmania spp., 
genetic variations in IL32 lead to functional consequences modulating IL-32γ 
expression and the production of proinflammatory cytokines (Figures 3,4 and 5). 
As all cytokines evaluated in this study have been shown to be involved in 
immunopathogenesis of leishmaniasis (15, 16, 51) and in the parasite control (52, 
53), the present data indicate a pivotal role of IL-32 in immune response against 
parasites that cause ATL. To investigate whether these genetic variations in IL32 
could be associated with susceptibility or resistance to ATL, we evaluated the 
differences in genotypes frequencies of ATL patients compared to controls. Genetic 
variations have been described associated with suscepitibility to complicated 
skin and skin structure infections (cSSSIs) and HIV infections (44, 54). Likewise in 
our study, we observed an increased frequency of IL-32 rs4786370-CC genotype in 
controls. This genotype was linked with high IL32γ  and IL-22 induction in PBMCs 
after exposure to L. amazonensis antigens, which suggest a possible role of IL-32 in 
decreasing the risk of developing ATL. Despite of in vitro cytokine alterations, the 
other IL32 genetic variants (rs4349147; rs1555001) presented similar frequencies 
between the groups of ATL patients and controls what could be ascribed due the 
low number of individuals included in the study.  This is the first study investigating 
the role of genetic variations in IL32 associated with susceptibility to ATL; thus it 
would be worthwhile to increase the number of individuals in the cohorts to 
validate our findings reported in the present study. 
After stratifying patients for their IL32 genotype and correlate it with clinical 
manifestation of the disease, it was observed the allele G of  the IL-32 rs4349147 
was more frequent in patients with LCL than ML. The G allele was associated with 
increased levels of IL32γ, IL-6, IL-1β and IL-22 in PBMCs exposed to L. amazonensis 
antigens, and with IL-1β and IL-22 to L. braziliensis antigens. Thus, these findings 
suggest that allele G might contribute to the development of the less severe form of 
the disease conferring protection against ML. 
Based on the expression of individual genes coding for immune host defense and 
being described related with IL-32 expression (29), early and late lesions from L. 
braziliensis skin that are transcriptionally indistinguishable (55) could be clearly 
separated from normal skin based on mRNA levels. Expression of IL32 and other 
genes that promote severe inflammation including cytokines, chemokines and 
also metalloproteinases, which can degrade the extracellular matrix leading to 
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more tissue damage, were higher in L. braziliensis lesions. Positive correlations 
between IL-32 and IL-22 were observed in L. braziliensis lesions. IL-22, as well IL-32, 
have  been described to be important for host defense against microorganisms 
and antimicrobial peptide secretion  (28, 29, 56). However, IL-22 has been pointed 
as a crucial cytokine for both chronic inflammation and maintenance of epithelial 
integrity (57, 58). 
In addition, we demonstrated that in our cohort of ATL patients, IL32γ mRNA 
expression was correlated with IL1α, IFNγ, IL17 and IL22. Especially IL22 was found 
to be highly correlated with IL32γ expression. Until now, it is unclear whether IL-22 
plays an important role in controlling Leishmania infection and thereby inducing 
severe skin inflammation. It would be of high interest to explore the role of cells 
present in the lesion of ATL patients that produce both IL-32 and IL-22, such as Th17 
or Th22 (59).  
Although IL-32γ is the most prevalent isoform in the lesions of ATL patients (present 
data; (35)), evaluated whether IL-32β and IL-32α isoforms were associated with 
proinflammatory cytokines in ATL lesions.  IL32β  mRNA was correlated with and  IL17 
and IL22; IL32α with IL1α and IL17 (Suppl fig. 2 and 3). These results suggests that the 
IL32γ and IL32α isoforms can be associated with a mixed Th1/Th17 profile whereas 
IL32β can be more associated with a Th17 profile. It is known that IL32γ can induce 
a mixed Th1/Th17 acquired immune response (33, 60). Previous data has shown that 
in other inflammatory skin diseases such as Psoriasis and Hydradinitis Superativa, 
IL-32β was the main isotype that was expressed (61). Although IL-32β is known to 
present proinflammatory properties (42), it has been shown that IL-32β induces IL-10 
production (62). IL-32α is regarded as anti-inflammatory member of the IL-32 family 
which is able to inhibit NK cell activation and JAK/STAT pathway (63).  Whether IL-
32β or IL32α acts as an anti-inflammatory mediators in lesions of ATL patients is not 
known at this moment.
In conclusion, this study raises the concept of an important role for endogenous 
IL-32 in modulation of the inflammatory response in humans that influences 
susceptibility to and progression of ATL. In ATL, IL-32 is a novel target and  may have 
promising therapeutic potential in the future. However, several aspects of the IL-
32 biological function of IL-32 in human immune cells remain elusive. The precise 
molecular mechanisms mediated by IL-32 in  lesions of Leishmania patients, including 
inflammatory pathways and control of parasite load, needs to be elucidated. Moreover, 
future studies should reveal whether the functional effects of genetic variations in 
IL32 observed in human PBMCs are also exerted in the ATL lesions environment. 
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Supplemental Data
Supplementary table 1
Gene  SNP ID  Region  Nucleotide  Change  TaqMan Assay ID 
IL-32  rs4786370 Promoter T >C C__27972515_10
IL-32 rs4349147  Enhancer G >A C__32104871_10
IL-32 rs1555001  Intron T >A C_11186529_10
a The first nucleotide is the ancestral nucleotide.
Supplemental figure 1: PBMCs from healthy donors from the 200FG cohort were stimulated with 
lysates (50 mg/ mL) of L. amazonenis and L. braziliensis for 24 hours. The invidivulas were stratified 
according with different genotypes of (A) NOD2 rs2066847, TLR4 rs4986791, TLR2 rs5743708, (B) 
CLEC7A rs16910526, CD206 rs1926736 and IL-32γ gene expression was determined. The data shown 
are the mean ± SEM of fold change in IL-32γ expression induced by Leishmania spp. normalized to 
RPMI control. 
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Supplemental figure 2: Correlation of IL-32β with IL-1β, IL-1α, IFNγ, IL-17 and IL22 gene expression 
in skin biopsies of ATL patients. The data shown are log2 of Relative expression adjusted for beta-2 
microglobulin expression (n=56); *p < 0.05 (IL-32β vs IL-1β  Spearman r= 0.09886; IL-32β vs IL-1α 
Spearman r= 0.1869; IL-32β vs IFNγ a  Spearman r= 0.1679; IL-32β vs IL-17 Spearman r= 0.3716; IL-
32β vs IL-22 Spearman r= 0.3493). 
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Supplemental figure 3: Correlation of IL-32α with IL-1β, IL-1α, IFNγ, IL-17 and IL22 gene expression 
in skin biopsies of ATL patients. The data shown are log2 of Relative expression adjusted for beta-
2 microglobulin expression (n=56); *p < 0.05 (IL-32α vs IL-1β  Spearman r= 0.1540; IL-32α vs IL-1α 
Spearman r= 0.3318; IL-32α vs IFNγ  Spearman r= 0.2993; IL-32α vs IL-17 Spearman r= 0.3595; IL-32α 
vs IL-22 Spearman r= 0.2377). 
156
157
Part II
Therapy targets in 
Leishmaniasis
158
To my paranymphs, Kathrin and Andreea,
There is no one with whom I can share my tears and 
fears, if you were not here. Thanks for being by 
my side, and always giving me reasons to cheer.
159
6
Chapter 6
The NOD2 receptor is crucial for immune 
responses towards New World Leishmania 
species
Jéssica Cristina dos Santos1,2, Michelle S.M.A. Damen1, Marije Oosting1, Dirk J. 
de Jong3, Bas Heinhuis1, Rodrigo Saar Gomes2, Carla Santos Araújo4, Mihai G. 
Netea1,5, Fátima Ribeiro-Dias2, Leo A.B. Joosten1,2
1  Department of Internal Medicine and Radboud Center of Infectious Diseases 
(RCI), Radboud University Medical Center, Nijmegen, The Netherlands; 
2  Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de 
Goiás, Goiânia, Goiás, Brazil; 
3  Department of Gastroenterology, Radboud Medical Center, Nijmegen; 
4  Universidade Federal do Vale do São Francisco, Petrolina, Pernambuco, 
Brazil. 5Human Genomics Laboratory, Craiova University of Medicine and 
Pharmacy, Craiova, Romania 
Scientific Reports 2017;7:15219
160
Abstract 
American Tegumentary Leishmaniasis is a chronic infection caused by Leishmania 
protozoan. It is not known whether genetic variances in NOD-like receptor (NLR) 
family members influence the immune response towards Leishmania parasites and 
modulate intracellular killing. Using functional genomics, we investigated whether 
genetic variants in NOD1 or NOD2 influence the production of cytokines by human 
PBMCs exposed to Leishmania. In addition, we examined whether recognition 
of Leishmania by NOD2 contributes to intracellular killing. Polymorphisms in the 
NOD2 gene decreased monocyte- and lymphocyte-derived cytokine production 
after stimulation with L. amazonensis or L.  braziliensis compared to individuals 
with a functional NOD2 receptor. The phagolysosome formation is important 
for Leishmania-induced cytokine production and upregulation of NOD2 mRNA 
expression. NOD2 is crucial to control intracellular infection caused by Leishmania 
spp. NOD2 receptor is important for Leishmania recognition, the control of 
intracellular killing, and the induction of innate and adaptive immune responses. 
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Introduction 
American Tegumentary Leishmaniasis (ATL) is a vector-borne parasitic disease 
caused by Leishmania protozoan that is characterized by lesions of the skin and 
oral or nasopharyngeal mucosa. Among the species of Leishmania and Viannia 
subgenus, L. (L.) amazonensis and L. (V.) braziliensis cause ATL leading to different 
clinical forms, which are dependent on the parasite species and the immune system 
of the host1. Both L. amazonensis and L. braziliensis can cause localized cutaneous 
leishmaniasis (LCL). In the most severe cases of Leishmaniasis, L. amazonensis can 
cause diffuse cutaneous lesions (DCL) and L. braziliensis can cause mucocutaneous 
lesions (ML)2. 
Innate immune cells such as macrophages, neutrophils, and natural killer cells 
recognize microorganisms through interaction between microbial ligands (MAMPs) 
with their pattern recognition receptors (PRRs). These PRRs include Toll-like 
receptors (TLRs) and NOD-like receptors (NLRs)3,4. The Leishmania membrane has 
lipophosphoglycans (LPG), glycoinositolphospholipids (GIPLs), and glycoprotein 
63 (gp63) as the main molecules that are recognized by innate immune cells5,6. 
Recent studies have shown the involvement of TLRs in recognizing some of these 
molecules. LPG and GIPLs are recognized by TLR4 and TLR2, respectively. TLR9 also 
plays a role in recognizing the DNA of Leishmania spp. These mechanisms lead to 
induction of cytokines and microbicidal molecules after exposure to Leismania 
spp.7–11. In addition to, NLRs are important receptors for recognition of several 
microorganisms12. However, few studies have described their role in Leishmania 
recognition. Lima Junior et. al13 have shown that the NLRP3 inflammasome plays 
an important protective role during L. amazonensis infection in a mouse model. 
Conversely, it was showed that NLRP3 activation followed by IL-1β production 
mediates the detrimental CD8+ T cell-mediated cytotoxicity in tegumentary 
leishmaniasis, causing lesions/chronic inflammation in mouse model of infections 
caused by L. braziliensis or L. major14. NLRP3 can also contribute to mouse 
susceptibility to L. major by increasing neutrophils recruitment, which plays a 
crucial role in the development of nonhealing lesions15. Recently, in patients with 
visceral leishmaniasis and in a murine infection model with L. infantum, the NOD2-
RIPK2 pathway has been found to be involved in the development of the Th1-type 
response16, the most important response against Leishmania spp. Because the 
innate immune response is important in driving the acquired immune response, the 
efficient recognition of the parasite by PRRs improves the host resistance16.
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Leishmania recognition by monocytes or macrophages through TLRs leads to 
the production of proinflammatory cytokines such as tumor necrosis factor 
(TNFα), interleukin (IL)-6, and interferon gamma (IFNγ), which all contribute for 
the exacerbated inflammation in leishmaniasis lesions11,17–19. Following NLRP3 
inflammasome activation, IL-1β can be produced and contributes to the control 
of murine Leishmania infection13. Besides inflammation, these proinflammatory 
cytokines are important for controlling the Leishmania infection by inducing 
microbicidal molecules, such as reactive oxygen and nitrogen intermediates (ROI, 
RNI), which are crucial for the parasite killing10,19–22.
Since it is known that the immunogenetic background of the patients is one of 
the most important factors to determine the clinical outcome of leishmaniasis23, 
we investigated the role of genetic variants in genes of the NLR family for the 
Leishmania-induced immune response. 
Methods
Ethics Statement 
The study was approved by Ethics Committee of Radboud University Nijmegen, 
the Netherlands (no. 42561.091.12). Experiments were conducted according to 
the principles expressed in the Declaration of Helsinki. All individuals gave written 
informed consent to donate blood. 
200FG cohort
Healthy individuals with a Dutch European genetic background that were recruited 
as part of the 200FG study34 participated in the study. The volunteers were between 
23-73 years old, and consisted of 77% men and 23% women. 
Isolation of genomic DNA and single-nucleotide polymorphism (SNP) 
analysis
DNA was isolated from whole blood by using the isolation Gentra Pure Gene Blood 
kit (Qiagen), according to the manufacturer’s protocol. SNPs in the analyzed receptor 
genes were selected from the National Center for Biotechnology Information 
SNP database (http://www.ncbi.nlm.nih.gov/snp/) upon previously described 
associations with human diseases and a minor allele frequency of at least 5% among 
different populations. In total, 7 SNPs in NOD1 and NOD2 receptors were selected 
and genotyped (Table 1). Gene fragments were amplified by commercially available 
TaqMan® SNP Genotyping Assays according to the manufacturer’s protocol on the 
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AB StepOnePlus polymerase chain reaction system (Applied Biosystems). Quality 
control was performed by the incorporation of positive and negative controls and 
duplication of random samples across different plates. 
Leishmania cultures and lysates 
L. amazonensis (IFLA/BR/67/PH8) reference strain and MHOM/BR/2003/IMG 
L. braziliensis, a clinical isolate obtained from a LCL patient (Leishbank IPTSP/
UFG)48, were used. Promastigote forms were cultured in Grace’s Insect Medium, 
(Gibco - Life Technologies) and prepared for experiments as described by dos 
Santos et al.19. To obtain lysates of Leishmania, promastigotes (1 x 10
9
cells/mL) were 
lysed by 5 freeze-thaw cycles in liquid nitrogen and water bath at 37oC followed 
by protein quantification using the Pierce BCA protein assay (Thermo Scientific). 
For cell stimulations, parasites were suspended in RPMI 1640 medium (Sigma) and 
added to the cultures as described below.
Human embryonic kidney cell line (HEK) stimulation
Transfection of HEK-293 cells with human NOD2 was performed as previously 
described by Laayouni et al.49 and culture conditions are described as 
supplementary material. Non-transfected or NOD2-transfected HEK-293 cells 
(1 x 106 cells) were added to 96-well flat-bottom plates (Greiner) in the presence of 
either E. coli lipopolysaccharide  (LPS, O111:B4, 10 ng/mL; Sigma), further purified 
based on50, muramyl dipeptide  (MDP, 10 μg/mL; Sigma), lysates or promastigotes 
(2 x 106 parasites) of L. braziliensis or L. amazonensis in a final volume of 200 μL. After 
24 h of incubation, at 37°C and 5% CO2, supernatants were collected and stored at 
-20°C until analysis of IL-8 production.
Isolation of human peripheral blood mononuclear cells (PBMC) and 
treatments
Venous blood was obtained from eight healthy individuals bearing the wild-type 
allele of NOD2 (wild type, wt) and from four homozygous individuals for the NOD2 
3020insC mutation presenting Crohn’s disease. Isolation of PBMCs was performed 
as described previously39, by density gradient centrifugation of blood diluted 1:1 
in pyrogen-free saline overlayed on Ficoll-Paque (Pharmacia Biotech). PBMCs 
were suspended in RPMI 1640 medium with 50 mg/mL gentamicin, 2 mmol/L 
L-glutamine, and 1 mmol/L pyruvate (Invitrogen). The number was adjusted to 5 
x 106 cells/mL. Cells (5 x 105cells/mL) were added to round-bottom 96-well plates 
(Greiner) and incubated with either culture medium (negative control), MDP (10 
μg/ml), FK-156 (10 μg/mL, Sigma), ultra-pure E. coli LPS as described by Battisti & 
Minnick50 (O111:B4 serotype, 10 ng/mL; Sigma) or 50 μg/mL of both Leishmania 
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pp. lysates or promastigotes (1 x 105 parasites) of L. braziliensis and L. amazonensis 
in the presence or absence of 10% of human pool serum. In some experiments, 
PBMCs were pre-incubated for 1 h with a RICK inhibitor (Ponatinib, 100 nM/mL; 
Selleckchem) and a phagolysosome inhibitor (Bafilomycin A1, 250 nM; Invivogen) 
before cells were stimulated with lysates or promastigotes. After 24 h or 7 days, 
the supernatants were collected and stored at -20 °C until further analysis. The cell 
monolayers were collected by adding 200 µL of TRIzol and stored at -80 °C until 
being used for mRNA extraction.
Measurement of cytokines 
Human TNFα, IL-1β, IL-6, IL-8, IL-17A and IFNγ were determined in culture 
supernatants using commercial Enzyme-Linked Immunosorbent Assay (ELISA) 
kits (Sanquin, Amsterdam, and R&D Systems, Minneapolis), according to the 
manufacturer’s protocols. 
Evaluation of mRNA expression by quantitative real-time PCR (qPCR) 
RNA isolation was carried out based on the method reported by Chomzynski & 
Sacchi51 and the qPCR method is shortly described in supplementary material. 
Primer sequences (Supplementary Table 1) for NOD1 and NOD2 receptors were 
obtained from the Harvard Primerbank database. Primers were purchased from 
Biolegio. Relative expression of mRNA levels was calculated and normalized for the 
housekeeping gene GAPDH.
Evaluation of Macrophage infection 
Monocyte-derived macrophages from healthy volunteers and from homozygous 
individuals for the NOD2 3020insC mutation were obtained from PBMCs (5 x 105 
cells/well) during 5 days at 37°C, 5% CO2. PBMCs were counted and plated into 
24-well plates (Costar) over coverslips in the presence of RPMI-1640 medium 
supplemented as described above and added with 10% of human pool serum. 
Medium was refreshed every 48 h. On day 5, macrophages were infected with 
promastigote forms of either L. braziliensis or L. amazonensis (2.5 x 105 parasites) 
during 4 h. Cells were washed to remove non-internalized parasites and incubated 
for 48 h. Additionally, is some experiments monocyte-derived macrophages were 
pre-treated or not with Ponatinib (100 nM/mL; Selleckchem) 1 h before infection 
and the drug was replaced after washings. Coverslips were collected to determine 
the macrophage infection index after cells were fixed and stained with Giemsa 
(Merck Millipore), according to52 and briefly described in supplementary material. 
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Statistical Analysis 
Data are expressed as median, interquartile, minimal and maximal values, unless 
otherwise indicated. Differences between experimental groups were tested by 
Mann-Whitney U test or unpaired t test according to the data, or by Wilcoxon paired 
test, using Prism software (version 6.0; GraphPad; San Diego, CA, USA). Differences 
with p < 0. 05 were considered significant.
Results 
Individuals heterozygous for NOD2 mutation produce less cytokines 
after Leishmania pp. exposure compared to individuals with wild-type 
NOD2
We explored whether SNPs in NLR family members NOD1 and NOD2 influence the 
production of cytokines after stimulation with Leishmania parasites. Through these 
analyses, we found that the NOD2 receptor plays an important role in the immune 
response against Leishmania spp. (Fig. 1). The results demonstrated that individuals 
heterozygous for NOD2 Leu1007insC polymorphism displayed significantly 
lower production of TNFα, IL-1β, IL-6, IL-8 and IFNγ for either L. amazonensis or 
L. braziliensis stimulation (Fig. 1A, 1B). Interestingly, NOD2 was only important for 
IL-17 induced by L. amazonensis, while L. braziliensis practically did not induce IL-17 
production (Fig. 1B). Confirming the relevance of this NOD2 mutation for cytokine 
induction, the NOD2 agonist MDP induced lower cytokine production when added 
to PBMCs from individuals with the Leu1007insC variance, compared to the control 
subjects (Fig. 1A). Evaluation of other common polymorphisms in the NOD2 gene 
revealed no differences in the Leishmania-induced cytokine production (Fig. S1-2). 
In addition to NOD2, we also investigated whether the NOD1 receptor could play a 
role in the cytokine induction after Leishmania exposure. In contrast to NOD2, no 
differences in monocyte- or lymphocyte-derived cytokine production were noted 
when PBMCs homozygous for NOD1 Glu796Lys were stimulated with L.  amazonensis 
or L. braziliensis (Fig. 1C). Using the NOD1 agonist FK156, we demonstrated that 
Glu796Lys variance results in loss of function of NOD1 (Fig. 1C). 
Phagolysosome formation is important for Leishmania-induced 
cytokine production and upregulation of NOD2 mRNA expression. 
In order to investigate whether Leishmania could upregulate the mRNA expression 
of NOD2, human PBMCs were incubated for 24 h with either parasite lysates or 
live promastigote forms of both L.  amazonensis or L. braziliensis. The use of both 
forms of Leishmania stimuli was determined by the need to examine whether NOD2 
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is activated by Leishmania fragments which means that the parasites needs to be 
degraded intracellularly. Fig. 2A showed that lysates as well as intact parasites of 
both Leishmania spp. were able to increase the NOD2 mRNA expression but not 
NOD1 mRNA. As positive controls FK-156 and MDP both could up-regulate NOD1 or 
NOD2 mRNA expression respectively (Fig. 2A).
Figure 1: NOD2 but not NOD1 plays an important role in monocyte-and lymphocyte-derived 
cytokines induced by after Leishmania pecies stimulation.  Peripheral blood mononuclear cells 
(PBMCs, 5 x 105 cells/100 μL) from healthy individuals genotyped for NOD1 (Glu796Lys) and NOD2 
(1007finsC) were stimulated with different stimuli including lysates of Leishmania spp. (50 μg/mL, 
L. (L.) amazonensis: L. amaz; L. (V.) braziliensis: L. braz), FK156 (10 μg/mL), MDP (10 μg/mL); Medium: 
non-stimulated cells. TNFα, IL-6, IL-1βand IL-8 concentrations were measured in supernatants by 
ELISA after 24 h of incubation. IFNγ and IL-17 were determined after 7 days of incubation: the NOD2 
(A-B) and NOD1 (C) genotype. Bars represent individuals carrying no SNP (wild type, Wt, white bars), 
heterozygous SNP carries (He, black bars), or homozygous variation (Ho, grey bars). Data represent 
the mean ± SEM. *p < 0.05; Mann-Whitney U-test (A-B; Wt vs He); (C; Wt vs Ho).
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Figure 2: Leishmania species induce NOD2 mRNA expression and phagolysosome formation 
is important for Leishmania-induced cytokine production. (A-B) Peripheral blood mononuclear 
cells (PBMCs, 5 x 105 cells/100 μL) from healthy individuals were stimulated with either lysates (50 
μg/mL) or promastigotes (1 x 105 parasites) of Leishmania species (L. (L.) amazonensis: L. amaz; L. (V.) 
braziliensis: L. braz); Medium (non-stimulated cells), FK156 (10 μg/mL), MDP (10 μg/mL) and LPS (10 
ng/mL) were used as controls. (B) In some experiments cells were incubated in the absence (white) 
or presence (gray) of bafilomycin A1 (250 nM).  Medium plus Vehicle (DMSO).  (A) NOD1 and NOD2 
mRNA expression were determined by quantitative real-time PCR after 24 h of incubation. (B) TNFα, 
IL-6 and IL-1β concentrations were determined in supernatants by ELISA after 24 h of incubation. 
Data represent the mean ± SEM, *p < 0.05; Wilcoxon test (A) (Medium vs stimuli) (B) (Vehicle vs 
Bafilomycin) (n = 6, in 2 independent experiments done in duplicates). (C) Embryonic kidney (HEK)-
293 cells (1 x 106 cells/100 µL) transfected or not with NOD2 were stimulated for 24 h with lysates 
of Leishmania species (50 μg/mL) or promastigote forms (2 x 106 parasites) in the stationary growth 
phase of L. amaz; L. braz. Medium, LPS (10 ng/mL), and MDP (10 μg/mL) were included as controls. 
Protein levels of IL-8 were determined by ELISA in supernatants. Data represent the mean ± SEM of 
three independent experiments, *p < 0.05; Paired t-test (HEK-293 vs HEK+NOD2). 
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To examine whether degradation of the parasite by the phagolysosome is essential 
for Leishmania-induced cytokine production we inhibited the formation of 
phagolysosomes. PBMCs were incubated in the absence or presence of bafilomycin 
A1, a chemical compound that prevents maturation of parasitophorus vacuoles 
by inhibiting fusion between phagosomes and lysosomes24. Fig. 2B shows a 
remarkable decrease in TNFα and IL-1β production after exposure to promastigote 
forms of either L.amazonensis and L. braziliensis in the presence of bafilomycin A1 
(Fig. 2B). For IL-6, a decrease was observed after exposure to L. amazonensis and 
despite a tendency to reduction after exposure to L. braziliensis the difference did 
not achieve statistical significance (p = 0.0938). No differences in TNFα, IL-1β or IL-6 
concentrations were observed when lysates of both Leishmania spp. were used to 
activate PBMCs in absence or presence of bafilomycin A1 (Fig. 2B). 
To confirm the pivotal role of NOD2 in the recognition of Leishmania, HEK-293 cells 
overexpressing NOD2 were exposed to either lysates or live promastigote forms 
of either L. amazonensis or L. braziliensis. We observed a strong increase in IL-8 
production after stimulation with either lysates or promastigote forms of Leishmania 
pecies when NOD2 was present in the HEK-293 cells (Fig. 2C). A similar effect in IL-8 
production was observed when NOD2 agonist MDP was added as a positive control. 
A potent TLR4 agonist (LPS) was used as negative control, showing no elevated IL-8 
production. To validate the HEK-293-NOD2 reporter cells, we determined NOD2 mRNA 
expression before and after MDP exposure by quantitative real-time PCR (Fig. S3). 
PBMCs isolated from patients bearing NOD2 (3020insC) mutation 
confirmed the crucial role of NOD2 for Leishmania-induced cytokine 
production.
Additional experiments were performed to confirm the role of NOD2 in Leishmania 
recognition. To this end, PBMCs carrying the NOD2 frameshift (3020insC) mutation 
were stimulated with live parasites or lysates of parasites for 24 h. The production 
of cytokines was compared with PBMCs isolated from healthy individuals (wt). As 
expected, cytokine concentrations were complete absent in individuals homozygous 
for the 3020insC frameshift mutation when PBMCs where stimulated with MDP (Fig. 
3A). LPS-induced cytokine production was similar between PBMCs isolated from 
subjects carrying the 3020insC frameshift mutation and healthy controls (Fig. 3A). 
Production of TNFα, IL-1β, IL-6  IL-8, IFNγ was significantly decreased in PBMCs 
bearing the 3020insC frameshift mutation NOD2 compared to PBMCs of individuals 
without this mutation after exposure to lysates or promastigote forms of both L. 
amazonensis and L. braziliensis (Fig. 3A-B). Of high interest, a reduction of IL-17 
production was only observed after exposure to L.  amazonensis (Fig. 3B). 
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Figure 3: NOD2 plays an important role in the cytokines after Leishmania stimulation. A, B: 
Peripheral blood mononuclear cells (PBMCs, 5 x 105 cells/100 μL) from healthy individuals (n = 8) 
carrying no mutation in NOD2 (3020insC) (Wt; white bars) and from individuals carrying a mutation 
in NOD2 receptor (n = 4; grey bars) were stimulated with either lysates (50 μg/mL) or promastigotes (1 
x 105 parasites) of Leishmania species (L. (L.) amazonensis: L. amaz; L. (V.) braziliensis: L. braz); Medium 
(non-stimulated cells), MDP (10 μg/mL) and LPS (10 ng/mL) were used as controls. (A) TNFα, IL-6 
and IL-1β concentrations were determined in supernatants by ELISA after 24 h incubation. (B) IFNγ 
and IL-17 were determined after 7 days of incubation in supernatants by ELISA; Data represent the 
mean ± SEM, *p < 0.05; Mann-Whitney U-test (Wt vs 3020insC). (C) Peripheral blood mononuclear 
cells (PBMCs, 5 x 105 cells/100 μL) from healthy individuals were stimulated with either lysates (50 
μg/mL) or promastigotes (1 x 105 parasites) of Leishmania species (L. (L.) amazonensis: L. amaz; L. (V.) 
braziliensis: L. braz) in the presence (grey bars) or absence (white bars) of the Ponatinib (100 nM); 
Medium (non-stimulated cells) plus Vehicle (DMSO) and MDP (10 μg/mL) were used as controls. 
TNFα, IL-6 and IL-1β concentrations were determined by ELISA, after 24 h incubation. Data represent 
the mean ± SEM, *p < 0.05; (DMSO vs Ponatinib; n = 6, in 2 independent experiments done in 
duplicates, by Wilcoxon test).
To investigate the downstream pathway of NOD2 signalling, we stimulated human 
PBMCs in the absence or presence of Ponatinib, a drug that potently inhibits the 
phosphorylation of RIPK225. RIPK2 is the important kinase for the NOD2 signalling 
cascade26. A significant reduction in TNFα, IL-1β and IL-6 production was observed 
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when PBMCs were incubated with lysates or promastigote forms of both 
L.  amazonensis and L.  braziliensis in the presence of Ponatinib (Fig. 3C). A dose-
response experiment with Ponatinib was performed and no cytotoxicity of Ponatinib 
to human cells or parasites was found (Fig. S4). 
Figure 4: NOD2 plays a role in control of Leishmania spp. infection. Monocyte-derived 
macrophages were obtained from PBMCs from wild type (wt) individuals (n = 4) carrying no 
mutations in NOD2 receptor (3020insC) (black circles) and individuals carrying mutations in NOD2 
(n = 2, black squares) (A), after 5 days of differentiation. On day 5, macrophages (5 x 105 cells) 
were infected with promastigote forms of either L. (V.) braziliensis and L. (L.) amazonensis (2.5 x 105 
parasites) during 4 h. (B) Macrophages from wt individuals (n = 4) were incubated in the absence 
(black balls - Vehicle DMSO) or presence (black squares) of Ponatinib (100 nM) 1 h before. Cells were 
washed out to remove the non-internalized parasites after 4 h, Ponatinib was added again and cells 
were incubated for 48 h. Coverslips were collected to determine macrophage infection index. Data 
represent individual values and horizontal lines represent medians. *p < 0.05; Wilcoxon test (DMSO 
vs Ponatinib).
NOD2 is important to control intracellular infection caused by 
Leishmania spp.
We investigated whether NOD2 plays a role in controlling Leishmania spp. infection 
in human primary macrophages. To this end, monocyte-derived macrophages 
from individuals homozygous for the NOD2 3020insC polymorphism were 
compared with macrophages from healthy individuals. Both types of macrophages 
were infected with either promastigote forms of L.  amazonensis or L. braziliensis. 
Fig. 4A shows an increase of the macrophage infection index in cells isolated 
from individuals carrying the NOD2 loss-of-function mutation compared with 
healthy controls (wt). Similar results were found in primary human macrophages 
pre-treated with Ponatinib, which showed an increase in the infection index 
compared to vehicle-treated macrophages (Fig. 4B). The results demonstrated 
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that the NOD2 receptor plays an important role in the control of Leishmania 
infection in human macrophages. 
Discussion
In the present study, we investigated the role of the NLR family members NOD1 
and NOD2 in the induction of cytokines in human PBMCs after exposure to New 
World Leishmania spp. Results showed that whereas NOD2 plays an important role 
in parasite-induced cytokines, NOD1 is not relevant. Moreover, NOD2 is important 
for microbicidal activity of human macrophages contributing to the control of 
Leishmania spp. infection. This is the first report describing the NOD2 involvement 
in activation of human cells by New World Leishmania spp. Recently, a study in 
mice with L. infantum demonstrated that the activation of NOD2-RIP2 pathway 
drives the development of a Th1 instead of Th17 immune response16. These results 
demonstrated an important role of NOD2 in controlling Leishmania infection.
SNPs in the NOD2 receptor are related to autoinflammatory diseases such as Crohn 
disease and Blau syndrome27–29. In general, as a consequence, individuals carrying 
these mutations have a reduced NF-κB activation after recognition of specific 
pathogen-associated NOD2 ligands, which interfere in cytokine production30. 
Mutations in NOD1 lead to a reduced capacity to detect their ligands31. To 
evaluate the role of genetic variance in NOD1 and NOD2 in the immune response 
to Leishmania antigens, we applied a functional genomics approach as reported 
recently32–34. Using whole exome sequencing data of 100 subjects, we selected 
SNPs that are frequently present in NOD1 or NOD2 with a predicted loss or gain 
of function35. Here, we showed that one particular genetic variance in NOD2 
(Leu1007finsC) downregulates the production of monocyte-derived cytokines 
such as TNFα, IL-1β, IL-6, IL-8 as well as IFNγ after exposure to lysates of either L. 
amazonensis or L. braziliensis. Remarkably, IL-17 was induced after exposure to 
lysates of L. amazonensis, but not L. braziliensis in a NOD2-dependent manner. The 
results indicate that in addition to its role in activation of the innate immunity, 
NOD2 shapes the adaptive immune response against Leishmania spp. Our results 
are partially in agreement with the results demonstrated by Nascimento et al. 16, 
in which, the authors showed that in a murine model of L. infantum infection, the 
development of Th1 responses and the production of IFNγ was dependent on 
NOD2.  However, the authors showed that the NOD2 pathway was not relevant 
for Th17 development. In contrast, we demonstrated that in human PBMCs, IL-17 
production is NOD2-dependent only after exposure to L. amazonensis. These results 
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could be ascribed to the differences among Leishmania spp. as well as to differences 
in human and mouse immune responses36. Here, besides Leishmania antigens 
(parasite lysates) or live promastigotes increased cytokines in a NOD2-dependent 
manner they upregulated NOD2, but not NOD1 mRNA expression in PBMCs. These 
results strengthened the involvement of NOD2 but not NOD1 in Leishmania spp.-
induced immune responses.
To confirm that NOD2 is relevant for Leishmania-induced cytokine production, we 
overexpressed NOD2 in HEK-293 cells and showed that these NOD2-transfected 
cells produced significantly higher IL-8 concentrations after exposure to parasite 
lysates or promastigote forms of either L. amazonensis or L. braziliensis, compared 
to control HEK-293 cells. Although, NOD2 is known as a receptor that recognizes 
structures present in the bacteria cell wall37,38, the results presented here suggest 
that the NOD2 receptor also recognizes protozoan structures. 
It is well described that PBMCs from patients with Crohn’s disease carrying the 
NOD2 (NOD2 3020insC) mutation display a reduction in cytokine production 
after exposure to several microbial ligands or pathogens39,40. In our study, we also 
used PBMCs from subjects carrying NOD2 3020insC mutation and demonstrated 
a significant decrease in the production of proinflammatory cytokines after 
Leishmania spp. exposure. These data are in line with the results of the NOD2 
genetic variance Leu1007finsC and the HEK-NOD2 cells, underlining the pivotal role 
of NOD2 in the recognition of Leishmania spp.
An additional line of evidence that the NOD2 pathway is important for Leishmania-
induced immune responses, are our results with the RIPK2 inhibitor (Ponatinib). 
The inhibition of RIPK2 led to almost complete abolishment of Leishmania cytokine 
production. These data demonstrate previously unknown role for human NOD2 in 
the recognition of L. amazonensis or L. braziliensis and make it tempting to speculate 
that individuals carrying NOD2 polymorphisms might be more susceptible to ATL. 
The ligand of Leishmania parasites that binds to NOD2 remains unknown but we 
showed that degradation of Leishmania is a prerequisite for cytokine production. 
Bafilomycin A1, a specific inhibitor of the phagosome acidification and blocker 
of phagosome maturation impaired the proinflammatory cytokine production 
only after exposure to live promastigote forms of L. amazonensis or L. braziliensis, 
whereas no effect was observed after exposure to lysates of both these species. 
Enzymes present in the phagolysosomes, such as lysozyme, may degrade 
Leishmania to release NOD2 ligands in a similar process that happens with Listeria 
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monocytogenes41. Future studies are warranted to investigate which microbial 
components of Leishmania are recognized by NOD2.
It is known that the production of proinflammatory cytokines can play a double 
role in infection caused by Leishmania spp., contributing to the control of the 
infection but also favoring inflammation and tissue destruction42,43. Here we 
demonstrated that loss of NOD2 signalling impairs intracellular Leishmania killing. 
The exact mechanisms involved in NOD2-mediated Leishmania killing need to be 
further explored, although it is known that proinflammatory cytokines promote 
the induction of microbicidal molecules after infection with Leishmania spp.10,19–22,44. 
Moreover, it is known that NOD2 plays an important role in induction of microbicidal 
mechanisms including autophagy, antimicrobial peptides and ROS production, 
which are essential to control infections caused by intracellular pathogens45–47.
To conclude, our study showed for the first time that the human NOD2 pathway is 
important for Leishmania recognition, the induction of innate and adaptive immune 
responses, and the control of intracellular killing of the parasite (Fig. 5). Our findings 
provide the first evidence that genetic variances in NOD2 are associated with 
differences in the human immune response towards Leishmania spp. The relevance 
of the NOD2 pathway in the susceptibility to or severity of human ATL needs to be 
investigated in the near future. 
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Supplemental Table 1. Single-Nucleotide Polymorphisms (SNPs) evaluated in this study.
Gene rs number Mutation Nucleotide change # Amino acid change #      
NOD1* - Ins/Del ND1+32656 Glu796Lys
NOD2
NOD2
NOD2
NOD2
NOD2
NOD2
NOD2
rs2066847
rs2066845
rs2066844
rs9302752
rs7194886
rs8057341
rs2066847
Frameshift
Missense
Missense
Unknown
Unknown
Unknown
Frameshift
C>G
C>T
C>T
C>T
A>G
Leu1007insC
Gly908Arg
Arg702Trp
Unknown
Unknown
Unknown
3020insC
# The first nucleotide (and corresponding amino acid) is the ancestral nucleotide and therefore is considered the wild-type allele. 
*NOD1 insertion/deletion (Ins/Del) polymorphism ND1+32656, partially identified as rs6958571.
Supplemental Table 2. Primers sequence
GAPDH FW primer: 5’-AGG-GGA-GAT-TCA-GTG-TGG-TG-3’ 
GAPDH RV primer: 5’-CGA-CCA-CTT-TGT-CAA-GCT-CA-3’
NOD2 FW primer: 5’-CCC-TGC-AGC-TGG-ACT-ACA-ACT-3’
NOD2 RV primer: 5’-AGA-TGC-CTC-GGT-CTG-AGA-TAT-TG-3’
NOD1 FW primer: 5’-AGA-GGC-TCT-GCG-GAA-CCA-3’
NOD1 RV primer: 5’-TGT-GGA-GAT-GCC-GTT-GGA-3’
MATERIALS AND METHODS
Human embryonic kidney cell line (HEK) 
HEK-293 cells were cultured in DMEM (Sigma) supplemented with 7.5% fetal 
bovine serum (Hyclone, Thermo Scientific), 100 U/mL penicillin and 100 μg/mL 
streptomycin (Invitrogen), at 37°C and 5% CO2. Plasmid selecting agent for NOD2, 
30 μg/mL blasticidin (Invivogen) and 100 μg/mL zeocine were added to the culture 
medium to ensure presence of this specific NOD2 receptor in HEK-293 cells. Correct 
NOD2 expression was confirmed by Reverse Transcription-polymerase chain 
reaction (RT-PCR). When 80% of cell confluence was reached, the HEK-293 cells were 
passaged, counted and used in stimulation experiments.
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Evaluation of mRNA expression by quantitative real-time PCR (qPCR) 
RNA was precipitated with isopropanol and washed with 75% ethanol followed 
by reconstitution in RNAse-free water. Subsequently, RNA was reverse transcribed 
into cDNA using the iScript cDNA synthese kit (Bio-Rad). Diluted cDNA was used for 
qPCR analysis that was performed with the use of the AB StepOnePlus polymerase 
chain reaction system (Applied Biosystems) with SYBR Green Mastermix (Applied 
Biosystems).
Evaluation of Macrophage infection 
Under a light microscope (1000x), 300 cells were analysed and the percentage 
of infected cells and the mean number of intracellular parasites per infected cell 
were determined. Infection index = percentage of infected cells × mean number of 
parasites per infected cell.
Supplemental Figure 1: Peripheral blood mononuclear cells (PBMCs, 5 x 105 cells/100 μL) from 
healthy individuals genotyped for the NOD2 were stimulated with different stimuli, including lysates 
of Leishmania parasites (50 μg/mL; L. (L.) amazonensis: L. amaz; L. (V.) braziliensis: L. braz). TNFα, IL-6, 
IL-1β and IL-8 concentrations were determined in supernatants by ELISA after 24 h of incubation. The 
results were stratified for the NOD2 genotype. Bars represent individuals carrying no SNP (wild type, 
Wt, white bars), heterozygous SNP carriers (He, black bars), or homozygous variation (Ho, grey bars). 
Data represent the mean ± SEM.
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Supplemental Figure 3: NOD1 and NOD2 mRNA expression in embryonic kidney (HEK)-293 cells 
(1 x 106 cells/100 µL) transfected or not with NOD2. Cells incubated in the absence (Medium) or 
presence of MDP (10 µg/mL) for 24 h. NOD1 and NOD2 mRNA expression were determined by 
quantitative real-time PCR. Data represent the mean ± SEM of three independent experiments, 
*p < 0.05; Unpaired t-test (HEK-293 vs HEK+NOD2). 
Supplemental Figure 4: Peripheral blood mononuclear cells (PBMCs, 5 x 105 cells/100 μL) from 
healthy individuals were stimulated with MDP (10 μg/mL), LPS (10 ng/mL) or β-glucan (5 μg/mL) 
in the absence (white) or presence (grey) of the Ponatinib (25 nM; 50 nM and 100 nM); Medium 
(non-stimulated cells) and DMSO (vehicle) were included as negative controls. TNFα concentration 
was determined in supernatants by ELISA, after 24 h of incubation; Data represent the mean ± SEM, 
*p < 0.05; (Vehicle vs Ponatinib; n = 6, in 2 independent experiments done in duplicates, by 
Wilcoxon test).
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To my labmates (brazilians and internationals),
“The best way to pay for a lovely moment is to 
enjoy it.” 
- Richard Bach
I’ve enjoyed every single moment shared with you.
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Chapter 7
β-glucan-induced trained immunity protects 
against Leishmania braziliensis infection:  
a crucial role for IL-32
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Abstract 
American Tegumentary Leishmaniasis is a vector-borne parasitic disease caused 
by Leishmania protozoans. Innate immune cells undergo long-term functional 
reprogramming in response to infection or vaccination via a process called trained 
immunity, conferring non-specific protection from secondary infections. Here we 
demonstrate for the first time that monocytes trained with the fungal cell wall 
component β-glucan confer enhanced protection against infections caused by 
Leishmania braziliensis through the enhanced production of proinflammatory 
cytokines. Mechanistically, this augmented immunological response was 
dependent on increased expression of interleukin 32 (IL-32), which was maintained 
via an epigenetic program. Studies performed using a humanized IL-32 transgenic 
mouse highlight the clinical implications of these findings in vivo. This study 
represents the first definitive characterization of the role of IL-32γ in the trained 
phenotype induced by β-glucan, the results of which improve our understanding 
of the molecular mechanisms governing trained immunity and Leishmania infection 
control. 
Keywords: Leishmania braziliensis, Trained Immunity, β-glucan, IL-32, epigenetic, 
proinflammatory cytokines, IL-32 transgenic mouse.
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Introduction 
Leishmaniases are vector-borne tropical diseases caused by protozoa of the 
Leishmania genus, characterized by a wide clinical spectrum and symptoms ranging 
from self-healing cutaneous lesions to lethal visceral disease. Leishmaniases are 
among of the most neglected infectious diseases with endemicity in 88 countries 
and affecting 12 million people worldwide. The annual incidence is around 2 
million cases, including both visceral and cutaneous diseases (1). In the Americas, 
L. (Viannia) braziliensis is the predominant species causing American Tegumentary 
Leishmaniasis (ATL), characterized by localized cutaneous leishmaniasis (LCL), 
disseminated cutaneous leishmaniasis (DL), and mucosal leishmaniasis (ML) (2). In 
the absence of efficient strategies to prevent infections with Leishmania parasites 
and to control the transmission of the parasites by vector insects, the treatment of 
leishmaniasis relies on drug therapy. Pentavalent antimony has been the first line of 
treatment for decades. This drug is expensive for low and middle-income countries 
and requires several injections that are toxic and painful. Furthermore, there is 
emergence of parasite resistance to antimonial drugs and the rate of treatment 
failure affects more than 47% of the cases. In some endemic areas, where the 
efficacy of pentavalent antimonial is very low it is replaced by other more effective 
drugs such as amphotericin B and miltefosine (3-5).
Leishmania is an intracellular parasite that can be taken up by phagocytic cells, 
including neutrophils, monocytes, macrophages, and resident dendritic cells. In 
macrophages there is the best evidence for parasite replication and long term-
survival (6). Therefore, targeting macrophages to enhance or modulate their anti-
microbial function may facilitate the development of novel therapeutic strategies. 
Among the effector mechanisms used by macrophages to control Leishmania 
replication are reactive oxygen species (ROS) and reactive nitrogen intermediates 
(RNI). Activation of macrophages is dependent on interferon gamma (IFNγ) 
and tumor necrosis factor (TNFα) (7-9). Additionally, studies have shown that 
macrophage interleukin (IL)-1γ signaling is important for controlling parasite 
replication and influences the clinical course of Leishmaniasis (10, 11). 
Recently, our group identified interleukin 32 (IL-32), an intracellular cytokine 
produced in different isoforms by immune and non-immune cells, as a pivotal 
mediator in controlling infections caused by New World Leishmania spp. (12). IL-
32γ is expressed in lesions of patients infected with L. braziliensis or L. amazonensis 
(13, 14). In addition, infection of human macrophages with Leishmania induces 
intracellular IL-32γ expression. Once produced, IL-32γ is associated with the 
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production of TNFα, IL-8, NO, and antimicrobial peptides such as cathelicidin and 
β-defensin 2 (15). Moreover, Leishmania infection of human IL-32γ transgenic (IL-
32γTG) mice resulted in improved control of lesions caused by L. braziliensis in 
associated with an increase of IFNγ, TNFα and IL-10 production (14). 
Clinical improvement in the treatment of ATL with Bacillus Calmette-Guérin (BCG) 
vaccination has been reported previously (16). In addition, we recently confirmed 
that BCG vaccination in combination with conventional treatment can increase 
circulating NK cells and proinflammatory monocytes, contributing to clinical 
remission of several lesions in a patient with diffuse cutaneous leishmaniasis (DCL) 
caused by L. (L.) amazonensis (17). Similarly, Obaid et al. (18) observed that β-glucan 
(a cell wall component of Candida albicans) as adjuvant together with Leishmania 
antigens lead to protection against L. (L.) donovani in hamsters. 
In monocytes/macrophages, BCG and β-glucan induce non-specific protection to 
secondary infections by long-term functional reprogramming via a process called 
trained immunity, which is dependent on metabolic and epigenetic rewiring 
(19-21). We therefore hypothesized that exposure of monocytes to β-glucan 
may induce non-specific protection against intracellular infection caused by 
Leishmania spp., which could offer novel immunotherapeutic strategies to patients 
with leishmaniasis. In both human primary cells and a murine model of trained 
immunity, we assessed the effects of β-glucan training in monocytes/macrophages 
using various biochemical and molecular approaches. In addition, we investigated 
the role of IL-32γ and IL-1 signaling for β-glucan-induced trained immunity. 
Methods
Experimental model and subject details
The study was approved by Ethics Committee of Radboud University Nijmegen, the 
Netherlands (no. 42561.091.12) and also by Ethics Committee for animal research 
of Universidade Federal de Goiás (CEUA/PRPI/UFG, protocol 042/16). All animal 
experiments were in accordance with the guidelines of legislation of ethics of the 
Brazilian Society of Science in Laboratory Animals (SBCAL) and National Council 
of Control of Animal Experimentation (CONCEA). Experiments were conducted 
according to the principles expressed in the Declaration of Helsinki. All blood 
donors (Sanquin Blood Bank, Nijmegen, The Netherlands) gave written informed 
consent before donating the blood.
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Leishmania braziliensis parasites
L. braziliensis (MHOM/BR/2003/IMG) strain was obtained as previously described 
(22). Promastigote forms were cultured in Grace’s insect medium (Gibco, Life 
Technologies, USA) supplemented with 20% of heat-inactivated fetal bovine serum 
(FBS, Gibco, Life Technologies, USA), 100 U/mL of penicillin/streptomycin (Sigma-
Aldrich) at 26°C. Stationary-phase parasites were obtained on 6th day of growth and 
washed three times with phosphate-buffered saline (PBS; 1000xg, 10 min 10°C). 
After, they were suspended in PBS and quantified by using hemocytometer after 
fixation with PBS/0.4% formaldehyde. Live parasites were used in macrophage 
infection experiments. In addition, parasite lysates were obtained by 5 freeze-thaw 
cycles of promastigotes in the presence of protease inhibitors (Protease inhibitor 
cocktail, Sigma-Aldrich), in liquid nitrogen followed by water bath at 37°C. Protein 
quantification was performed by using Pierce BCA protein assay kit (ThermoFisher 
Scientific, USA).
Peripheral Blood Mononuclear Cells (PBMC) and monocyte isolation
PBMC isolation was performed by dilution of blood in pyrogen-free PBS and 
differential density centrifugation over Ficoll-Paque (GE healthcare, UK) as 
previously described (23). Percoll isolation of monocytes was performed as 
previously described (24). Briefly, 150-200 x 106 PBMCs were layered on a hyper-
osmotic Percoll solution (48.5% Percoll, 41.5% sterile water, 0.16 M NaCl) and 
centrifuged for 15 minutes at 580 g (4 oC). The interphase layer was collected and 
cells were washed with cold PBS. Cells were resuspended in RPMI 1640 culture 
medium (Roswell Park Memorial Institute medium; Invitrogen, USA) supplemented 
with 50 μg/mL gentamicin, 2 mM glutamax (Gibco, Life Technologies, USA), and 1 
mM pyruvate (Gibco) and quantified. Cells (10 x 106 cells/10 mL) were allowed to 
adhere on petri dishes plates (Corning, NY, USA) for 1 h at 37°C. Non-adherent cells 
were washed out with warm PBS and monocytes were recovered from the plates by 
adding 6 mL of versene (Gibco, Life Technologies, USA) for 30 min, at 37°C. 
Monocyte training, treatments and macrophage infection
Trained immunity was induced in adherent monocytes as described previously 
(25). Cells were incubated either with culture medium containing 10% pooled 
human serum, referred as complete medium, as a negative control or 5 μg/mL of 
β-glucan (γ-1,3-(D)-glucan was kindly provided by Professor David Williams, College 
of Medicine, Johnson City, USA). After 24 h (37oC), cells were washed once with 10 
mL of warm PBS and incubated for 5 days with one change of complete medium. 
On day 6, cells were harvested and counted. 1 x 106 cells were stored in 200 μL of 
TRIzol (Invitrogen) at -80°C until RNA extraction. 1 x 106 cells were stored in 100 μL 
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of 0.5 % TritonX-100 (Sigma-Aldrich) for intracellular IL-32 measurement. 5 x 105 
cells in a final volume of 500 μL of complete medium were added into 24-well plates 
on 12 mm coverslips (Corning, NY, USA), adhered for 1 h at 37°C and infected with 
stationary-phase promastigotes of L. braziliensis (2.5 x 106/well; MOI 5:1). Percentage 
of infected macrophages, number of parasites per infected cells and infection index 
were measured after 2 h, 4 h and 24 h of infection. 1 x 105 cells in a final volume of 
100 μL of culture medium were added into flat-bottom 96-well plates (Corning, NY, 
USA), adhered for 1 h at 37°C and restimulated with 10 ng/mL of lipopolysaccharide 
(LPS) from E. coli serotype O55:B5, (Sigma-Aldrich), further purified as described (26) 
and L. braziliensis promastigotes (5 x 105/well; MOI 5:1). Supernatants were collected 
after 2 h, 4 h and 24 h and stored at -20°C. In some experiments cells were pre-
incubated (before β-glucan) for 1 h with 10 μg/mL of recombinant interleukin-1 
receptor antagonist (IL-1Ra; Synergen, USA) to evaluate the IL-1 effects during 
the priming with β-glucan. After 24 h stimuli and inhibitors were washed away 
and the assay continued as described above. Additionally, 1 x 106 monocytes were 
stimulated with 10 ng/mL of rhIL-1β (R&D systems) for 24 h at 37°C. After 24 h cells 
were stored in 200 μL of TRIzol until RNA extraction. 
Evaluation of Macrophage infection 
Infection index were performed as previously described (15). Coverslips were 
collected, cells were fixed and stained with Giemsa (Merck Millipore) and analyzed 
under a light microscope (1000x) to determine the infection index. Three hundred 
cells were analyzed and the percentage of infected cells and the mean number 
of intracellular parasites per infected cell (at least 50) were determined. Infection 
index = percentage of infected cells × mean number of parasites per infected cell. 
Reactive oxygen species and nitric oxide measurements 
For measurement of ROS production, a luminol-enhanced luminescence assay was 
used. After detachment and counting of trained monocytes, a total of 1 x 105 cells 
were added per well of a white-96 well assay plate (Corning) in a volume of 200 μL. 
Cells were either stimulated with zymosan from Saccharomyces cerevisiae (1 mg/mL; 
Sigma-Aldrich) or with stationary-phase promastigotes of L. braziliensis (5 x 105/well; 
MOI: 5:1). Luminol (145 μg/mL) was added and chemiluminescence was measured 
for 1 h. For NO, 1 x 106 cells were trained and nitrite was determined in supernatants 
on day 6 by using Griess reagent (Sigma-Aldrich). Prior to the assay, the human 
serum was precipitated from the supernatants using perchloric acid (PCA 13.5% - 
Fluka) and neutralized with 4 N NaOH. 
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Chromatin immunoprecipitation (ChIP)
Monocytes were isolated and trained with β-glucan as described above. On day 
6, cells were harvested and fixed in 1% methanol-free formaldehyde. Fixed cell 
preparations were sonicated using Diagenode Bioruptor Pico sonicator using 
5 cycles of 30 s on/30 s off and CHIP was performed using antibodies against 
H3K4me3, H3K9me3, H3K4me1 (Diagenode, Seraing, Belgium). A MinElute PCR 
purification Kit (QIAGEN) was used for DNA isolation. Afterward, qPCR analysis was 
performed using SYBR Green method and samples were analyzed by a comparative 
Ct method. Primers are listed in S1 Table. 
Genetic Analysis in the 200FG cohort
Genetic variation was assessed in the genes of IL-32 and IL-1β in healthy 
individuals of Western European descent from the 200FG cohort ((27), www.
functionalgenomicprotject.com). The volunteers (n = 120) were between 23 and 73 
years old and consisted of 77% males and 23% females. Monocytes were isolated 
and trained with β-glucan as described above. After 24 h, supernatants were 
collected and IL-6 and TNFα production was measured by ELISA. 
Animals
Transgenic mice for human IL-32 were generated (28) and kindly donated by 
Professor Charles Dinarello (University of Colorado, Denver, USA). IL-32γTG mice 
between 8-10 weeks old were used in the experiments. Mice were maintained in 
animal facility of Instituto de Patologia Tropical e Saúde Pública of Federal University 
of Goiás, Goiás, Brazil. 
In vivo γ- glucan training experiments
IL-32γTG mice were injected intraperitoneally (i.p.) with 1 mg (29) of γ-D-glucan 
from barley (Sigma- Aldrich) in 200 μL of PBS; as control, i.p. injection of PBS alone 
was performed; After 7 days, animals were infected with stationary-phase of 
L. braziliensis promastigotes (1 x 105/50 mL of PBS per mice) subcutaneously into 
the left posterior footpad. Lesion size (mm) was measured weekly using a digital 
caliper and expressed as the difference between the thickness of the infected and 
uninfected footpad. After 3 weeks and 8 weeks of infection, mice were euthanized 
and their footpads were removed for analyses. Infected paw was weighed and 
macerated in PBS. Parasite load was then analyzed by the limiting dilution assay. 
The results were expressed as the negative logarithm of the parasite titer per 
footpad (30). To measure cytokines concentrations in the lesion, tissue samples 
were prepared as previously described (31).
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Ex vivo bone marrow stimulation after in vivo γ- glucan training
Mice were injected with β-glucan as described above. On day 7, bone marrow from 
both femurs and tibiae was harvested in culture RPMI 1640 medium supplemented 
with 10% heat-inactivated FBS. Cells were counted and the concentration was 
adjusted for 5 x 106 cells/mL. 1 x 106 cells were stored in 200 μL of TRIzol at -80°C for 
RNA extraction. Subsequently, 5 x 105 cells in 100 μL were seeded in flat-bottom 96-well 
plates, stimulated with 100 μL of LPS (10 ng/mL) or L. braziliensis lysates (50 μg/mL) and 
incubated for 24 h, at 37°C. Supernatants were collected for cytokine measurements 
and cell monolayers were stored in 200 μL of TRIzol at -80°C for RNA extraction. 
Cytokine and lactate measurements 
Cytokine production was determined in supernatants using commercial ELISA 
kits (R&D Systems) for human TNFα, IL-6, IL-10 and IL-32. For mouse, bone marrow 
culture supernatants, and supernatants from footpad homogenates were used 
to measure TNFα and IL-32 (kits from R&D Systems), according the instructions of 
the manufacturer. Lactate concentration was measured in supernatants of human 
macrophages using Lactate Fluorometric Assay kit (Biovision, CA, USA). 
RNA isolation and qPCR
RNA was isolated using Trizol (32). RNA was precipitated with isopropanol and 
washed with 75% ethanol followed by reconstitution in RNAse-free water. 
Subsequently, RNA was reversely transcribed into cDNA by using iScript (Bio-Rad, 
Hercules, CA, USA). Diluted cDNA was used for qPCR that was done by using the 
StepOnePlus sequence detection systems (Applied Biosystems, Foster City, CA, USA) 
with SYBR Green Mastermix (Applied Biosystems). Genes evaluated in humans were: 
IL-32, cathelicidin, β-defensin 2, and in mice were: mki67, IL-1β, hif-1α, pfkp3, hk3. The 
mRNA analysis was done with the 2^-dCt x 1000 method and normalized against 
the housekeeping gene γ2M for humans and 18s for mouse. Primer sequences are 
listed in Table S1. 
Histopathological analysis
Paraformaldehyde fixed-footpad lesions of L. braziliensis-infected mice (3 or 8 weeks 
of infection) were embedded in paraffin to be processed for histological analysis. 
Sections of 5 μm in thickness were stained with Hematoxylin and Eosin (H&E). 
Histopathological changes between PBS and β-glucan group mouse lesions were 
analyzed using a digital microscope VisionTek (Sakura, Japan), determining the cell 
density in the inflammatory infiltrate. One hundred microscope fields per section 
were analyzed. Semi-quantitative score was performed according with the number 
of cells per field and classified in 0: none; 1: mild; 2: moderate; 3: intense. 
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Immunohistochemical (IHC) analysis for F4/80
Paraffin-embedded sections of footpad lesions were stained  by the DAB (3’3 
diaminobenzidine) method using  rat primary monoclonal  anti-mouse  F4/80 
antibody (AbD Serotec, UK) followed by secondary biotinylated  rabbit anti-
rat antibody  (Vector Laboratories, USA). Tissues were counterstained with 
Meyer´s hematoxylin. Macrophages were visualized with 3,3-diaminobenzidene 
precipitation (DAB, Vector Laboratory). All sections were analyzed using VisionTek 
(Sakura, Japan) Live Digital microscope. 
Statistical analysis
Differences were analysed using Student t test, Wilcoxon signed-rank test and 
Mann-Whitney U test, where applicable. For cytokine production before and after 
β-glucan training, the data is shown as fold increases or raw cytokine compared to 
the RPMI control. The statistics analyses were performed on these ratios. Analyses 
were performed using Prism software version 6.0 (GraphPad, San Diego, CA, USA). 
Significance was established as p < 0.05. 
Results
β-glucan-induced trained immunity controls L. braziliensis infection in 
primary human macrophages
Since trained immunity has been reported to protect against non-specific infections, 
we investigated whether training induced by β-glucan could control infection 
caused by L. braziliensis. Human primary monocytes incubated with β-glucan for 24 
hours were washed and incubated in normal culture conditions for an additional 5 
days and infected at day 6 with promastigote forms of L. braziliensis. Production of 
TNFα, IL-6 and IL-10 was evaluated after 2h, 4h and 24h of infection (Figure 1A). 
Training of monocytes with β-glucan induced higher TNFα and IL-6 production after 
stimulation with LPS, compared to control cells (Figure S1A and S1B). L. braziliensis 
infection did not induce these cytokines in naive macrophages, whereas a 
significant increase in IL-6 and IL-10 production was observed after 2h and 4h of 
infection in β-glucan-trained macrophages (Figure 1B, 1C and 1D). In parallel, a 
greater percentage of macrophages had ingested the parasite after training with 
β-glucan at these time points (Figure 1E). Remarkably, after 24 h of infection the 
percentage of infected macrophages strongly decreased in β-glucan-treated 
macrophages (Figure 1E). Similar results were observed with regard to the number 
of parasites per infected cell and infection index (Figure 1F and 1G). Interestingly, 
the number of parasites per infected cell was significantly decreased as early as 4 h 
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after infection, indicating rapid killing of the parasites in β-glucan-trained cells 
(Figure 1F). Accordingly, β-glucan-trained macrophages contained 3-fold less live 
parasites compared to control macrophages (Figure S1C).
Figure 1. Trained immunity with β-glucan is important for controlling L. braziliensis infection 
in human macrophages. 
Monocytes were trained with RPMI or β-glucan for 24 h. On day 6 after β-glucan exposure, 
macrophages were infected with stationary-phase L. braziliensis promastigotes for 2 h, washed, and 
incubated for a total of 24 h infection (A). (B-D) TNFα, IL-6 and IL-10 production were measured in 
supernatants by ELISA. (E) Percentage of infected macrophages after 2 h, 4 h and 24 h of infection. 
(F) Number of parasites per infected cell after 2 h, 4 h and 24 h of infection. (G) Infection Index after 
2 h, 4 h and 24 h of infection. The data shown are the mean ± SEM, n = 6. *p < 0.05 (RPMI vs β-glucan; 
by Wilcoxon test).
To investigate potential mechanisms underlying these initial observations, we 
evaluated whether known microbicidal molecules such as reactive oxygen species 
(ROS), nitric oxide (NO), cathelicidin, and γ-defesin could explain the better parasite 
control in β-glucan-trained primary macrophages. No differences in ROS or NO 
production were observed when comparing trained or non-trained macrophages 
(Figure S2A and S2B). In contrast, cathelicidin and β-defensin 2 mRNA expression 
were significantly increased in β-glucan-trained macrophages (Figure S2C and S2D). 
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β-glucan-induced epigenetic modifications results in upregulation of 
IL-32 expression in human macrophages.
We previously described a role for IL-32-dependent cathelicidin and β-defensin 
2 expression in host defense against Leishmania spp. (15), thus prompting us to 
explore if IL-32 was involved in β-glucan induced protection against L. braziliensis 
infection in human macrophages. In accordance with our hypothesis, IL-32γ mRNA 
expression as well as intracellular IL-32 protein levels were significantly increased 
in β-glucan trained macrophages (Figure 2A and 2B). These results indicated 
that IL-32 is upregulated on a transcriptional level. Indeed, intracellular IL-32 
expression was previously shown to be influenced by genetic variation in the IL-
32 promoter region (http://genenetwork.nl/bloodeqtlbrowser/; (33)). Using the 
200FG cohort (27) of healthy volunteers we examined if the IL32 promoter single 
nucleotide polymorphism (SNP) rs4786370 could interfere with β-glucan-induced 
trained immunity. The presence of CC genotype was associated with greater 
production of TNFα and IL-6 compared with the CT and TT genotypes (Figure 2C 
and 2D). Additionally, in individuals carrying the CC genotype, a tendency to higher 
production of lactate was observed compared with the TT genotype (Figure 2E). 
We next examined the chromatin landscape surrounding IL-32 expression in cells 
trained with β-glucan. Levels of H3 histones trimethylated at lysine 4 (H3K4me3), 
a mark generally associated with transcriptional activation, were unexpectedly 
depleted from the IL-32 promoter region in trained cells (Figure 2F). Furthermore, 
transcriptionally repressive lysine 9 trimethylation of H3 histones (H3K9me3) was 
not significantly altered by β-glucan training (Figure 2G). A recent study identified 
a distal regulatory element that is crucial for IL-32 transcriptional regulation in CD4+ 
T cells (34). Activation of such elements can be epigenetically distinguished by 
enrichment for H3 histones monomethylated at lysine 4 (H3K4m1) (35). Paralleling 
the transcriptional upregulation of IL-32, we observed significant enrichment of 
H3K4m1 at the distal enhancer region (Figure 2H).
Human monocyte training with β-glucan upregulates IL-32γ expression 
in an IL-1β dependent manner 
Trained immunity induced by β-glucan is reported to be dependent on bioactive IL-
1β production in mice (36). Moreover, IL-1β induces IL-32 production (37). To further 
investigate this link between IL-1β and IL-32γ, primary monocytes were treated with 
human IL-1β which resulted in a significant increase in IL-32γ mRNA expression 
(Figure 3A). Further, we examined the effect of genetic variations in IL-1/IL-1R genes 
on β-glucan-induced trained immunity. Cytokine production was significantly 
decreased when there were polymorphisms located in the promoter region of the 
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IL-1β-encoding gene (IL-1β; rs16944) (Figure 3B) or a missense SNP in the IL-1α 
gene (IL-1α, rs17561) (Figure 3C), respectively. Similarly, an intronic SNP on IL1RAP 
(interleukin 1 receptor accessory protein; rs34590034) gene also influenced the 
training capacity of monocytes by decreasing the production of TNFα by individuals 
carrying the TT genotype compared to AA and AT genotypes (Figure 3D). 
Figure 2. IL-32γ is upregulated in β-glucan trained macrophages and is relevant for training. 
Monocytes were trained or not with β-glucan for 24 h. (A-B) On day 6 after β-glucan exposure IL-
32γ mRNA expression and intracellular IL-32 protein were measured. (C-E) Genetic variations in IL-
32 were assessed in DNA samples from 83 healthy volunteers from the 200FG cohort. On day 6, 
after LPS restimulation, TNFα, IL-6 and lactate production in β-glucan-trained macrophages were 
assessed in the 3 genotypes for IL-32 rs4786370 SNP. The data shown are fold increased normalized 
to RPMI. Mean ± SEM; *p < 0.05 (Mann-Whitney U test). (F-H) Chromatin was fixated on day 6 and 
ChIP-qPCR was performed. H3K4me3 and H3K9me3 were determined at the promoter of IL-32 gene 
(P1 and P2). H3K4me1 was determined at the distal enhancer region of IL-32 gene (E1 and E2). The 
data shown are the mean ± SEM, n = 6. *p < 0.05 (RPMI vs β-glucan; by Wilcoxon test). 
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Figure 3. IL-1β and IL-32γ expression mediate β-glucan-training.
(A) IL-32γ mRNA expression in monocytes after 24 h stimulation with rhIL-1β. Monocytes were trained 
with RPMI or β-glucan for 24 h. (B-D) Genetic variations in IL-1β (rs16944), IL-1α (rs17561) and IL-
1RAP (rs34590034) were assessed in DNA samples from healthy volunteers from the 200FG cohort. 
Following LPS restimulation on day 6, TNFα and IL-6 production in β-glucan-trained macrophages 
were assessed. The data shown are fold increased normalized to RPMI. Mean ± SEM; *p < 0.05 (Mann-
Whitney U test). Monocytes were trained with β-glucan ± rhIL-1Ra for 24 h. On day 6 after β-glucan 
exposure, macrophages were infected with stationary-phase L. braziliensis promastigotes. (E) IL-32γ 
mRNA expression. (F) Infection index after 24 h of infection. The data shown are the mean ± SEM, 
n = 6. *p < 0.05 (RPMI vs β-glucan; by Wilcoxon test).
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The effects of impaired IL-1 signaling could be ascribed to a decrease in IL-32 
production. In fact, when monocytes were trained with β-glucan in the presence of 
interleukin-1 receptor antagonist (IL-1Ra), we observed lower levels of IL-32γ mRNA 
than monocytes trained in the absence of IL-1Ra (Figure 3E). Additionally, when 
these macrophages were infected with L. braziliensis, we observed a significant 
higher infection index than monocytes trained in the absence of IL-1Ra (Figure 3F). 
The importance of IL-1β for β-glucan induced training was confirmed by a reduction 
in TNFα and IL-6 production when cells were trained in the presence of IL-1Ra and 
challenged after 6 days of culture with LPS (Figure S3A and S3B). Thus, we showed 
that β-glucan-induced intracellular IL-32γ expression is dependent on IL-1 signaling, 
which is crucial for the control of L. braziliensis infection.
β-glucan-induced trained immunity in human IL-32γ transgenic mice 
improves resistance to Leishmania braziliensis.
To further confirm that IL-32γ is important for β-glucan training and control of L. 
braziliensis infection, we performed experiments with human IL-32γ transgenic mice 
(IL-32γTG). Recently, it was reported that β-glucan-induced trained immunity in 
C57BL/6 mice induced proliferation of bone marrow progenitors of myeloid lineage, 
which was associated with increased production of innate immune mediators 
such as IL-1β, and with adaptations in cell metabolism (38). Next we investigated 
whether β-glucan also induces changes in bone marrow cells (BM) of hIL-32γTG 
mice. Human IL-32γTG mice received intra-peritoneal β-glucan injections and after 
seven days, bone marrow cells were analyzed. An increased cellularity was observed 
in the β-glucan-injected group compared to the PBS control animals (Figure 4A). 
Furthermore, β-glucan-treated mice displayed higher expression of mki67 mRNA, a 
gene related to cell cycle regulation (Figure 4B). We next analyzed IL-32 expression 
after 24 h of ex vivo stimulation with LPS or L. braziliensis lysates. Levels of IL-32γ 
and IL-1β mRNA were significantly higher in BM cells from the β-glucan-injected 
mice compared with cells from the PBS group after stimulation with either LPS or 
lysates of L. braziliensis (Figure 4C and 4D). Besides cytokines, expression of genes 
encoding key regulatory enzymes of the glycolytic pathway were evaluated. We 
observed significantly increased expression of hif-1a, pfkp3, hk3 mRNA expression 
in BM cells from β-glucan-injected mice in comparison with cells from PBS injected 
IL-32γTG mice (Figure 4E, 4F and 4G). 
These results indicated that IL-32γTG mice can be trained by β-glucan, leading 
to metabolic alterations and an improved immune response to L. braziliensis 
antigens. Thus, we further explored whether β-glucan could induce protection 
against L. braziliensis infection in vivo in IL-32γTG mice. To this end, IL-32γTG mice 
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Figure 4. β-glucan-induced trained immunity acts in the bone marrow of IL-32γ transgenic 
mice.
 Humanised IL-32γ transgenic (IL-32γTG) mice were injected with β-glucan or PBS, and bone marrow 
analyses were performed after 7 days. (A-B) On day 7, the number of cells in the bone marrow 
(femur) and mki67 mRNA expression was measured. (C-G) IL-32γ, IL-1β, hif-1α, pfkp3, hk3 mRNA 
expression after ex vivo 24 h stimulation with LPS or lysates of L. braziliensis (L. braz). The data shown 
are mean ± SEM of representative group of experiments performed with 5 mice per group. *p < 0.05 
(PBS vs β-glucan; by Student t test).
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were injected with β-glucan or PBS and infected 7 days later with stationary-phase 
promastigotes of L. braziliensis (Figure 5A). β-glucan-trained IL-32γTG mice showed 
a significant increase in lesion size after 3 weeks of infection compared with the PBS 
control group. Remarkably, after week 5 of infection a significant decrease in lesion 
size was observed in β-glucan trained mice (Figure 5B). At the later stages of the 
infection, a significant decrease in parasite load was observed in β-glucan trained 
mice compared with the PBS group (8 weeks, Figure 5C). No significant differences 
in TNFα and IL-32 levels were observed at this time point (Figure 5D and 5E).
The increased size of the lesion on the third week of infection observed in the 
β-glucan-trained mice could be ascribed to a marked increase in the inflammatory 
infiltrate (Figure 6B, 6C and 6D). After 8 weeks of infection, β-glucan-trained mice 
showed a significant reduction of inflammation when compared with the PBS group 
(Figure 6E, 6F and 6G). The predominant cells in the lesions were macrophage-like 
cells in both β-glucan-trained or PBS-treated IL-32γTG mice (Figure 7).
Discussion
Several recent studies describe the ability of human innate immune cells to build 
a de facto immunological memory against pathogens and microbial products (20, 
39). The fungal cell wall component β-glucan is a prototypical inducer of trained 
immunity in vitro and in vivo, stimulating a long-term pro-inflammatory macrophage 
phenotype capable of mounting an augmented response to infection. Importantly, 
the trained immunity response is heightened non-specifically, triggered by 
infections unrelated to the initial training stimulus (40). In this series of experiments, 
we demonstrated for the first time that induction of trained immunity by β-glucan 
modulates IL-32-mediated control of Leishmania infection via IL-1 signaling and 
epigenetic changes. These findings improve our understanding of the mechanism 
of trained immunity induced by β-glucan, and simultaneously point toward novel 
avenues for pharmacotherapy for improved treatment of leishmaniasis.
Specifically, we have shown that induction of trained immunity by β-glucan 
increases the efficiency of phagocytosis and killing of L. braziliensis, in parallel with 
increased cytokine production, specifically IL-6 and IL-10. It has previously been 
demonstrated that dectin-1 and the complement receptor 3 (CR3) receptors are 
required to induce training of monocytes with β-glucan (21). These findings could 
at least partly explain the increased capacity for phagocytosis by β-glucan trained 
cells, since both dectin-1 and CR3 are reportedly involved in Leishmania uptake by 
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Figure 5. β-glucan-training in IL-32γTG mice improves the control of infection caused by 
L. braziliensis. 
IL-32γTG mice were injected with β-glucan or PBS, and subcutaneously infected in footpad with 
stationary-phase L. braziliensis promastigotes after 7 days (A). (B) Lesion size (in millimeters; for each 
mouse, the size of the infected footpad was subtracted by size of the uninfected control footpad) 
was monitored weekly. (C) Parasite load of tissue measured after 8 weeks of infection. (D-E) TNFα 
and IL-32 production per mg of tissue measured in the footpad macerated after 8 weeks of infection. 
The data shown are mean ± SEM of representative group of experiments performed with 6 mice per 
group. *p < 0.05 (PBS vs β-glucan; by Student t test).
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macrophages (41). Considering macrophage microbicidal activity, we assessed 
induction of ROS and NO production (42). However, β-glucan training did not alter 
any of these mediators. These results are in line with previous findings (25) that 
reported no differences in ROS and NO induction in β-glucan trained cells compared 
with naive cells. On the other hand, β-glucan trained cells produced higher levels of 
antimicrobial peptides such as cathelicidin and β-defensin 2, which have been 
Figure 6. Histopathological analyses of paw´s lesions of IL-32γTG mice previously treated with 
β-glucan and infected with L. braziliensis. 
IL-32γTG mice were injected with β-glucan or PBS, and subcutaneously infected in footpad with 
stationary-phase L. braziliensis promastigotes after 7 days. Representative photomicrographs of 
histopathological profile of footpad lesions: (A) Uninfected, (B) PBS group after 3 weeks of infection, 
(C) β-glucan group after 3 weeks of infection. (D) Inflammation scores after 3 weeks of infection. (E) 
PBS group after 8 weeks of infection, (F) β-glucan group after 8 weeks of infection. D and G : Scores 
based on cell density as 0: no inflammation; 1: mild; 2: moderate; 3: intense; scale bar is 100 μm. The 
data shown are mean ± SEM of representative group of experiments performed with 4 mice per 
group. *p < 0.05 (PBS vs β-glucan; by Student t test).
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previously associated with improved killing of Leishmania spp. in human 
macrophages (15, 43). 
Figure 7. Macrophage identification in the lesions of IL-32γTG mice infected with L. braziliensis. 
IL-32γTG mice were injected with β-glucan or PBS, and subcutaneously infected in the footpad with 
stationary-phase L. braziliensis promastigotes after 7 days. F4/80 staining of footpad lesions after 3 
weeks and 8 weeks of infection. (A) Negative control (no primary antibody), (B) Uninfected, (C) PBS 
group after 3 weeks of infection, (D) β-glucan group after 3 weeks of infection, (E) PBS group after 8 
weeks of infection, (F) PBS group after 8 weeks of infection. Scale bar is 20 μm. 
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Since IL-32 has been described as a crucial mediator to control Leishmania 
infections through transcriptional induction of antimicrobial peptides, we explored 
the role of IL-32 in β-glucan-induced trained immunity. Significant induction of 
IL-32 expression suggested that β-glucan training influenced gene regulatory 
mechanisms. Indeed histone methylation changes, namely H3K4me3 enrichment, 
are induced by β-glucan at the promoters of numerous pro-inflammatory genes 
such as TNFα, and IL-6 (21). In contrast, we observed that the IL-32 gene promotor 
region became depleted of H3K4me3 upon training with β-glucan. Importantly, we 
identified a training-specific H3K4me1 enhancer signature located downstream of 
the IL-32 gene transcription start site. Enhancers are distal cis-regulatory elements 
essential to controlling gene expression programs (44) and are thought to play 
crucial roles in the establishment of distinct macrophage phenotypes (45). Recently, 
it has been demonstrated that this particular enhancer element modulates the 
expression of the different isoforms of IL-32 to regulate inflammatory states of 
immune cells during HIV-1 infection (34). Thus, from our limited profiling of the 
chromatin landscape surrounding IL-32 transcriptional regulation, it might be 
tempting to speculate that activating histone modifications at distal regulatory 
elements may be more important for IL-32 expression than those at proximal 
elements. 
However, the importance of the IL-32 promoter cannot be overlooked, as shown 
by the fact that the expression of IL-32 is also altered by promoter SNPs (33). The 
CC genotype of IL-32 rs4786370 SNP was previously associated with enhanced IL-
32 protein production. We therefore examined the effect of this particular SNP in 
β-glucan-induced trained immunity. In accordance with previous reports (46) we 
found that TNFα, IL-6, and lactate production were higher in individuals carrying the 
CC genotype compared with those carrying the TT genotype in β-glucan-trained 
cells. Further work is required in order to understand the mechanistic significance 
of genetic variation in the IL-32 promoter, including epigenetic mechanisms not 
explored in the current study such as DNA methylation (47), as well as transcription 
factor binding. 
It has previously been shown that IL-32 is able to induce several proinflammatory 
cytokines, such as IL-1β, IL-8, and TNFα. Furthermore, IL-1 and TNFα can induce 
IL-32 (37, 48, 49). Recent reports pointed towards a role for IL-1 in the induction 
of β-glucan-induced trained immunity in vivo (38). In addition, Arts et al. (50) 
demonstrated that IL-1β itself can induce trained immunity. Here, we confirmed 
the role of IL-1 in the induction of trained immunity by using functional genomics 
analysis and IL-1 receptor blockade. Inhibition of IL-1 signaling downregulated IL-32 
203β-glucan-induced trained immunity protects
7
expression which in turn decreased the killing of Leishmania parasites. It cannot be 
discounted that the IL-1-dependent TNFα and IL-6 induction after β-glucan training 
might also play a role in the induction of IL-32, therefore contributing to the killing 
of Leishmania parasites. As demonstrated by previously (48), IL-32 and TNFα are part 
of an inflammatory loop. Moreover, TNFα has also been associated with IL-32 in ML 
caused by L. braziliensis (13). 
As the results indicated that IL-32 is important for β-glucan-induced trained 
immunity in human macrophages in vitro, we evaluated the effect of β-glucan-
induced trained immunity in human IL-32γTG mice infected with L. braziliensis. 
In these mice, β-glucan training induced proliferation of bone marrow cells, 
accompanied by enhanced IL-32 and IL-1β expression, as well as upregulation 
of genes involved in glycolysis, upon exposure to LPS or lysates of L. braziliensis 
(Figure 4). These findings are in line with those from a previous study, in which 
changes in progenitor cells such as increased production of IL-1β and enhanced 
glycolysis accompany the induction of trained innate immunity (29, 38). Netea et al. 
(51) previously described that IL-32 contributes to differentiating monocytes into 
macrophage-like cells, resembling the phenotypical changes seen after β-glucan 
exposure. Additionally, IL-32 modulates the expression of ABCA1 and ABCG1 
resulting in changes in lipid concentrations in primary human hepatocytes (52). 
Although we have not evaluated deviations in lipid metabolism, it is likely that IL-32 
plays a role in metabolic changes necessary for cell adaptation during the induction 
phase of trained immunity with β-glucan. 
Successful treatment of leishmaniasis is limited in the most parts of the world due 
to the toxicity and costs of effective medication. Moreover, a functional vaccine 
against the Leishmania spp. infections in human is still under development. 
However, a safe and effective leishmaniasis vaccine might be based on whole 
irradiated live parasites, defined antigens such as LEISH-F or DNA vaccines (53). 
It would be of considerable interest to combine vaccine components that target 
the enhancement of Th1 responses against Leishmania with strategies such as 
induction of trained immunity, especially to improve memory development 
for long-term protection. In therapy, especially in the cases where an acquired 
immune response is not present or is not effective such as in diffuse cutaneous 
leishmaniasis, induction of trained immunity may be crucial to contain the parasite 
proliferation and dissemination. As a proof of concept, treatment of patients with 
diffuse cutaneous leishmaniasis with BCG provides control of parasites and long 
periods without relapses, improving the quality of the patient life (16, 17). Thus, in 
addition to BCG training, β-glucan training represents another approach to control 
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leishmaniasis in these patients. Moreover, β-glucan treatment may be an alternative 
when BCG, after several injections, could no longer be used due to the induction of 
strong acquired immune response in the local site of injection (17). 
In conclusion, we have shown that β-glucan improves host defense against L. 
braziliensis via the induction of trained immunity, highlighting IL-1 signaling and 
IL-32γ as important mediators for the eradication of Leishmania parasites. This 
study represents the first definitive characterization of the role of IL-32γ in the 
trained phenotype induced by β-glucan. Our results begin to unravel the molecular 
mechanisms governing trained immunity and Leishmania infection control. Finally, 
the demonstration that β-glucan is able to improve the control of Leishmania 
infection using several mechanisms opens the gates for new treatment strategies 
using trained immunity. 
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Supplemental Information
Figure S1. Cytokine production and Leishmania viability in primary human macrophages 
trained with β-glucan. 
(A) Monocytes were trained with RPMI or β-glucan for 24 h. On day 6 after β-glucan exposure, 
macrophages were restimulated with LPS for 24 h.  (B) TNFα and IL-6 production were measured in 
supernatants by ELISA. (C) After 24 h of infection, Grace’s insect medium was added into the wells 
and live L. braziliensis were quantified by using hemocytometer. The data shown are the mean ± 
SEM, n = 6.  *p < 0.05 (RPMI vs β-glucan; by Wilcoxon test).
Figure S2. Microbicidal molecules produced in primary human macrophages trained with 
γ -glucan. 
Monocytes were trained with RPMI or β-glucan for 24 h. On day 6 after γ -glucan exposure, (A) 
production of ROS, (B) NO (nitrite measurement) and iNOS expression, (C-D) cathelicidin and γ 
-defensin 2 mRNA expressions were measured. The data shown are the mean ± SEM, n = 6. *p < 0.05 
(RPMI vs γ -glucan; by Wilcoxon test).
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Figure S3. IL-1Ra treatment abrogates TNFα and IL-6 production n primary human 
macrophages trained with γ -glucan. 
Monocytes were trained with β-glucan ± rhIL-1Ra for 24 h. On day 6 after β-glucan exposure, 
macrophages were restimulated for 24 h with LPS and (A) TNFα and (B) IL-6 concentrations were 
measured in the supernatant. The data shown are the mean ± SEM, n = 6.  *p < 0.05 (RPMI vs γ 
-glucan; by Wilcoxon test).
S1 Table.  Primer sequences 
Gene Forward primer Reverse Primer 
hb2microglobulin ATGAGTATGCCTGCCGTGTG CCAAATGCGGCATCTTCAAAC
hIL-32g AGGCCCGAATGGTAATGCT CCACAGTGTCCTCAGTGTCACA 
hcathelicidin TGCCCAGGTCCTCAGCTAC GTGACTGCTGTGTCGTCCT 
hb-defensin2 GGTGTTTTTGGTGGTATAGGCG AGGGCAAAAGACTGGATGACA 
hiNOS GCGCAGACATGATCGCCATA CCTCACCGAACTCACCAGC 
m18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
mki67 CATCCATCAGCCGGAGTCA TGTTTCGCAACTTTCGTTTGTG
mIL-1b GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT
mhif-a ACCTTCATCGGAAACTCCAAAG CTGTTAGGCTGGGAAAAGTTAGG
mpfkp3 AGCACCGTGTCCATTCGATAG CTTCAGCTCTGCCACTGGTTG
mhk CGTGTCCCTACCTTTGGGTT CCAGGTCAAACTCCTCTCGC
promoter IL-32/ P1 CCCTGCAGAGGGTCCTATCT  CAGGAACTGCCGGACCTAAG
promoter IL-32/ P2 GGATCCCACTTGGCTGACG GAGCCCAGGAATGGGCTGC
enhancer IL-32/ E1 GTGGGTGACTGGAGAAAGGG TGGAAGGTGTCCTGCTGTTC
enhancer IL -32/E2 GCAAAAAGTGCTCCCTTCCC TGTGTTCTCTGGGTCGCTTCA
Primer sequences used for qPCR analysis (5’-3’)
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Abstract 
Leishmania (Viannia) braziliensis is the most prevalent species causing American 
Tegumentary Leishmaniasis. The spectrum of clinical manifestations of the 
disease ranges from self-healing cutaneous lesions to chronic ulcers and mucosal 
involvement. Innate immune cells undergo long-term functional reprogramming 
after certain infections or vaccinations, a process called trained immunity. Here we 
demonstrate that monocytes exposed to promastigotes antigens of Leishmania 
braziliensis develop an enhanced response to subsequent engagement of 
TLR2 or TLR4 receptors. The induction of trained immunity in monocytes by L. 
braziliensis was mediated by TLR4, CR3, and endocytosis followed by parasite 
recognition through the NOD2 receptor, and dependent on glycolysis, oxidative 
phosphorylation, and glutaminolysis. The increased inflammatory response was 
associated with enrichment of H3K4me3 and H3K4me1 modifications at the TNF 
promoter. L. braziliensis-induced trained immunity enhanced in vitro killing of 
C. albicans and protected against a lethal C. albicans infection in vivo. This study 
represents the first evidence of L. braziliensis-induced trained immunity, the results 
of which improve our understanding of the immunological effects in Leishmaniasis 
and open new avenues for therapeutic approaches. 
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Introduction
Leishmania (Viannia) braziliensis is the most prevalent species causing American 
Tegumentary Leishmaniasis (ATL) in Latin America. The spectrum of clinical 
manifestations of Leishmania (V.) braziliensis infections range from self-healing 
cutaneous lesions to chronic ulcers and mucosal involvement (1, 2). The chronic 
stage of the disease is characterized by lesions with prolonged evolution, scarce but 
persistent number of parasites in the lesion accompanied by increased number of 
CD68+ macrophages, CD4+ and CD8+ T lymphocytes, as well as unresponsiveness to 
treatment (3, 4). Conversely, the self-healing manifestations have been associated with 
high number of parasites and strong, yet limited, T cell activation (5).  Macrophages 
are the main host cells for the intracellular replication of parasites and long-term 
survival (6). Activation of macrophages by interferon gamma (IFNg) and tumor 
necrosis factor (TNFα) contribute to control the growth of the parasite. Nevertheless, 
increased numbers of macrophages in the lesion site have been associated with 
lesion size and necrotic area throughout the course of the disease, suggesting a direct 
role for macrophages in pathology of L. braziliensis-induced lesions (3, 7-9). 
The increased inflammatory response associated with L. braziliensis infections and 
parasite growth contributes to the clinical outcome of the patients. Consitent with 
these findings, inflammatory cytokines produced by innate immunce cells such as 
TNFα and interleukin (IL)-1β have been associated with development of severe forms 
of ATL (10-12). TNFα is especially important since it has previously been correlated 
with lesion size (13). Moreover, the blockade of TNFα in combination with antimonial 
treatment increases the cure rate among patients infected with L.braziliensis (14-16). 
Exposure of human peripheral blood mononuclear cells (PBMCs) and intermediate 
monocytes isolated from  L.braziliensis-infected patients to Leishmania antigens and 
lipopolysaccharide (LPS) lead to high production of TNFα. In addition, besides its role 
in TNFα production, the intermediate monocytes are known to be increased in the 
circulation of patients  and express CCR2, which would promote their migration into 
the lesions and enhance the inflammatory response (10, 17). 
It was recently shown that monocytes/macrophages can build a memory of 
previous stimulations and develop a long-term functional reprogramming via 
a process called trained immunity upon exposure both of pathogen associated 
molecular patterns (PAMPs), such as cell wall component β-glucan from Candida 
albicans, and damage-associated molecular patterns (DAMPs) such as IL-1α (18-
21). The enhanced state of immune activation of innate immune cells is dependent 
on metabolic and epigenetic rewiring (22). Of note, transcriptional and epigenetic 
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profiling have revealed that genes coding for proinflammatory cytokines, such as 
TNFα and IL-6, are strongly upregulated in trained monocytes (23). This upregulation 
was accompained by changes in several cellular metabolic pathways such as 
glycolysis, oxidative phosphorylation, fatty acid and amino acid metabolism (18, 
24). Interestingly, numerous metabolites that are generated as a product of these 
changes in cellular metabolism can act as cofactors for epigenetic writers and erasers 
linking immunometabolic activation with long-term changes in gene regulation (25). 
Among the epigenetic changes at the chromatin level, enrichment of trimethylation 
of lysine 4 of H3 histones (H3K4me3), H3K4 monomethylation (H3K4me1) and H3K27 
acetylation at regulatory elements of proinflammatory cytokines genes is associated 
with increased transcriptional competency (20, 23, 26). 
However, the close association of macrophages and TNFα with the state of 
hyperactivation of the inflammatory response by which influence the clinical 
outcome of L. braziliensis-infected patients remains elusive. In the present study, 
we hypothesized that the exposure of human monocytes to Leishmania spp. 
induces long-term functional reprogramming of monocytes/macrophages via 
induction of trained immunity, thus contributing to the clinical outcome of 
patients. We investigated the effect the exposure of primary human monocytes 
to antigens of L. braziliensis by assessing the changes in TNFα production, cellular 
metabolism pathways and epigenetic enrichment. In addition, non-specific 
protection to secondary infections was examined through in vitro and in vivo 
experiments. Deciphering how myeloid cells are epigenetically reprogrammed for a 
hyperinflammatory state during Leishmania infections could offer novel therapeutic 
strategies for patients with leishmaniasis. 
Methods
Experimental model and subject details
The study was approved by Ethics Committee of Radboud University Nijmegen, the 
Netherlands (no. 42561.091.12) and also by Ethics Committee for animal research 
of Universidade Federal de Goiás (CEUA/PRPI/UFG, protocol 042/16). All animal 
experiments were in accordance with the guidelines of legislation of ethics of the 
Brazilian Society of Science in Laboratory Animals (SBCAL) and National Council 
of Control of Animal Experimentation (CONCEA). Experiments were conducted 
according to the principles expressed in the Declaration of Helsinki. All blood donors 
(Sanquin Blood Bank, Nijmegen, The Netherlands) gave written informed consent 
before donating the blood.
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Leishmania braziliensis parasites
L. (V.) braziliensis (MHOM/BR/2003/IMG), L. (V.) guyanensis MHOM/BR/2006/
PLR6, both strains from Leishbank IPTSP/UFG and L. amazonensis (IFLA/BR/67/
PH8), a reference strain, were used. Promastigote forms were cultured in Grace’s 
insect medium (Gibco, Life Technologies, USA) supplemented with 20% of heat-
inactivated fetal bovine serum (FBS, Gibco, Life Technologies, USA), 100 U/mL of 
penicillin/streptomycin (Sigma-Aldrich) at 26°C. Stationary-phase parasites were 
obtained on 6th day of growth and washed three times with phosphate-buffered 
saline (PBS; 1000xg, 10 min 10°C). After, they were suspended in PBS and quantified 
by using hemocytometer after fixation with PBS/0.4% formaldehyde. Live parasites 
were used in macrophage infection experiments. In addition, parasite lysates were 
obtained by 5 freeze-thaw cycles of promastigotes in the presence of protease 
inhibitors (Protease inhibitor cocktail, Sigma-Aldrich), in liquid nitrogen followed 
by water bath at 37°C. Protein quantification was performed by using Pierce BCA 
protein assay kit (ThermoFisher Scientific, USA).
Peripheral Blood Mononuclear Cells (PBMC), monocyte training and 
treatments
Human peripheral blood mononuclear cells (PBMCs) was performed by dilution of 
blood in pyrogen-free PBS and differential density centrifugation over Ficoll-Paque 
(GE healthcare, UK) as previously described (27). Percoll isolation of monocytes was 
performed as previously described (28).  Briefly, 150-200 x 106 PBMCs were layered 
on a hyper-osmotic Percoll solution (48.5% Percoll, 41.5% sterile water, 0.16 M NaCl) 
and centrifuged for 15 minutes at 580 g (4 oC). The interphase layer was collected 
and cells were washed with cold PBS. Cells were resuspended in RPMI 1640 culture 
medium (Roswell Park Memorial Institute medium; Invitrogen, USA) supplemented 
with 50 μg/mL gentamicin, 2 mM glutamax (Gibco, Life Technologies, USA), and 1 
mM pyruvate (Gibco) and quantified. Adherent monocytes were trained as described 
previously (depicted in figure 1) (29). Briefly, 100.000 cells were incubated either with 
culture medium containing 10% pooled human serum, referred as complete medium, 
as a negative control or 5 μg/mL of β-glucan (β-1,3-(D)-glucan was kindly provided 
by Professor David Williams, College of Medicine, Johnson City, USA), lysates of L. 
braziliensis (50 μg/mL, 25 μg/mL, 10 or μg/mL), lysates of L. guyanensis (25 μg/mL) 
or lysates of L. amazonensis  (25 μg/mL). After 24 h (37oC), cells were washed once 
with 200 μL of warm PBS and incubated for 5 days with one change of complete 
medium. On day 6, cells were restimulated with either 200 μL RPMI, 10 ng/mL of 
lipopolysaccharide (LPS) from E. coli serotype O55:B5 (LPS - Sigma) or 10 μg/mL of 
Pam3Cys (Sigma). After 4 and 24 h supernatants were collected and stored at -20oC. 
In inhibition experiments, cells were pre-incubated with the inhibitors 1 h prior to 
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adding the stimuli (lysates of L. braziliensis). Inhibitors used were either RPMI or 
RPMI+DMSO as a negative control, 1 mM 2-deoxyglucose (2-DG, Sigma), 50 μM BPTES 
(Sigma), 50 μM etomoxir (Sigma), 10 μM oligomycin (Sigma), 10 μM fluvastatin sodium 
hydrate (Sigma), 1 mM methyltioadenosine (MTA - Sigma) or 100 μM cyproheptadine 
(CHP - Sigma). For receptor blockade experiments, Bartonella quintana LPS (30) (5 
μg/mL), 10 μg/mL of anti-dectin-1 antibody and control IgG2b (R&D systems),  10 
μg/mL of anti-dectin-2 antibody and control IgG (R&D systems), 10 μg/mL of anti-
MMR (CD206) antibody, anti-CR3 antibody and control goat IgG (R&D systems), 1 μg 
cytochalasin B (Sigma), 100 nM Ponatinib (Selleckchem), 50 nM Syk inhibitor (574711, 
EMD Millipore), 1 μM raf-1 inhibitor (GW5074, Sigma). In all experiments, either RPMI 
or RPMI+DMSO (vehicle) were used as negative controls.
For experiments of reactive oxygen species (ROS), oxygen consumption rate (OCR), 
intracellular acidification rate (ECAR) and cell counting, 10 x 106 cells were trained in 
vitro in petri dishes plates (Corning, NY, USA) in 10 mL medium volume for 24 h as 
described above. On day 6, cells were detached from the plate with versine (Gibco) 
and counted. The analyses were proceeded as described below. 
Microscopy 
Cell morphology was studied by conventional light microscopy. Pictures were 
taken before restimulation at 20x magnification using Leica LAS EZ Software (Leica 
Microsystems). 
Reactive oxygen species (ROS)
Monocytes were isolated and trained with lysates of L. braziliensis or Bacillus 
Calmette-Guérin (BCG - 10 μg/mL) as described above. For measurement of ROS 
production, a luminol-enhanced luminescence assay was used. After detachment 
and counting of trained monocytes, a total of 100.000 cells was added per well of 
a white-96 well assay plate (Corning) in a volume of 200 μL. Cells were stimulated 
with zymosan from Saccharomyces cerevisiae (1 mg/mL; Sigma). Luminol (145 μg/
mL) was added and chemiluminescence was measured for 1 h. 
Cytokine and lactate measurements 
Cytokine production was determined in supernatants using commercial ELISA kits 
(R&D Systems) for human TNFα, IL-6, IL-10. Lactate concentration was measured in 
supernatants of human macrophages using Lactate Fluorometric Assay kit (Biovision, 
CA, USA). 
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Assessment of oxygen consumption and acidifications rates
Real-time analysis of ECAR and OCR on monocytes was performed using an XF-
96 Extracellular Flux Analyzer (Seahorse Bioscience) as previously described (31). 
Monocytes were isolated and trained with lysates of L. braziliensis as described 
above. On day 6, 200.000 macrophages/well were seeded in quintuplicate in XF-
96 cell culture plates in the presence of XF Base Medium (unbuffered DMEM 
with 5.5 mM glucose and 2 mM L- glutamine, pH adjusted to 7.4). The metabolic 
rates of monocytes were analyzed in four consecutive measurements. After three 
basal measurements, three consecutive measurements were taken following 
the addition of 1.5 μM oligomycin, 1 μM carbonyl cyanide-4-(tri-fluoromethoxy) 
phenylhydrazone (FCCP), 2 μM antimycin together with 1 μM rotenone, in order 
to determine basal and maximum OCR and ECAR. All compounds used during the 
Seahorse runs were acquired from Sigma. 
Mice and in vivo L. braziliensis training experiments
Male Wild-type (C57BL/6) mice between 8-10 weeks old were used in the 
experiments. Mice were maintained in animal facility of Instituto de Patologia 
Tropical e Saúde Pública of Federal University of Goiás, Goiás, Brazil. Wild-type C57/
Bl6 mice were injected intraperitoneally (i.p.) with 1 of lysate of L. braziliensis (n=9) 
in 200 μL of PBS; as control, i.p. injection of PBS (n=10) was performed; After 7 days, 
the mice were intravenously infected with freshly cultured Candida albicans (5x107) 
UC820 in the tail vein in a volume of 200μL. Survival was monitored over a period 
of 14 days.
Fungal killing assay
Monocytes were isolated and trained with lysates of L. braziliensis as described 
above. On day 6, After detachment and counting of trained monocytes, a total of 
1x105 cells was added per well of a white-96 well assay plate (Corning) in a volume 
of 100 μL. 1 x 106/mL live Candida was added for 24 hours. Following incubation, the 
cell contents were serial diluted in sterile water and plated on Sabouraud agar for 
counting of colony forming units (CFUs) after 24 hour of incubation. 
Chromatin immunoprecipitation (ChIP)
Monocytes were isolated and trained with lysates of L. braziliensis as described 
above. On day 6, cells were harvested and fixed in 1% methanol-free formaldehyde. 
Fixed cell preparations were sonicated using Diagenode Bioruptor Pico sonicator 
and immunoprecipitated using antibodies against H3K4me3 and H3K4me1 
(Diagenode, Seraing, Belgium). A MinElute PCR purification Kit (QIAGEN) was used 
for DNA isolation. Afterward, qPCR analysis was performed using SYBR Green 
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method and samples were analyzed by a comparative Ct method. Myoglobin 
was used as negative control and H2B as a positive control according to the 
manufacturer’s instructions. Primers sequences are described in (32). 
Statistical analysis
Differences were analysed using Student t test or Wilcoxon signed-rank test. For 
cytokine production before and after Leishmania training, the data are shown as 
fold increases or raw cytokine compared to the RPMI control. The statistical analyses 
were performed on these ratios. Analyses were performed using Prism software 
version 6.0 (GraphPad, San Diego, CA, USA). Significance was established as p < 0.05. 
Results 
Trained immunity by Leishmania parasites induces increased cytokine 
production and morphological changes in human primary monocytes
Monocytes/macrophages have been associated with the severe immuno-
pathogenesis of L. braziliensis-infected patients (3, 10). Moreover, monocytes can 
develop a persistent inflammatory phenotype after exposure to microorganisms 
or microbial ligands (20, 23). In order to evaluate whether L. braziliensis induces 
trained innate immunity, we exposed human primary monocytes to different 
concentrations of lysates and stationary-phase L. braziliensis promastigotes. After 
24 hours of exposure, the cells were washed, incubated for additional 5 days and 
challenged at day 6 with TLR4 (LPS) or TLR2 (Pam3Cys) ligands. Cytokine production 
was evaluated after 4h and 24h incubation by enzyme-linked immunosorbent 
assay (Figure 1A). Pre-exposure to 10 - 50 µg/mL of L. braziliensis lysate increased 
the production of TNFα and IL-6 after both 4h and 24h restimulation with LPS 
(Figure 1B and Figure S1A). Similar effects were observed in monocytes exposed 
to β-glucan, a prototypical inducer of trained immunity used here as positive 
control. No differences were observed for TNFα induction using 1 μg/mL of lysates 
(Figure 1B). Based on these results, subsequent experiments were performed 
using 25 µg/mL of lysates of L. braziliensis parasites. When Pam3Cys was used as 
a secondary stimulus, production of TNFα and IL-6 was similarly increased after 
24 hours (Figure S1B). Next, we trained monocytes with different ratios of live 
parasites/cell (MOI) 50:1, 10:1, 5:1 or 2:1 to explore whether live parasites induced 
similar results. Increased production of TNFα and IL-6 after 24-hour restimulation 
with LPS was observed, indicating that live parasites were able to induced innate 
memory (Figure 1C). In parallel, we examined whether other Leishmania species 
induce trained innate immunity by exposing monocytes to lysates of L. guyanensis 
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Figure 1. Lysates and stationary-phase L. braziliensis promastigotes induce trained immunity. 
(A) Schematic overview of trained immunity assay. Monocytes were trained with RPMI, β-glucan, 
Leishmania spp. lysates or stationary-phase L. braziliensis promastigotes for 24 h. On day 6, macrophages 
were challenged with LPS for 24 h. (B) TNFα, IL-6 ELISA measurements of supernatants from monocytes 
trained with lysates of L. braziliensis. (C) TNFα, IL-6 ELISA measurements of supernatants from monocytes 
trained with stationary-phase L. braziliensis promastigotes. (D) TNFα, IL-6 and IL-10 ELISA measurements 
of supernatants from monocytes trained with lysates of L. braziliensis, L. guyanensis and L. amazonensis 
(25 μg/mL). (E) Cell morphology of monocytes trained with RPMI (negative control), β-glucan (positive 
control) and lysates of L. braziliensis (25 μg/mL). Pictures were taken before restimulation at day 6 
(20x).  (F) Relative cell counts before restimulation at day 6. The data are represented as fold increase 
normalized to RPMI (non trained cells). The data shown are mean ± SEM, (n = 6, *p < 0.05 compared to 
RPMI control; #p < 0.05  compared to L. amazonensis; by Wilcoxon test).
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and L. amazonensis. All Leishmania species induced enhanced TNFα and IL-6 
production when the cells were restimulated at day 6 (Figure 1D). Interestingly, an 
increase in IL-10 production was observed only after exposure to L. amazonensis, 
and not after exposure to L. braziliensis or L. guyanensis (Figure 1D). 
Previous studies have described morphological changes that accompany the 
heightened response of trained macropahges to secondary stimuli (29). We therefore 
analyzed cell morphology and proliferation in L. braziliensis-trained monocytes at 
day 6 before restimulation. Lysates of L. braziliensis induced remarkable changes 
in cell morphology. The cells were larger than non-trained cells (RPMI + 10% 
human serum) and the effect on the size was comparable with β-glucan-trained 
cells (Figure 1E). Moreover, L. braziliensis training induced a significant increase in 
cell numbers at day 6 compared to the control medium (Figure 1F). Importantly, 
before restimulation the cells were detached, counted and plated at the same 
concentration per well. Therefore, the cytokine production upon restimulation at 
day 6 was always performed with equal cell numbers. 
To further characterize the functional phenotype of trained monocytes we 
measured the oxidative burst in L. braziliensis-trained cells. Contrary to BCG-trained 
monocytes, L. braziliensis-trained monocytes did not increase reactive oxygen 
species (ROS) compared to RPMI control when cells were stimulated with zymosan 
(Figure S1C). 
Induction of trained immunity by L. braziliensis is dependent on 
endocytosis via CR3 and TLR4, and the intracellular NOD2 receptor
Leishmania spp. recognition by human cells is dependent on several pattern 
recognition receptors (PRRs) such as TLRs, C-type lectin receptors, complement 
receptors (CR) and NOD-like receptor (NLRs) (27, 33-36). To investigate which 
receptors were involved in L. braziliensis-induced trained immunity in human 
monocytes, we inhibited different PRRs during the first 24 hours and assessed 
TNFα production after restimulation at day 6. The blockade of several C-type lectins 
receptors with specific monoclonal antibodies against dectin-1, dectin-2, mannose 
receptor (MR), Mincle and DC-SIGN did not result in changes in TNFα production 
upon training with L. braziliensis (Figure 2A-E). In addition, inhibition of spleen 
tyrosine kinase (Syk) (Figure 2F) and noncanonical serine-threonine kinase Raf-
1 (Figure 2G) did not show differences in TNFα production upon training with 
L. braziliensis.
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Figure 2. C-type lectins receptors are not required in L. braziliensis-induced training in human 
monocytes. 
Monocytes were trained with lysates of L. braziliensis for 24 h in the presence or absence of (A) 
Bartonella quintana LPS, (A) anti-Dectin-1 antibody, (B) anti-Dectin-2 antibody, (C) anti-Mannose 
antibody, (D) anti-Mincle antibody, (E) anti- DC-SIGN antibody, (F) Syk kinase inhibitor and (G) Raf-1 
inhibitor. On day 6, macrophages were challenged with LPS for 24 h. TNFα production was measured 
in supernatants by ELISA. The data are represented as fold increase normalized to RPMI (non trained 
cells). The data shown are the mean ± SEM, (n = 6, *p < 0.05 compared to isotype control antibody); 
by Wilcoxon test).
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To evaluate whether endocytosis is involved in the induction of trained immunity by 
L. braziliensis, monocytes were treated the first 24 hours with cytochalasin B, which 
caused a significant decrease in the TNFα production measured upon training with 
L. braziliensis (Figure 3A). Since CR3 is also involved in phagocytosis of parasites, we 
examined whether this receptor played a role in the induction of trained immunity 
(37). Blockade of CR3 led to a significant decrease in the production of TNFα 
after LPS restimulation (Figure 3B). In accordance with our results, TLR4 has been 
described important for  Leishmania recognition (34, 38). The blockade of TLR4 with 
the natural antagonist Bartonella quintana LPS, caused a significant decrease in 
the TNFα production measured upon training with L. braziliensis (Figure 3C). Apart 
from phagocytosis, intracellular receptors such as NOD2 might play a role in the 
induction of trained immunity (23). To investigate the role of the NOD1/2 receptors 
in L. braziliensis-induced trained immunity the downstream RIP2 kinase was 
inhibited with ponatinib. Blockade of RIP2 kinase showed a significant reduction 
in the TNFα production after restimulation by LPS upon training with L. braziliensis 
(Figure 3D). 
Trained immunity induction by L. braziliensis is associated with 
concomitant increases in glycolysis and oxidative phosphorylation  
It was previously reported that the induction of trained immunity is characterized 
by increased glycolytic metabolism and intracellular accumulation of fumarate and 
mevalonate (19, 32, 39, 40). Trained immunity induced by β-glucan is accompanied 
by the repression of oxidative phosphorylation (oxPHOS), reminiscent of the classical 
Warburg metabolism, whereas BCG-induced trained immunity is supported by 
concomitant increases in glycolysis and oxPHOS (41). To investigate the metabolic 
phenotype of monocytes trained with lysates of L. braziliensis, the accumulation of 
lactate production in the culture medium was measured. A significant increase in 
the lactate concentrations in the supernatants of L. braziliensis-trained monocytes 
(Figure 4A) was accompanied by an increase of basal and maximum extracellular 
acidification rate (ECAR) (Figure 4B and 4C). Next, we assessed the oxidative 
capacity of monocytes by measuring oxygen consumption rate (OCR) (Figure 4C). 
Importantly, the basal OCR was also higher in L. braziliensis-trained monocytes. No 
differences were observed in the maximum OCR (Figure 4D).  
Glucose metabolism drives L. braziliensis-induced trained immunity in 
human primary monocytes 
To examine the contribution of metabolic pathways for enhanced cytokine 
production by L. braziliensis-trained monocytes, we measured TNFα upon inhibition 
of glucose uptake (2-DG), oxidative phosphorylation (oligomycin), fatty acid 
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oxidation (Etomoxir), glutaminolysis (BPTES) or the enzyme HMG-CoA-reductase 
(fluvastatin) (Figure 5A). Minimal morphological changes were observed in 
macrophages at day 6 after treatment with these compounds (data not shown). We 
confirmed the importance of glycolysis in these processes as 2-DG significant 
decreased TNFα production in L. braziliensis-trained monocytes (Figure 5B). 
Furthermore, the impairment of oxidative phosphorylation also caused a significant 
decrease in the TNFα production upon training with L. braziliensis (Figure 5C). In 
addition, we found that treatment with etomoxir also caused decreased TNFα 
production (Figure 5D). Of high interest, the glutaminolysis revealed to crucial for 
the L. braziliensis-induced trained immunity since BPTES strongly reduced the TNFα 
Figure 3. CR3, TLR4 and receptors are required in  L. braziliensis-induced training in human 
monocytes. 
Monocytes were trained with lysates of L. braziliensis for 24 h in the presence or absence of (A) 
cytochalasin B (Cyto B), (B) anti-CR3 antibody, (C) Bartonella quintana LPS, (D) RIPK inhibitor 
(Ponatinib). On day 6, macrophages were challenged with either Pam3Cys or LPS for 24 h. TNFα 
production was measured in supernatants by ELISA. The data are represented as fold increase 
normalized to RPMI (non trained cells). The data shown are the mean ± SEM, (n = 6, *p < 0.05 
compared to isotype control antibody or vehicle (DMSO); by Wilcoxon test).
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production after LPS restimulation (Figure 5E). It has been demonstrated that the 
cholesterol pathway was involved in the induction of trained immunity (32). Here 
we showed that the cholesterol pathway was not involved in L. braziliensis-induced 
trained immunity (Figure 5F). Using the statin inhibitor fluvastatin, we observed no 
effect on the TNFα production after restimualtion on day 6.  
Figure 4. L. braziliensis-trained monocytes increases oxidative phosphorylation and 
glycolysis. Monocytes were trained with RPMI or lysates or lysates of L. braziliensis for 24 h. On 
day 6, (A) Lactate production of L. braziliensis-trained monocytes was assessed. (C) Basal and 
maximum extracellular acidifications rates (ECAR) of L. braziliensis-trained monocytes. (C) Basal 
oxygen consumption rates (OCR) and real-time changes in the OCR were assessed during sequential 
treatment with oligomycin, carbonyl canide-4-(trifluoromethoxy) phenylhydrazone (FCCCP) and 
antimycin A + rotenone by Seahorse. (D) Basal and maximum oxygen consumption rates (OCR) of L. 
braziliensis-trained monocytes. The data shown are the mean ± SEM, (n = 6, *p < 0.05 compared to 
RPMI control; by Wilcoxon test).
L. braziliensis training enriches chromatin modifications associated 
with active transcription at the TNF promoter 
The intracellular metabolic shifts that occur in trained immunity results in 
epigenetic regulation of the promoters of several inflammatory cytokine genes 
(19). In order to address whether L. braziliensis training result in epigenetic 
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Figure 5. Inhibition of oxidative phosphorylation and glycolysis decrease L. braziliensis-
induced trained immunity. 
(A) Scheme of the chemical inhibitors used and their target enzymes.  Monocytes were trained 
with lysates of L. braziliensis for 24 h in the presence or absence of (B) 2-deoxy glucose (2-DG), (C) 
oligomycin, (D) Etomoxir, (C) BPTES and (D) Fluvastatin. On day 6, macrophages were challenged 
with LPS for 24 h. TNFα production was measured in supernatants by ELISA. The data are represented 
as fold increase normalized to RPMI (non trained cells).  The data shown are the mean ± SEM, (n = 6, 
*p < 0.05 compared to RPMI or vehicle (DMSO); by Wilcoxon test).
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changes, we first evaluated the role of histone methylation in the induction of 
trained immunity by L. braziliensis. To this end we added methyltioadenosine 
(MTA, a non-selective methyltransferase inhibitor) during the first 24 hours of 
the training protocol. MTA prevented L. braziliensis-induced enhancement of 
TNFα production after restimulation (Figure 6A). Next, we analyzed whether L. 
braziliensis training was associated with enrichment of transcriptionally permissive 
histone modifications at the proximal TNFΑ promoter. H3 histone monomethylated 
(H3K4me1) or trimethylated (H3K4me3) at lysine 4 were both significantly enriched 
at the TNFα promoter in cells trained with L. braziliensis (Figure 6B). The Set7 lysine 
methyltransferase (also known as Set9 (42), Set7/9 (43) or KMT7 (44), and encoded 
by the SETD7 gene is an important writer of the H3K4me1 modification (45, 46), a 
mark strongly implicated in the epigenomic rewiring that occurs in cells trained with 
β-glucan (47). Furthermore, our previous transcriptome profiling studies identified 
significantly elevated levels of SETD7 expression in cells trained by β-glucan (20). 
We observed similar significant upregulation of SETD7 mRNA expression in L. 
braziliensis-trained monocytes on day 6 (Figure 6C). To directly test the role of Set7 
in trained immunity induced by L. braziliensis, we added the recently described 
inhibitor of Set7 Cyproheptadine (CPH) (45) to the medium during the first 24 hours 
of the training protocol, which prevented L. braziliensis-induced trained immunity 
in terms of TNFα production after LPS restimulation (Figure 6D).
L. braziliensis-induced trained immunity in vivo results in protection 
against lethal Candida albicans infection
Epigenetic reprogramming of monocytes by trained immunity has been reported to 
induce nonspecific protection against different pathogens such as C. albicans and 
Staphylococcus aureus (20, 23). To explore whether L. braziliensis induced trained 
immunity in monocytes enhanced the in vitro killing of C. albicans, we incubated live 
C. albicans with trained monocytes and the amount of colony forming units (CFU) 
was determined after 24 hours. Figure 7A showed that an inhibition of growth 
was observed in L. braziliensis-trained macrophages compared to RPMI control. We 
next assessed whether induction of trained immunity by promastigotes antigens 
of Leishmania parasites could protect against a systemic fungal infection caused 
by C. albicans. In a following set of experiments, we investigated whether injecting 
wild-type C57/Bl6 mice with lysates L. braziliensis were more resistant to a lethal C. 
albicans infection. Intraperitoneal application of L. braziliensis lysates resulted in a 
better survival rate than the vehicle-injected animals (Figure 7B). 
229Leishmania braziliensis induces metabolic rewiring
8
Figure 6. Epigenetic regulation of L. braziliensis-induced trained immunity.
Monocytes were trained with lysates of L. braziliensis for 24 h in the presence or absence of 
methyltransferase inhibitors (A) MTA and (D) CPH. On day 6, macrophages were challenged with LPS 
for 24 h. TNFα production was measured in supernatants by ELISA. On day 6, (B) H3K4me3 and 
H3K4me1 at the promoter’s regions (R1 and R2) of TNFA were assessed in L. braziliensis-trained 
macrophages. (C) SETD-7 mRNA expression was assessed by qPCR. The data shown are the mean ± 
SEM, (n = 6, *p < 0.05 compared to RPMI or vehicle (DMSO); by Wilcoxon test).
Figure 7. L. braziliensis-induced trained immunity protects against secondary infections.
(A)  C. albicans growth in the presence in L. braziliensis-trained macrophages. Pictures were taken 
after 24 h incubation with C. albicans (20x). The data shown are the mean ± SEM, (n = 6, *p < 0.05 
compared to RPMI). (B) C57BL/6 mice were injected with lysates of L. braziliensis (1mg/mL) or PBS, 
and intravenously infected with live C. albicans after 7 days. Survival rate was determined during 14 
days of infection. Area under the curve is shown (n= 10 PBS; n=9 L. braz). 
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Discussion
In this study we describe for the first time the molecular mechanisms linking 
L. braziliensis parasite with the induction of trained immunity, leading to a robust 
innate host response after a secondary challenge. Training of monocytes with 
L. braziliensis induced a significant increase in the production of proinflammatory 
cytokines, which were accompanied by distinct morphological changes. These 
processes are mediated by phagocytosis followed by parasite recognition through 
the NOD1/2 receptors. Furthermore, the induction of trained immunity by 
L. braziliensis in monocytes is dependent on glycolysis, oxidative phosphorylation 
and glutaminolysis. Lastly, the increased inflammatory responses observed 
in human monocytes upon training with L. braziliensis has been shown to be 
associated with enrichment of the transcriptional-permissive H3K4me3 and 
H3K4me1 chromatin modifications at the TNFA promoter. Of particular interest, 
trained immunity induced by L. braziliensis enhanced in vitro killing of C. albicans 
and protected against a lethal C. albicans infection in vivo. These findings improve 
our understanding of the mechanism by which Leishmania parasites induce a 
long-term reprogramming of monocytes, and simultaneously point toward novel 
pharmacological targets for improved treatment of leishmaniasis. 
Mononuclear phagocytes are the main host cells that produce cytokines and 
chemokines, thereby triggering events that contributed the host immune response 
against Leishmania spp. (48). In addition, increased concentrations of TNFα are 
reported during in vitro culture with soluble Leishmania antigens or LPS stimulated 
PBMCs obtained from patients with ATL (10). Based on that, we recently argued that 
the mechanism of trained immunity by which innate immune cells undergo long-
term functional reprogramming in response to infectious agents or vaccines, such 
as C. albicans and BCG (Bacillus Calmette-Guérin) respectively (20, 23), could explain 
the persistent inflammatory status of macrophages observed during chronic stages 
of ATL. Specifically, we have shown in this report that L. braziliensis-induced trained 
immunity results in an increased responsiveness of monocytes and macrophages, 
with effector functions such as production of TNFα and IL-6 upon a secondary 
TLR ligand or enhanced killing of  C. albicans. Of note, we have demonstrated that 
contrary to BCG, monocytes exposed to L. braziliensis did not increase the ROS 
production capacity. It is well known that Leishmania species and the duration of the 
lesion influence the immune response of the patient (49). Regarding the induction 
of TNFα and IL-6, similar effects were observed after monocytes were exposed to 
other Leishmania species that causes ATL (50). However, an increased level of IL-10 
was observed for L. amazonensis, which corroborates previous studies showing that 
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this species is associated with higher levels of IL-10 production than species that 
belongs to the Viannia subgenus (51).
These data support our hypothesis that Leishmania parasites serve as a robust 
inducer of trained immunity. In ATL, proinflammatory cytokines act like a double-
edged sword that may induce protection against secondary infections, but at the 
same time may be also implicated in the severe tissue destruction at increased 
levels (52). We foresee that Leishmania-infected patients might have hyperactivate 
macrophages (e.g. trained) at the site of lesion in ways that these latter cells 
contribute to the control of parasite growth but promotes tissue damage. 
In this study, exposure of human primary monocytes to either promastigotes 
antigens or live forms of L. braziliensis induced trained immunity. Remarkably, 
even the lower ratio of live parasites/cell (MOI) led to increased production of 
inflammatory cytokines. Notably, analyses of Leishmania-infected mucosal sites 
in patients typically show few parasites (53). Moreover, these parasites have been 
reported to be more resistant to oxidative stress, ensuring an effective ability to 
infect macrophages, survive and disseminate (54, 55). These findings underscore 
the hypothesis that the spread of few parasites to other sites may provide a 
prolonged and continuous stimulation of the innate immune cells contributing to 
the development of an enhanced state of immune activation, which is now known 
as trained immunity (19). 
Microbial PAMPs are recognized by PRRs on innate immune cells which mediate the 
long-term effect on the functional program of the cell (56). For example, β-glucan 
upregulates cytokine production in monocytes trained in a dectin-1 dependent 
manner (20). Similar training effects driven by BCG are depending on NOD2 
signaling. Interestingly, in monocytes trained with by L. braziliensis, the training 
effects were shown to be dependent on several PRRs rather than a one specific 
receptor. In particular, blockade of  endocytosis and phagocytosis receptors (37), 
including cytochalasin B and CR3 led to a strong decreased TNFα production of 
macrophages trained with L. braziliensis. Previous studies describe the role of TLR4 
in driving the TNFα production in PBMCs upon stimualation with L. braziliensis 
parasites (34).  Of note, TLR4 was found to play an important role in L. braziliensis-
induced trained immunity. Similar to BCG, the inhibition of RIP2 kinase point 
towards a possible role for the intracellular receptors NOD1/NOD2 in the induction 
of trained immunity by L. braziliensis. It is not yet known which components of the 
cell surface of Leishmania are recognized by monocytes. Leishmania spp. expresses 
a variety of glycoconjugates in its cell surface. However, lipophosphoglycan (LPG) 
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is the major glycoconjugate in promastigotes known as a mediator of Leishmania-
macrophages interactions. Nonetheless, the composition and size of the LPG vary 
according the species of Leishmania (57). Therefore, future studies are warranted 
to investigate the potential role of LPG as a inducer of trained immunity aiming 
to understand the mechanisms and consequences for disease and potential 
therapeutic applications. 
Another important discovery is the difference in the induction of cellular 
metabolism in trained monocytes (58). β-glucan has been shown to drive a 
metabolic shift to activated cells which is associated with enhanced glycolysis and 
diminished oxidative phsphorylation and this has been shown to occur via the Akt-
mTOR-HIF-1α pathway (59). Interestingly, for the induction of trained immunity in 
human monocytes by BCG, it was shown that not only glycolysis but also glutamine 
metabolism has an essential role (40). Bekkering et al. described that the cholesterol 
synthesis pathway is essential for induction of trained immunity by β-glucan as well 
oxidized LDL (32). In the present study, we showed that the glucose metabolism is 
crucial for L. braziliensis-induced trained immunity. An increased in glycolytic rate 
and lactate production and oxygen consumption were observed.  In order to fulfill 
the necessary energy requirements, L. braziliensis induction of trained immunity (e.g. 
increased TNFα production after restimulation) is dependent on the use of glycolysis, 
oxidative phosphorylation, glutaminolysis and fatty acid oxidation. Contrary 
to β-glucan and oxLDL, the cholesterol pathway does not seem to be involved 
in the enhanced production of TNFα induced by L. braziliensis training. At this 
moment, the effect of Leishmania spp. on cellular metabolism has not been studied 
extensively. Furthermore, the metabolic processes occurring in macrophages can 
change according to the type of parasite (60). Ovalle-Bracho et al. have shown that 
cholesterol biosynthesis was downmodulated in U937 macrophages infected with 
L. braziliensis, which might explain the independency of the cholesterol pathway on 
the induction of trained immunity seen in this study. Supporting our findings that 
fatty acid oxidation plays a role in the training phenotype induced by L. braziliensis, 
increased intracellular levels of polyunsaturated fatty acids found in monocytes 
have been shown to be associated with training cell phenotypes (31, 61). In line with 
these data, Morato et al. have reported an early production of leukotriene B4, a lipid 
mediator generated from arachidonic acid (an unsaturated fatty acids), induced 
by L. braziliensis in human macrophages. These data indicate that L. braziliensis-
induced trained immunity is dependent different metabolic programs. 
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One of the important findings of the present study is that the enhanced TNFα 
production in L. braziliensis-trained monocytes was dependent of long-term 
epigenetic reprograming represented by an increased H3K4me3 and H3K4me1 
markers at the promoter region of TNFA. These findings are in accordance with 
previous descriptions for other inducers of trained immunity such as β-glucan (20). 
Furthermore, these findings could help to explain the excessive concentrations of 
TNFα produced by macrophages in the lesions of ATL patients. It has been shown 
that the topical application of anti-TNFα antibodies in combination with paromycin 
chemotherapy were effective in terms of parasite elimination and inflammation 
reduction in experimental mice model of infections with L. major (62). Thus, the 
identification of the metabolic pathways and epigenetic changes that contribute 
to L. braziliensis-induced trained immunity in human macrophages opens new 
therapeutic approaches for the treatment of ATL patients. 
In monocytes/macrophages, BCG and β-glucan induce non-specific protection to 
secondary infections (20, 63). In the present study, we confirmed these effects in 
vitro and in vivo showing that either L. braziliensis-trained human macrophages or 
mice were protected against fungal infection caused by C. albicans. In addition, 
recent studies have shown that vaccination of BALB/c with live attenuated 
L. major parasites combined or not with a TLR4 agonist displayed protection against 
secondary L. major infection. A crucial role for CCR2+ monocytes as effector cell 
responsible for parasite elimination at sites of secondary challenge was described 
(64, 65). Interestingly, as a proof of principle, treatment of patients with diffuse 
cutaneous leishmaniasis with BCG in combination with promastigotes antigens of 
Leishmania spp.  provides control of parasites and long periods without relapses, 
improving the quality of the patient life (66, 67).
In ALT patients, secondary infections in cutaneous lesions are common and the most 
frequent bacterium observed is Staphylococcus aureus. However, knowledge of the 
impact of secondary bacterial infections in the lesions is controversial (68). In this 
context, studies have shown that Leishmania/viral co-infections led to significantly 
enhanced disease in L. major-infected mice, which was associated with an increased 
levels CD8+ T cells producing granzyme B (69). In the other hand, it has been shown 
that in a co-infection murine model of Plasmodium yoelli and L. braziliensis, the 
parasitemia was lower than in P. yoelli single-infected group suggesting a protective 
effect of L. braziliensis co-infection in malaria progression. Regarding Leishmaniasis, 
co-infected group presented smaller lesions and less ulceration than L. braziliensis 
single-infected animals (70). Malaria and Cutaneous Leishmaniasis are co-endemic 
throughout large regions in tropical countries (71). Since it has been shown that 
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P. falciparum induces of trained innate immunity (72) and we have shown the same 
L. braziliensis, it might be worthwhile to investigate whether trained immunity plays 
a role in these alterations in Malaria/Leishmania co-infections. Mostly importantly, 
it is necessary to evaluate whether the presence of bacterial in ATL lesions can be 
responsible for Leishmania-trained monocytes reactivation contributing to the 
immunopathogenesis of the disease. 
In conclusion, we provide the first evidence that L. braziliensis exposure of human 
monocytes induces trained immunity, resulting in a long-lasting inflammatory 
phenotype with increased production of proinflammatory cytokines after secondary 
challenge. In addition, the identification of the metabolic pathways and epigenetic 
markers contributing to induction of trained immunity by L. braziliensis improves 
understanding of pathogenesis of Leishmaniasis and identifies new potential 
therapeutic targets. 
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Supplemental information
Figure S1: Monocytes were trained with RPMI, β-glucan or lysates  of L. braziliensis promastigotes for 
24 h. On day 6, macrophages were challenged with LPS for 4 h. (A) TNFα, IL-6 ELISA measurements 
of supernatants from trained monocytes. (B) TNFα, IL-6 ELISA measurements of supernatants from 
trained monocytes exposed to Pam3Cys for 24 h.  (C) On day 6, L. braziliensis and BCG-trained 
monocytes were stimulated with zymosan and ROS production were assessed . The data are 
represented as fold increase normalized to RPMI (non trained cells). The data shown are mean ± 
SEM, (n = 6, *p < 0.05 compared to RPMI control; by Wilcoxon test).
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Chapter 9
Summary and General Discussion 
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Leishmaniasis is one of the most important neglected tropical diseases, with 350 
million people in 88 countries worldwide living at risk of developing one of the 
many forms of the disease (1). New therapies for the disease are urgently needed 
because the most of the drugs currently used to treat patients are either toxic or 
expensive, and may require several rounds or treatment. Recent evidences suggest 
that host-pathogen interaction induces different mechanisms which can contribute 
to parasite survival and persistence. Understanding the diversity in parasite-host 
interactions during infection will be important in guaranteeing the development 
of appropriate vaccines, novel drugs and immunotherapeutic strategies. This thesis 
represents a scientific attempt to better comprehend the interactions between 
parasite and host immune cells, with a focus on the identification of novel targets 
for leishmaniasis control. In part I of this thesis, we have focused on IL-32 and 
its relation with host defense against Leishmania infections. In part II, we have 
proposed new therapeutic targets for the treatment of patients infected with 
Leishmania parasites, as also summarized in Chapter 1. 
To begin with, we have studied IL-32 properties and its involvement in the induction 
of mediators important to control infections caused by Leishmania parasites. 
We described that IL-32, in experimental conditions or through genetic factors, 
is intertwined with the development of immune response and susceptibility in 
leishmaniasis. 
Subsequently, we have targeted potential therapeutic candidates in order to assess 
whether we could to identify new pathways involved with an effective immune 
response resulting in control of parasite growth. We have used functional genomic 
approaches and validation studies to identify receptors that could influence 
the immune response during Leishmania infections. We showed that NOD2 as a 
crucial receptor for cytokine induction and parasite control during infections with 
L. (L.) amazonensis and L. (V.) braziliensis species.
Thereafter, we highlighted trained innate immunity as novel treatment strategy for 
Leishmania spp. infections. We revealed that β-glucan-induced trained immunity 
confers protection against L. braziliensis infection in an IL-1/IL-32 dependent manner. 
Finally, we showed that the exposure of primary monocytes to L. braziliensis 
promastigotes antigens resulted in trained immunity induction. We studied the 
involvement of cytokines, metabolic pathways and epigenetic modifications with 
the training phenotype developed by myeloid cells in response to Leishmania 
stimulations. 
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This chapter summarizes the work we have presented in the previous sections and 
discusses some of the future perspectives for research in the field. 
In Chapters 2 and 3 of this thesis, we focused on the mechanism through which 
IL-32 influence the course of infections caused by L. amazonensis and L. braziliensis 
using in vitro and murine models for leishmaniasis. It was previously reported that 
amastigotes forms of L. braziliensis were able to induce IL-32γ in peripheral blood 
mononuclear cells (PBMCs) from healthy individuals. Next, it was demonstrated that 
IL-32γ has was expressed in L. braziliensis-induced cutaneous and mucosal lesions 
of patients with American Tegumentary Leishmaniasis (ATL) (2). Several cells were 
expressing IL-32γ in the lesion: as keratinocytes/epithelial and endothelial cells 
as well in the inflammatory infiltrate such as mononuclear cells and giant cells. 
Furthermore, it was shown that IL-32γ and TNFα levels were positively correlated in 
mucosal lesions. It is well-known that TNFα is highly produced in mucosal lesions 
and mediates tissue destruction (3, 4). These findings suggested an association 
between IL-32γ and immunopathogenesis of mucosal lesions. In addition, IL-32γ 
was detected in the lesions independent of the duration of the lesion indicating its 
role in acute as well as in chronic leishmaniasis (2). 
In Chapter 2, we continue evaluating the role of IL-32 in Leishmania spp. infections 
using THP-1-derived human macrophages silenced or overexpressed for IL-32γ 
followed by infection with L. amazonensis and L. braziliensis. As PBMCs infected 
with L. braziliensis amastigotes (2), THP-1-derived macrophages only produced the 
IL-32γ isoform after Leishmania spp. infection. The presence of this cytokine was 
needed for TNFα and IL-8 production after infection with either L. braziliensis or L. 
amazonensis. Nevertheless, it seems to be that IL-32γ does not interfere with the 
production of IL-1β or the natural antagonist of IL-1 receptor (IL-1Ra) after infection 
with L. braziliensis. Although L. amazonensis did not induce IL-1β in this model, it 
induced high amounts of IL-1Ra which was dependent on IL-32. The production 
of Leishmania-induced IL-10 was not affected by IL-32. Thus, the data suggested 
that during Leishmania infection IL-32γ seems to play a proinflammatory role in 
L. braziliensis and L. amazonensis infections. However, if there is any production 
of IL-1β during L. amazonensis infection, the high production of IL-1Ra, mediated 
by IL-32γ can dampening the proinflammatory actions of IL-1β. In consequence 
L. amazonensis infection lead to less inflammation than L. braziliensis infection 
(5, 6). Concerning parasite control, IL-32γ seemed to be important to inhibit 
the Leishmania ssp. growth, which might be mediated by nitric oxide (NO) and 
antimicrobial peptides (Cathelicidin and β-defensin 2) produced in an IL-32γ-
dependent manner. Thus, we have concluded that IL-32γ is a crucial intracellular 
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mediator for the production of both cytokines and microbicidal molecules by 
human macrophages after Leishmania spp. infections.
In Chapter 3, we have shown that IL-32 is also present in L. amazonensis-induced 
skin lesions in patients. As next, IL-32 was evaluated in murine Leishmania infection 
to better understand the mechanisms of its actions in the immunopathogenesis 
of leishmaniasis or the control of the parasites. Using IL-32γ transgenic mice with 
ubiquitous expression of human IL-32γ (7), a intradermal infection with Leishmania 
ssp. was performed. In C57BL/6 wild type mice, L. amazonensis leads to a skin lesion 
development that is not controlled whereas L. braziliensis induces a lesion formation 
which can be controlled in this same strain of mice. In human IL-32γTg mice the 
lesions size caused by L. amazonensis was similar to WT mice after nine weeks of 
infection. However, there was an improvement in the control of L. braziliensis-
caused lesions. This response was associated with an increase in the production of 
TNFα, IFNγ and IL-10 in IL-32γTg mice. The balanced inflammatory process led to 
the healing of the lesion. Contrary to L. amazonensis-infected mice, during infection 
with L. braziliensis, no parasite dissemination to the spleen was observed. Although 
IL-32γ did not contribute to the healing of the lesions caused by L. amazonensis, it 
limits the parasite spreading from the site of infection. These findings suggested 
that despite the ability for both species to induce IL-32 in humans, the connections 
between this cytokine and other immune players induced by related species of 
parasites can lead to distinct outcomes of the murine infections. 
In Chapter 4, we hypothesized that besides its role in American Tegumentary 
leishmaniasis, IL-32 could be important for visceral leishmaniasis. We demonstrated 
that during L. infantum infection, IL-32γTg mice showed a lower parasite load in 
spleen and liver than WT mice. This effect was associated with the development of 
high T(h) helper 1 and Th17 immune responses. The control of the parasites could 
be ascribed to an increased production of NO in an IFNγ and IL-17A-dependent 
manner. In addition, a higher number and larger areas of hepatic granulomas was 
observed in IL-32γTg mice compared to the WT mice. Thus, this study revealed a 
protective role of IL-32 in an experimental model of visceral Leishmaniasis in mice. 
In Chapter 5, we studied the induction of IL-32 by L. amazonensis and L. braziliensis 
in primary human PBMCs. The results obtained in this study indicated that live 
amastigotes as well as live promastigotes and lysates/antigens are IL-32 inducers. 
Furthermore, we have shown that the expression of IL-32 isoforms is dependent on 
duration of exposure to Leishmania antigens. IL-32γ was predominantly expressed 
during the early stages of exposure with promastigotes antigens of both L. 
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amazonensis and L. braziliensis. However, after 7 days of exposure, IL-32α and IL-
32β isoforms were identified. It can reflect the ability of IL-32γ mRNA to be spliced 
during long term Leishmania exposure. Additionally, as reported in chapter 2, IL-
32γ was the main isoform expressed by THP-1-derived macrophages exposed to 
Leishmania spp. It can also be that depending on the subset of cells, myeloid or 
lymphoid, different IL-32 isoforms are produced. Subsequently, we showed that 
NOD2, TLR4 and Dectin-1 receptors are important for the early induction of IL-32γ by 
Leishmania spp. Functional genomics has been pointed as a valuable tool to identify 
novel pathways in infectious diseases (8). In this present study, we assessed genetic 
variations that influenced IL-32γ expression and we evaluated their impact on 
Leishmania-induced innate and adaptive cytokines in vitro. The present of genetic 
variations in the promoter (rs4786370), distal regulatory (enhancer – rs4349147) 
and intronic (rs1555001) regions of the IL32 gene led to an altered cytokine profile 
after Leishmania stimulation in vitro. In line with the results presented in chapter 2, 
we have confirmed the involvement of IL-32 with proinflammatory cytokines known 
to be involved in immunopathogenesis of leishmaniasis and in parasite control. 
Looking more closely into the genetic variations in IL32, despite the effects on 
cytokine production, we investigated whether these genetic variations in IL32 could 
be associated with susceptibility or resistance to ATL. We observed an increased 
frequency of IL-32 rs4786370-CC genotype in controls whereas the IL32 rs4349147 
was associated with susceptibility to the development of different clinical forms of 
ATL. Finally, as shown previously (9) and in chapter 4 for VL, we suggested that IL-
32 may influence the development of Th1 and Th17 cellular responses in ATL. The 
IL-32γ mRNA expression in lesions of ATL patients was positively correlated with 
the expression IL1A, IFNγ, IL17, and IL22. In addition, IL-32α mRNA expression was 
positively correlated with IL1A, and IL17 mRNA expression whereas IL-32β mRNA 
expression was associated with IL17 and IL22 mRNA expression. These findings 
pointed that the IL-32γ and IL-32α isoforms can be associated with a mixed Th1/
Th17 profile whereas IL-32β can be more associated with a Th17 profile. Although 
the exact mechanism by which IL-32 interacts with immune cells and influences 
inflammatory pathways and controls parasite growth needs to be further 
investigated, from these we described IL-32 as an important, novel mediator in 
modulation of host defense against infections caused by Leishmania species. 
In Part II of this thesis, possible therapeutic approaches have been studied. In 
Chapter 6, we identified NOD2 as crucial receptor for the induction of innate and 
adaptive immune response after PBMCs exposure with both L. amazonensis and 
L. braziliensis. A study in mice with L. infantum demonstrated that the activation 
of NOD2-RIP2 pathway drives the development of a Th1 instead of Th17 immune 
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response (10). However, this was the first report describing the NOD2 involvement 
in activation of human cells by New World Leishmania spp. We studied the NOD2 
function by selecting genetic variations that are frequently present in NOD1 and 
NOD2 with a predicted loss or gain of function. We showed that one particular genetic 
variance in NOD2 (Leu1007finsC) downregulates the production of monocyte-derived 
cytokines such as TNFα, IL-1β, IL-6, IL-8 as well as IFNγ after exposure to lysates of 
either L. amazonensis or L. braziliensis. Interestingly, we demonstrated that in human 
PBMCs, IL-17 production is NOD2-dependent only after exposure to L. amazonensis. 
Moreover, we have confirmed the pivotal role of NOD2 in cytokine production 
using PBMCs from subjects carrying NOD2 3020insC mutation and demonstrated a 
significant decrease in the production of proinflammatory cytokines after exposure 
with both Leishmania spp. antigens or live promastigotes. Exposure of PBMCs to 
Leishmania spp. also led to an increased expression of NOD2 strengthening its 
involvement in Leishmania-induced immune responses. The ligand of Leishmania 
that is recognized by NOD2 needs to be further elucidated. However, we indicated 
that degradation of Leishmania by enzymes present in the phagolysosomes is a 
prerequisite for cytokine induction. It has been shown that NOD2 plays an important 
role in induction of microbicidal mechanisms including autophagy, antimicrobial 
peptides and ROS production, which are essential to control infections caused by 
intracellular pathogens (11, 12). In the present study, we demonstrated that loss of 
NOD2 signaling impairs intracellular Leishmania killing. Of note, NOD2 was one of 
the receptors important to the induction of IL-32γ as shown in chapter 5. Together, 
these findings have pointed NOD2 as an important player for immune responses in 
Leishmania infections. The relevance of the NOD2 pathway in the susceptibility to or 
severity of human ATL needs to be investigated in the near future. However, it is a 
plausible hypothesis that individuals carrying NOD2 polymorphisms could be more 
susceptible to ATL. Furthermore, in cases of patients with an absence of an effective 
activation of the immune response for example, NOD2 agonists could be used as an 
alternative method to boost the NOD2 pathway conferring protection. 
In Chapter 7 and 8, the use of trained innate immunity as a potential treatment 
option for patients with leishmaniasis is explored. The hypothesis that innate 
immune cells undergo long-term functional reprogramming in response to 
infection or vaccination conferring non-specific protections from secondary 
infections led us tempted to investigate the role of trained immunity in infections 
caused by Leishmania parasites. 
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In Chapter 7, we examined the capacity of β-glucan, a fungal cell wall component, 
to control infections caused by L. braziliensis in both primary cells and in murine 
model of trained immunity. It was shown before that BCG vaccination in combination 
with conventional treatment contribute to clinical remission of lesion in a patient 
with diffuse cutaneous leishmaniasis (DCL) (13). Based on that, BCG would be very 
suitable to treat patients with Leishmaniasis. However, the administration of BCG 
has some contraindications, as the microorganisms may cause disseminate disease, 
the presence of immunodeficiencies is an example (14). This gave the incentive to 
explore the use of β-glucan as an alternative trained immunity inducer. In chapter 7, 
we showed for the first time that monocytes trained with β-glucan confer enhanced 
capacity of phagocytosis and killing of L. braziliensis in vitro. Once again, we used 
functional genomics analysis to demonstrate the importance of IL-32 and IL-1 
family members in the induction of trained immunity by β-glucan. Mechanistically, 
β-glucan-trained monocytes increased expression of IL-32 via IL-1 signaling and 
epigenetic program. Interestingly, looking at macrophage microbicidal activity, we 
showed that β-glucan trained cells produced higher levels of antimicrobial peptides 
such as cathelicidin and β-defensin 2, which have been previously associated with 
IL-32 (Chapter 2) and can be related to improved killing of Leishmania spp. in 
human macrophages. Next, we refer to a murine model of trained immunity induced 
by β-glucan using IL-32γTG mice where we confirmed the association of IL-32 with 
the trained immunity phenotype. We assessed bone marrow of IL-32 γTG mice and 
the results showed an enhanced production of IL-32, IL-1β as well upregulation of 
genes involved in glycolysis upon exposure to LPS or promastigotes antigens of L. 
braziliensis. Furthermore, β-glucan could induce protection against L. braziliensis 
infection in vivo in IL-32γTG mice. An increased lesion size and inflammation was 
observed in β-glucan-treated mice after 3 weeks of infection compared with the PBS 
control group. However, at the later stages of the infection, a significant decrease in 
parasite load and reduction of inflammation was observed in β-glucan trained mice 
compared with the PBS injected group. Hence, the induction of trained immunity 
by β-glucan can be linked to the enhanced function of the innate immune system 
providing novel avenues for improved treatment of leishmaniasis. Nevertheless, 
this study represents the first definitive association of IL-32 with in the training 
phenotype. This was a very important finding where we could demonstrate one 
more time the relation of IL-32 with the control of Leishmania sp. infection. 
In Chapter 8, we focused on the causes of the persistence state of hyperactivation 
of the inflammatory response by which influence the clinical outcome of 
L. braziliensis-infected patients. The spectrum of clinical manifestations of 
L. braziliensis infections range from self-healing cutaneous lesions to chronic 
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ulcers and mucosal involvement (15, 16). Furthermore, it has been shown that 
inflammatory cytokines produced by innate immune cells such as TNFα and IL-
1β are associated with the development of the severe forms of the disease (17-
19). In this study we hypothesized that monocytes exposed to Leishmania sp. 
develop a long-term functional reprogramming of monocytes/macrophages via 
induction of trained immunity contributing to clinical outcome of patients. We 
reported previously the role of trained innate immunity conferring protection of 
the host against reinfections (20, 21). However, the “dark side” of innate immunity 
has been shown, in which increased inflammatory responses towards exogenous 
or endogenous stimuli could have deleterious effects, such as atherosclerosis and 
gout (22, 23). Following up on this, we described that training of monocytes with 
L. braziliensis induces an increased production of TNFα and IL-6 accompanied by 
morphological changes. These processes are mediated by phagocytosis followed 
by parasite recognition through the NOD1/2 receptors. Furthermore, the induction 
of L. braziliensis trained immunity in monocytes rely on glycolysis, oxidative 
phosphorylation and glutaminolysis. Based on studies of our group linking 
metabolic changes to histone marks alterations at specific gene promoter regions, 
we tested two initial candidates through CHIP (H3K4me3 and H3K4me1) at the TNF 
promoter. Of high interest, we could find a significant enrichment of these two 
marks in response to promastigotes antigens of L. braziliensis. We also investigated 
whether L. braziliensis-induced trained immunity confers protection against non-
related infectious pathogens using in vitro and in vivo model of Candida albicans 
infection (21). Interestingly, the induction of trained immunity by L. braziliensis 
enhanced in vitro killing of C. albicans and protects against lethal infection in vivo. 
In this study, we provided the first evidence that L. braziliensis exposure of human 
monocytes induces trained immunity, resulting in a long-lasting inflammatory 
phenotype with increased production of inflammatory cytokines after rechallange. 
Based on these findings, we have raised an important point for discussion in the 
context of induction of trained immunity. On one side, we have the beneficial role 
favoring infection control and on the other side it contributes to the development 
of an enhanced state of activation which might explain the severe tissue damage 
observed in the lesion of ATL patients. Nevertheless, by understanding the 
mechanism by which Leishmania induces these long-term reprogramming of 
myeloid cells opened a very exciting field for new possibilities to treat leishmaniasis. 
Apart from modulating the inflammatory properties, inhibition of certain metabolic 
pathways or reversing the epigenetic state of innate immune cells may represent a 
valid approach to target disease severity deserving future studies. 
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Future perspectives 
In this thesis, I have attempted to address several questions that were aimed to 
understand the host-Leishmania interactions intending to develop new ways of 
combating the infection. 
With the advent of big data analysis and genomic research, functional genomics 
approaches can be undertaken to investigate how phenotypes found in the 
leishamniasis patients are influenced by the genetic variation of the patients. By 
using these tools we have identified target candidates that has to be validated in 
the context of Leishmania spp. infections. The need for genetic associated studies 
where matched asymptomatic and healthy controls are used as reference is a 
promising new endeavor within the scientific community in the field of Leishmania 
research. 
We have unraveled very interesting findings in relation to IL-32 as an important 
mediator controlling parasite growth. We have seen that IL-32 is intertwined with 
innate as well as adaptive immune responses. We have obtained indications that 
IL-32 might be associated with the diseases susceptibility and clinical outcome of 
patients. Although we have contributed to the current knowledge about IL-32 in 
leishmaniasis, many scientific questions remain to be addressed. For example, we 
have shown which are the immune receptors that leads to the induction of IL-32 
upon Leishmania exposure. Besides that, we have used different approaches to 
demonstrate the association of IL-32 with several inflammatory mediators known to 
be involved with the pathogenesis of leishmaniasis (18, 19, 24). However, whether 
IL-32 has a direct role in the immunopathogenesis of the disease is tempted 
to be investigated. Furthermore, a recent study has shown that IL-32 also can 
function as a transcription factor, because IL-32 appears to bind to DNA impairing 
the transcription and viral replication of Hepatitis B virus (25). It would be very 
interesting to investigated whether IL-32 would translocated to the nucleus when 
cells are stimulated as observed for other transcription factors. In addition, it was 
previously reported that IL-32γ can be secreted (26), likely by proteinase-3 (PR3) 
processing (27). Moreover, several studies that applied extracellular recombinant 
IL-32γ (28-31), reported potent effects of IL-32. On the other hand, we have 
shown that upon Leishmania spp. exposure IL-32 is mainly expressed intracellular. 
Additionally, intracellular overexpression of IL-32γ resulted in enhanced cytokine 
production, whereas silencing of IL-32 showed the opposite effects. It might be 
that IL-32 has a dual-functions like other cytokines such as IL-1α, IL-33, IL-37, which 
show extracellular and intracellular functions (32, 33). It is worthwhile to make the 
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use of biochemical approaches to understand more about the IL-32 properties, 
including identification of its receptor in innate and adaptive immune cells. In 
addition, the fact that genetic variations in IL32 influences the genotype-specific 
expression of IL-32 agrees with data from the blood eQTL browser (34) that showed 
that IL-32 gene (among others) as having a significant genetic contribution to its 
expression levels. Furthermore, we showed that these same genetic variations that 
influences IL32 expression might be associated with disease susceptibility and 
development of different clinical forms. Of note, it was also showed that Leishmania 
spp. can induce different isoforms of IL-32 in a time dependent manner. In the 
lesions of patients, these isoforms correlate with cytokines that have beneficial or 
pathologic roles in the context of leishmaniasis. Our results provide insight into the 
phenomenon that IL-32 might be a target molecule in patients with leishmaniasis. 
Our methodological approaches could be expanded by the use of CRISPR/CAS9 
technologies allowing the development of allele specific knockouts cells aiming to 
determine how the change of one nucleotide could lead to a change in the type 
of IL-32 isoform. Hence, determining the exact mechanisms which associates IL-32 
with disease susceptibility or pathogenesis would contribute to novel therapies and 
interventions tailored to specific patient populations. 
Another important point of study is the validity of the NOD2 pathway. We have 
provided evidences that the NOD2 might play an important role for the disease. 
Mutations or variations is NOD2 receptor has been shown to be associated with 
diseases phenotypes (35). Therefore, could be an interesting hypothesis for genetic 
susceptibility in leishmaniasis. In addition, it has been previously shown that BCG, 
the vaccine against tuberculosis, drives its protective role through activation 
of NOD2 (20). Following the same thoughts, a case report of diffuse cutaneous 
leishmaniasis, leishmania-BCG combined vaccination-initiated healing of all lesions 
(13). Hence, targeting NOD2 could be another step in the direction of effective 
strategies of treatment for the patients infected with Leishmania spp. 
The evidences reported in the thesis that trained innate immunity might play a 
crucial role in leishmaniasis is a very important research question that has to be 
addressed. In situations where the immune system cannot eliminate chronic 
infection for example, induction of trained immunity, and therefore enhancing 
the immune response, could be a potential additional treatment. Moreover, the 
knowledge that the parasite itself can induce trained innate immunity might not 
only be important for the understanding of pathogenesis, but holds promise for 
therapy. Infections with live parasites was used as the most successful way to prevent 
leishmaniasis; this procedure was named leishmanization (36). It was used to protect 
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against disfiguring lesions on exposed parts of the body. Although usually effective, 
leishmanization can be associated with loss of parasite virulence, difficulty in 
standardization and the development of non-healing lesions. Hence, this approach 
is not used today. Nevertheless, the success of leishmanization together with our 
findings that the parasite can activate innate immune cells provide support for the 
idea that a vaccine is possible for leishmaniasis. Importantly, researchers have kept 
their focus in the development of a vaccine and adjuvants that could generate a 
long-term adaptive-mediated immunity (37, 38). In the present thesis we proposed 
the use of innate immune memory as a candidate for long term protection against 
infections caused by Leishmania parasites. 
The current treatments available for leishmaniasis have high failure rates, 
possible because they only target the parasite, which may not alleviate the 
immunopathological responses that drive disease in many forms of cutaneous 
leishmaniasis. Thus, in addition to the effect of conferring parasite killing, the 
knowledge about trained innate immunity in leishmaniasis opens possibilities to 
reduce the severe tissue destruction seen in the disease. Thus, the main goal might 
be to reduce parasite load by activating innate immune cells and later use drugs 
that can confer epigenetic regulation for example, aiming to reduce the production 
of inflammatory mediators and avoid the most severe clinical forms of the disease. 
Finally, despite many years of endeavors to prevent and treat leishmaniasis it still 
remains a tremendous public health problem in the countries affected by this 
infectious disease. Continuing these investigations by which innovative strategies 
are required to integrate the new findings that leads to biologically relevant 
conclusions which provide new insights towards the development of effective 
treatment strategies in the future.  
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“O que vale na vida não é o ponto de partida 
e sim a caminhada. Caminhando e semeando, 
no fim terás o que colher.”
- Cora Coralina
259
A
Appendix
260
Resumo 
(Portuguese summary)
A leishmaniose é uma das mais relevantes doenças tropicais negligenciadas. Estima-
se que 350 milhões de pessoas distribuídas em 88 países do mundo estão sob o risco 
de desenvolver uma das formas da doença. Novas terapias contra a leishmaniose são 
urgentemente necessárias, pois as terapias atuais são muitas vezes tóxicas, requerem 
múltiplas administrações e têm um alto custo associado. Estudos recentes sugerem 
que a interação patógeno-hospedeiro induz diferentes mecanismos que podem 
contribuir para a sobrevivência e persistência do parasita. Sendo assim, entender a 
diversidade nas interações parasita-hospedeiro durante a infecção é importante para 
garantir o desenvolvimento de vacinas, novas drogas e estratégias imunoterapêuticas. 
Esta tese representa uma tentativa científica de compreender melhor as interações 
entre o parasita e as células imunes do hospedeiro, tendo como foco a identificação 
de novos alvos terapêuticos para o controle da leishmaniose. A parte I desta tese 
focou-se na IL-32 e a sua relação com a defesa do hospedeiro durante infecções com 
espécies de Leishmania. Na parte II, propusemos novos alvos terapêuticos para o 
tratamento de pacientes infectados com Leishmania spp..
No capítulo 2, o papel da IL-32 em infecções por Leishmania spp. foi avaliado 
utilizando macrófagos humanos derivados de células THP-1 com ou sem a expressão 
de IL-32g. Em seguida, estes macrófagos foram infectados com L. amazonensis e 
L. braziliensis. Os resultados mostraram que os macrófagos derivados de THP-1 
produziram apenas a isoforma g da IL-32 após infecções com Leishmania spp.. A 
presença dessa citocina foi necessária para a produção de TNFα e IL-8 após infecções 
com L. braziliensis ou L. amazonensis. No entanto, a IL-32 não interferiu na produção 
de IL-1β ou do antagonista natural do receptor de IL-1 (IL-1Ra) após a infecção com 
L. braziliensis. Embora L. amazonensis não tenha induzido a produção de IL-1b neste 
modelo, a produção elevada de IL-1Ra se mostrou dependente da IL-32. A produção 
de IL-10 induzida por ambas as espécies de Leishmania não foi afetada pela IL-
32. Assim, os dados sugerem que a IL-32g parece ter um papel pró-inflamatório 
nas infecções causadas por L. braziliensis e L. amazonensis. Em relação ao controle 
parasitário, a IL-32g se mostrou importante para inibir o crescimento dos parasitas. 
Este efeito pode ser mediado pela produção de óxido nítrico (NO) e peptídeos 
antimicrobianos (catelicidina e b-defensina 2) de maneira dependente da IL-32g. 
Assim, concluímos que a IL-32g é um mediador intracelular crucial para a produção 
de citocinas e moléculas microbicidas produzidas por macrófagos humanos após 
infecções com Leishmania spp.
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No capítulo 3, mostramos que a IL-32 também está presente nas lesões cutâneas 
de pacientes infectados com L. amazonensis. A produção de IL-32 foi avaliada no 
modelo murino de infecção com Leishmania com o objetivo de compreender o 
seu mecanismo de ação na imunopatogênese da leishmaniose ou no controle dos 
parasitas. Os camundongos selvagens C57BL/6 e os camundongos transgênicos 
para a IL-32g foram infectados com Leishmania spp.. Os resultados mostraram que 
nos camundongos transgênicos infectados com L. amazonensis, o tamanho da lesão 
foi similar à lesão apresentada pelos camundongos selvagens após nove semanas 
de infecção. No entanto, houve melhora no controle das lesões causadas por L. 
braziliensis. Essa resposta foi associada a um aumento na produção de TNFα, IFNg e 
IL-10 nos camundongos transgênicos. O equilíbrio do processo inflamatório levou à 
cicatrização da lesão. Ao contrário dos camundongos infectados por L. amazonensis, 
durante a infecção por L. braziliensis não foi observada disseminação do parasita 
para o baço. Embora a IL-32g não tenha contribuído para a cicatrização das lesões 
causadas pela L. amazonensis, ela limitou a disseminação do parasita a partir do local 
inicial da infecção. Estes resultados sugerem que, apesar da capacidade de ambas 
as espécies induzirem a IL-32 em humanos, a relação entre esta citocina e outras 
moléculas produzidas pelo sistema imune no modelo murino de infecção, podem 
ocasionar respostas distintas de maneira dependente da espécie do parasita.  
No capítulo 4, hipotetizamos que além da leishmaniose tegumentar americana 
(LTA), a IL-32 poderia ser importante para a leishmaniose visceral. Nós demonstramos 
que durante a infecção por L. infantum, os camundongos transgênicos apresentaram 
umenor carga parasitária no baço e no fígado do que camundongos selvagens. Este 
efeito foi associado com o desenvolvimento de respostas imunológicas do tipo T 
auxiliares 1 (Th1) e Th17. Sugerimos que o controle dos parasitas está relacionado 
a uma produção aumentada de NO de maneira dependente da produção de 
IFNg e IL-17A. Além disso, elevados números e grandes áreas com granulomas 
hepáticos foram observados nos camundongos transgênicos em comparação com 
camundongos selvagens. Este estudo revelou um papel protetor da IL-32 em um 
modelo experimental de leishmaniose visceral em camundongos.
No capítulo 5, estudamos a indução de IL-32 por L. amazonensis e L. braziliensis em 
células mononucleares humanas. Os resultados obtidos neste estudo indicaram 
que lisados/antígenos de promastigotas de ambas as espécies de Leishmania são 
indutores de IL-32. Além disso, demonstramos que a expressão das isoformas de 
IL-32 é dependente da duração da exposição aos antígenos de Leishmania spp.. A IL-
32g foi predominantemente expressa durante os estágios iniciais de exposição aos 
antígenos de promastigotas de L. amazonensis e L. braziliensis. No entanto, após 7 
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dias de exposição, as isoformas IL-32α e IL-32b foram identificadas. Posteriormente, 
demonstramos que os receptores NOD2, TLR4 e Dectina-1 são importantes para a 
indução precoce de IL-32g durante a infecção com Leishmania spp.. No presente 
estudo, identificamos variações genéticas no gene IL32 que influenciam a expressão 
de IL-32g. Em seguida, avaliamos a influência destas variações na produção de 
citocinas da imunidade inata e adaptativa após exposição de células mononucleares 
a Leishmania spp. in vitro. A presença de variações genéticas nas regiões promotora 
(rs4786370), regulatória distal (rs4349147) e intrônica (rs1555001) do gene 
IL32 influenciaram a produção de citocinas após a estimulação das células com 
Leishmania spp.. Além disso, investigamos se estas variações genéticas no gente da 
IL32 poderiam estar associadas à suscetibilidade à LTA. Observamos um aumento 
na frequência do genótipo IL-32 rs4786370-CC nos controles, enquanto que o 
genótipo IL32 rs4349147 foi associado à suscetibilidade de desenvolver diferentes 
formas clínicas da LTA. Finalmente, sugerimos que a IL-32 pode influenciar o 
desenvolvimento de respostas imunes celulares Th1 e Th17 na LTA. A expressão do 
RNAm da IL-32g em lesões de pacientes com LTA foi positivamente correlacionada 
com a expressão dos genes IL1A, IFNg, IL17 e IL22. Além disso, observou-se que a 
expressão do RNAm da IL-32α foi positivamente correlacionada com a expressão do 
RNAm de IL1A e IL17, enquanto que a expressão de RNAm da IL-32b foi associada 
à expressão do RNAm de IL17 e IL22. Esses achados apontaram que as isoformas 
IL-32g e IL-32α podem estar associadas a um perfil misto Th1/Th17, enquanto 
a IL-32b esta associada a um perfil Th17. Embora o mecanismo exato pelo qual a 
IL-32 interage com as células imunes, influência as vias inflamatórias e controla o 
crescimento dos parasitas precise ser investigado, neste estudo descrevemos a IL-
32 como um mediador importante na modulação da defesa do hospedeiro contra 
infecções causadas por espécies de Leishmania. 
Na parte II desta tese, diferentes abordagens terapêuticas foram estudadas. 
No capítulo 6, identificamos o NOD2 como receptor crucial para a indução da 
resposta imune inata e adaptativa após a exposição de células mononucleares a L. 
amazonensis e L. braziliensis. Estudamos a função do NOD2 selecionando variações 
genéticas que estão frequentemente presentes em ambos receptores, NOD1 e 
NOD2, e que ocasionam perda ou ganho de função dos mesmos. Identificamos 
que a variação genética (Leu1007finsC) no receptor NOD2 regula negativamente 
a produção de citocinas produzidas por monócitos, tais como TNFα, IL-1b, IL-6, 
IL-8, assim como a produção de IFNg após a exposição de células mononucleares 
humanas a lisados  de L. amazonensis ou L. braziliensis. Curiosamente, demonstramos 
que em células mononucleares humanas, a produção de IL-17 é dependente de 
NOD2 somente após exposição a L. amazonensis. Além disso, confirmamos o papel 
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fundamental do NOD2 na produção de citocinas utilizando células mononucleares 
de indivíduos portadores da mutação NOD2 3020insC. Os resultados mostraram 
uma diminuição significativa na produção de citocinas pró-inflamatórias pelas 
células mononucleares após exposição a antígenos e a promastigotas vivas 
de ambas as espécies de Leishmania. A exposição de células mononucleares a 
Leishmania spp. também levou a um aumento da expressão do NOD2, evidenciando 
seu envolvimento na resposta imune induzida por Leishmania spp.. Os ligantes 
dos parasitas que interagem com receptor NOD2 precisam ser elucidados. No 
entanto, indicamos que a degradação de Leishmania spp. por enzimas presentes 
nos fagolisossomas é um pré-requisito para a indução de citocinas. No presente 
estudo, demonstramos que a perda da sinalização de NOD2 prejudica o controle 
intracelular dos parasitas. Em resumo, essas descobertas apontaram o NOD2 como 
um importante agente para a resposta imune nas infecções por Leishmania spp.. A 
relevância da via NOD2 na suscetibilidade ou gravidade da LTA humana precisa ser 
investigada em um futuro próximo.
Nos capítulos 7 e 8, foi explorado o uso da imunidade inata treinada como uma 
possível opção de tratamento para pacientes com leishmaniose. A hipótese de que 
as células imunes inatas sofrem reprogramação funcional a longo prazo em resposta 
à infecção ou vacinação conferindo proteção inespecífica a infecções secundárias, 
levou-nos a investigar o papel da imunidade treinada em infecções causadas por 
Leishmania spp..
No capítulo 7, examinamos a capacidade de b-glucana, um componente da parede 
celular fúngica, controlar infecções causadas por L. braziliensis em monócitos 
humanos primários e em modelo murino de imunidade treinada. Pela primeira vez, 
demonstramos que monócitos treinados com b-glucana conferem maior capacidade 
de fagocitose e controle da infecção por L. braziliensis in vitro. Em seguida, utilizamos 
análise genômica funcional para demonstrar a importância da IL-32 e dos membros 
da família IL-1 na indução de imunidade treinada por b-glucana. Mecanisticamente, 
os monócitos treinados com b-glucana apresentaram uma expressão aumentada 
de IL-32 de maneira dependente de IL-1 e de reprogramação epigenética. 
Curiosamente, observando a atividade microbicida de macrófagos, demonstramos 
que as células treinadas com b-glucana produziram níveis mais altos de peptídeos 
antimicrobianos, especificamente catelicidina e b-defensina 2 comparado com 
as células não treinadas. Em seguida, confirmamos a associação da IL-32 com o 
fenótipo de imunidade treinada induzida por b-glucana usando camundongos 
transgênicos para a IL-32. As células da medula óssea de camundongos transgênicos 
foram expostas a antígenos de L. braziliensis ou a lipopolissacarídeo de E. coli (LPS). 
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Os resultados mostraram uma produção aumentada de IL-32 e IL-1b, assim como a 
regulação positiva de genes envolvidos na via da glicólise. Além disso, a b-glucana 
foi capaz de induzir proteção contra a infecção por L. braziliensis em camundongos 
transgênicos. Ainda, um aumento do tamanho da lesão e do infiltrado inflamatório 
foram observados em camundongos tratados com b-glucana após 3 semanas de 
infecção em comparação com o grupo controle. Todavia, nos últimos estágios da 
infecção, observou-se uma redução significativa na carga parasitária e inflamação 
nos camundongos treinados com b-glucana em comparação com o grupo controle. 
Assim, a indução da imunidade treinada pela b-glucana pode ocasionar o aumento 
da função do sistema imune inato, proporcionando novos caminhos para o melhor 
tratamento da leishmaniose.
No capítulo 8, focamos nas causas do estado de persistência da hiperativação 
da resposta inflamatória que influenciam o desfecho clínico dos pacientes 
infectados por L. braziliensis. Neste estudo hipotetizamos que monócitos expostos 
a L. braziliensis desenvolvem uma reprogramação funcional a longo prazo através 
da indução de imunidade treinada. Sendo assim, este fenótipo pode contribuir 
para o desfecho clínico dos pacientes. Descrevemos que o treino de monócitos 
com L. braziliensis induz um aumento da produção de TNFα e IL-6 e alterações 
morfológicas. Este processo se mostrou dependente da indução de fagocitose 
seguido do reconhecimento dos parasitas através dos receptores NOD1/2. Além 
disso, as vias da glicólise, fosforilação oxidativa e glutaminólise se mostraram 
importantes para a indução da imunidade treinada por L. braziliensis em monócitos. 
Interessantemente, um aumento significativo dos marcadores H3K4me3 e H3K4me1 
foram observados em resposta aos antígenos de L. braziliensis. Nós também 
investigamos se a imunidade treinada induzida por L. braziliensis confere proteção 
contra patógenos infecciosos não-relacionados usando modelos de infecção in vitro 
e in vivo por Candida albicans. Curiosamente, a indução de imunidade treinada por 
L. braziliensis aumentou a morte in vitro de C. albicans e protegeu contra a infecção 
letal in vivo. Neste estudo, fornecemos a primeira evidência de que a exposição de 
monócitos humanos a L. braziliensis induz imunidade treinada, resultando em um 
fenótipo inflamatório de longa duração com aumento da produção de citocinas 
inflamatórias após estimulo secundário.
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Nederlandse samenvatting
(Dutch summary)
Leishmaniasis is een van de meest belangrijke maar vergeten tropische ziekte, met 350 
miljoen mensen verspreid over 88 landen wereldwijd die een verhoogd risico lopen op 
het ontwikkelen van een van de vele vormen van Leishmaniasis.
Nieuwe opties voor behandeling zijn dringend nodig aangezien huidige therapieën 
niet toereikend, potentieel toxisch en erg duur zijn. Recente studies laten zien dat 
de interactie tussen de gastheer en een pathogeen micro-organisme kan leiden tot 
activatie van verschillende mechanismen die betrokken zijn bij de instandhouding 
van de infectie. Het proberen te begrijpen van de onderliggende mechanismen 
die betrokken zijn bij gastheerpathogeen interacties kan een belangrijke bijdrage 
leveren aan de ontwikkeling van onder andere nieuwe vaccins, medicatie en 
immuuntherapieën. Dit proefschrift beschrijft de wetenschappelijke ontwikkelingen 
met betrekking tot het beter te leren begrijpen van de interacties tussen de Leishmania 
parasiet en immuun cellen van de gastheer en focust zich rondom het identificeren van 
nieuwe targets voor de behandeling van Leishmaniasis. In Deel I van dit proefschrift 
is er gekeken naar de rol van het cytokine interleukine (IL)-32 en de relatie met de 
immuun response tegen Leishmania parasiet. Deel II van dit proefschrift oppert 
mogelijk nieuwe behandelmethoden en/of targets voor patiënten die geïnfecteerd 
zijn met Leishmania parasieten. 
In Hoofdstuk 2 wordt de rol van IL-32 in Leishmania spp. infecties bestudeert in 
humane THP-1 macrofagen, waarin IL-32γ wordt onderdrukt of tot over expressie 
gebracht is, gevolgd door een infectie met L. amazonensis en L. brasiliensis. We laten 
zien dat IL-32γ alleen geproduceerd wordt na infectie met Leishmania spp. en dat IL-
32γ nodig is voor de productie van TNFα en IL-8 na L. amazonensis en L. brasiliensis 
infectie. Daarentegen was de productie van IL-1β en IL-1Ra niet afhankelijk van IL-32γ 
na infectie met L. braziliensis. Infectie met L. amazonensis leidde niet tot IL-1β productie, 
maar wel tot hoge concentraties IL-1Ra afhankelijk van IL-32. De productie van IL-10 
was niet afhankelijk van IL-32. Deze data suggereren dat IL-32γ een belangrijke pro-
inflammatoire rol speelt tijdens L. amazonensis en L. brasiliensis infecties. Daarnaast 
lijkt IL-32γ belangrijk te zijn voor het remmen van de intracellulaire groei van 
Leishmania spp. Dit wordt mogelijk bepaald door IL-32γ afhankelijke productie van 
stikstofmonoxide (NO) en antimicrobiële peptiden (cathelicidine en b-defensin 2). Dus, 
IL-32γ blijkt een cruciale intracellulaire mediator voor de productie van zowel cytokines 
als antimicrobiële moleculen tijdens Leishmania spp. infecties in macrofagen.
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In Hoofdstuk 3, hebben we laten zien dat IL-32 aanwezig is in huidlaesies van 
patiënten met L. amazonensis infectie. Daarnaast werd er gekeken naar de IL-32 
expressie in humaan IL-32 transgene muizen die geïnfecteerd waren met Leishmania 
parasieten om een beter inzicht te krijgen van de mechanismen die betrokken bij 
de pathogenese van Leishmaniasis en de overleving van de parasieten. Muizen 
transgeen voor humaan IL-32γ werden blootgesteld aan intradermale infecties 
met Leishmania spp. Infectie met L. amazonensis in C57BL/6 wild type muizen 
leidde tot ongecontroleerde huidlaesies terwijl infecties met L. brasiliensis wel 
gecontroleerd bleven. IL-32 transgene muizen geïnfecteerd met L. amazonenesis 
lieten vergelijkbare huidlaesies zien als de C57Bl/6 wild type muizen. Daarentegen 
was er een sterke verbetering in de huidlaesies te zien in de IL-32 transgene muizen 
geïnfecteerd met L. brasiliensis door een toename in de productie van TNFα, IFNg 
en IL-10. In tegenstelling tot L. amazonensis infectie liet de L. brasiliensis infectie 
geen groei van de parasieten zien in de milt van de IL-32tg muizen. Ondanks 
dat de aanwezigheid van humaan IL-32γ geen bijdrage had aan het beperken 
van de huidlaesies, had IL-32g wel een rol in het voorkomen van spreiding van 
parasieten naar de milt. Deze bevindingen laten zien dat afhankelijk van de species 
van Leishmania, de productie van cytokines en immuun response tot compleet 
verschillende ziektebeelden kan leiden in IL-32tg muizen.
In Hoofdstuk 4, hebben we onderzocht of IL-32 naast een rol in American 
Tegumentary Leishmaniasis (ATL), ook belangrijk zou zijn kunnen in viscerale 
Leishmania infecties. We vonden dat het aantal parasieten lager was in de milt 
en lever van IL-32 transgene muizen tijdens een L. infantum infectie (veroorzaakt 
viscerale Leishmaniasis) vergeleken met C57Bl/6 wild type muizen. Dit verschil kon 
worden verklaard door de toename in T-helper (Th) 1 en Th17 immuun responsen 
met een stijging van de IFNγ en IL-17A afhankelijke NO-productie. In aanvulling 
hierop, lieten IL-32 transgene muizen meer en grotere lever granulomata zien t.o.v. 
wild type muizen. Deze resultaten suggereren dat IL-32 een beschermende rol 
speelt in muizen geïnfecteerd met L. infantum parasieten.
In Hoofdstuk 5, hebben we de inductie van IL-32 bestudeerd in primaire humane 
PBMC’s na infectie met L. amazonensis en L. braziliensis parasieten. De resultaten 
lieten zien dat lysaten en/of antigenen van de parasieten zorgden voor de inductie 
van IL-32. Verder toonden we aan dat de expressie van de verschillende IL-32 
isovormen afhankelijk was van de duur van expositie met Leishmania antigenen. IL-
32γ was vooral aanwezig in het begin na de blootstelling met L. amazonensis en L. 
braziliensis lysaten, terwijl na 7 dagen vooral de isoformen IL-32α en IL-32β aanwezig 
waren. De vroege expressie van IL-32γ was deels afhankelijk van de aanwezigheid 
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van NOD2, TLR4 en Dectine-1 receptoren. Naast deze observaties, hebben we 
gekeken naar genetische variaties die de IL-32γ expressie konden beïnvloeden en 
welke uitkomst dit had op Leishmania-geïnduceerde aangeboren en verworven 
cytokineproductie in vitro. De aanwezigheid van genetische variaties in de promoter 
(rs4786370), een distal regulatory element (enhancer – rs4349147) en intron 
(rs1555001) regio’s van het IL32 gen resulteerden in veranderde cytokine productie 
na stimulatie met Leishmania lysaten. Naast de effecten op cytokineproductie werd 
er ook gekeken naar vatbaarheid voor een Leishmania infectie in mensen in de 
aanwezigheid van deze genetische variaties. We vonden een stijging in het aantal 
individuen met het IL-32 rs4786370-CC-genotype in de controlegroep t.o.v. een 
toename in het IL32 rs4349147 genotype dat geassocieerd is met de vatbaarheid 
voor ATL infecties. Daarnaast observeerden we dat er een positieve associatie 
was tussen IL-32γ mRNA levels in huidlaesies van een ATL positieve patiënten en 
mRNA expressie in de geïnfecteerde huid van de genen IL1A, IFNγ, IL17 en IL22. IL-
32α mRNA expressie was gecorreleerd met IL1A en IL17 mRNA waar IL-32β vooral 
gecorreleerd was met IL17 en IL22. Deze bevindingen ondersteunen de hypothese 
dat IL-32γ en IL-32α expressie geassocieerd kunnen zijn met Th1/Th17 response en 
dat de IL-32β expressie vooral met Th17 response geassocieerd is. Echter, zijn de 
exacte moleculaire mechanismen hoe IL-32 communiceert met diverse immune 
cellen tijdens een Leishmania infectie en de rol van IL-32 op inflammatoire processen 
en/of de controle van de parasitaire groei zijn nog niet volledig duidelijk.  
In Deel II van dit proefschrift zijn de mogelijke therapeutische benaderingen voor 
Leishmania infecties onderzocht. In Hoofdstuk 6, laten we zien dat NOD2 een 
cruciale intracellulaire receptor is voor de inductie van zowel het aangeboren als 
verworven immuunsysteem na infectie van humane PBMC’ met L. amazonensis and 
L. braziliensis. De functie van NOD2 werd onderzocht door te kijken naar genetische 
variaties in NOD1 en NOD2 die geassocieerd zijn met een “loss”- of een “gain” in 
functie. Een specifieke genetische variatie in NOD2 (Leu1007finsC) gen onderdrukt 
de productie van monocyt-afgeleide cytokines zoals TNFα, IL-1β, IL-6, en IL-8  na 
blootstelling aan lysaten van zowel L. amazonensis als L. braziliensis. Verder toonden 
we aan dat de IL-17 productie door humane PBMC’s alleen afhankelijk was van 
de NOD2 receptor na een infectie met L. amazonensis. Daarnaast laten we zien 
dat in individuen met de NOD2 3020insC mutatie de proinflammatoire cytokine 
productie onderdrukt is na blootstelling aan beiden Leishmania spp, zowel lysaten 
of levende promastigote parasieten. Humane PBMC’s die in aanraking kwamen 
met Leishmania spp. lieten ook een inductie van de NOD2 receptor zien, wat de rol 
van NOD2 in tijdens een Leishmania infectie versterkt. De afbraak van Leishmania 
parasieten door enzymen aanwezig in de fagolysozomen is een vereiste voor 
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de inductie van cytokines. De huidige studie laat daarnaast zien dat afwezigheid 
van NOD2 signalering route intracellulaire afbraak van Leishmania beperkt. Deze 
observaties laten zien dat NOD2 een belangrijke component is m.b.t. de humane 
immuunrespons tegen Leishmania infecties. 
In Hoofdstuk 7 en 8 werd de rol van “trained immunity” bestudeerd als mogelijke 
nieuwe therapie voor het behandelen van Leishmania infecties. De hypothese 
dat het aangeboren immune systeem een langdurige functionele verandering 
kan ondergaan als reactie op een infectie of vaccinatie en dit bijdraagt aan een 
aspecifieke bescherming tegen secundaire infecties, gaf ons het idee om de rol van 
“trained immunity” te onderzoeken in infecties veroorzaakt door Leishmania. 
In Hoofdstuk 7 hebben we de capaciteit van β-glucan, een onderdeel van de 
celwand van bepaalde schimmels, onderzocht als potentiele component die 
bijdraagt aan de controle van een Leishmania infectie door L. braziliensis in zowel 
primaire cellen als een muis model voor trained immunity. Hier laten we voor het 
eerst zien dat we instaat waren om aan te tonen dat monocyten getraind met 
β-glucan een betere opname (fagocytose) en het doden (killing) van L. brasiliensis 
lieten zien. β-glucan getrainde monocyten hadden een verhoogde expressie van IL-
32 door middel van de IL-1 signaal route en een epigenetische herprogrammering. 
Een andere interessante bevinding was dat β-glucan getrainde macrofagen een 
verhoogde hoeveelheid antimicrobiële peptiden (zoals cathelicidene en β-defensin 
2) produceerden wat eerder al geassocieerd was met IL-32 concentraties en 
een verbeterde killing van Leishmania parasieten in macrofagen. Vervolgens 
demonstreerden we in IL-32γ transgene muizen dat het “trained immunity” fenotype 
inderdaad geassocieerd is met IL-32. Beenmergcellen van IL-32γ transgene muizen 
werden geïsoleerd en na stimulatie van deze cellen met LPS of promastigotes 
antigenen van L. braziliensis lieten deze cellen een inductie zien van zowel IL-32 als 
IL-1β en genen gerelateerd aan glycolyse. Hiernaast observeerden we dat β-glucan 
toediening een bescherming gaf tegen L. brasiliensis infectie in IL-32γ transgene 
muizen. Tijdens de eerste 3 weken van de infectie waren de laesies groter in de 
β-glucan geïnjecteerde groep muizen, echter in de latere fases van de infectie was 
er significante vermindering in de hoeveelheid parasieten en ook de ontsteking, 
vergeleken met de PBS controle groep. We concludeerden daarom dat β-glucan 
training van het aangeboren immuunsysteem daadwerkelijk kan bijdragen aan een 
verbeterde bescherming tegen Leishmania infecties en als een mogelijk nieuwe 
therapeutische behandeling kan dienen. 
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In Hoofdstuk 8 hebben we ons meer gefocust op de aanhoudende hyperactivatie 
van het immuunsysteem en de effecten hiervan op de klinische verschijnselen 
tijdens een  L. brasiliensis infectie. Onze hypothese was dat patiënten blootgesteld 
aan Leishmania spp. een langdurige functionele verandering in hun monocyten/
macrofagen ondergaan door middel van trained immunity wat uiteindelijk resulteert 
in hun  ziekte expressie. We beschrijven in hoofdstuk 8 dat het trainen van humane 
monocyten leidt tot een verhoging in TNFα en IL-6 productie en in morfologische 
veranderingen in de cellen. Deze processen zijn mogelijk geassocieerd aan de 
opname (fagocytose) en herkenning van de parasiet door de NOD1/2 receptoren. 
Daarnaast observeerden we dat de effecten van trained immunity afhankelijk 
waren van glycolyse, oxidatieve fosforylering en glutaminolyse. Een zeer 
belangrijke bevinding was de toename in de epigenetische markers H3K4me3 en 
H3K4me1 na blootstelling aan antigenen die afkomstig waren van L. brasiliensis 
promastigoten. Als laatste hebben we ook gekeken naar de mogelijke bescherming 
tegen secundaire aspecifieke infecties na training met L. brasiliensis antigenen 
Trained immunity geïnduceerd door L. brasiliensis lysaten leidde tot een verhoogde 
in vitro killing van Candida albicans en beschermde tegen een lethale dosis van C. 
albicans in vivo. Deze studie biedt het eerste bewijs dat blootstelling van humane 
monocyten aan L brasiliensis antigenen trained immunity induceert wat leidt tot 
een langdurig inflammatoir fenotype van deze monocyten geassocieerd met een 
verhoogde cytokine productie na een secundaire stimulatie en/of infectie. 
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